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ABSTRACT 
 
Biliary obstruction results in cholestasis characterised by progressive fibrosis, cholangiocyte 
hyperplasia and cirrhosis ultimately leading to liver failure.  Underlying molecular mechanisms remain 
unclear but likely involve deregulation of signalling pathways within bipotent progenitor cells. 
Transduction of cell lines with vectors containing serial transcription factor (TF) binding sequences 
upstream of a minimal promoter driving luciferase expression have been widely used to study TF 
activity in vitro. The presented data expands upon this technology both in vitro and in vivo to enable 
quantification of bioluminescent output in living cell cultures and animals.  A library of lentiviral 
vectors expressing either firefly luciferase or secreted NanoLuc luciferase was generated.  Validation 
was performed by agonist-mediated activation and subsequent luciferase readout. Human hepatocellular 
HepaRG cells can be cultured as bipotent progenitors capable of differentiating into cholangiocytes or 
hepatocytes, and are a valuable tool for understanding cholangiocyte hyperplasia. HepaRGs transduced 
with WNT, Notch, or alpha-1 antitrypsin (α1AT) NanoLuc reporters were temporally assayed from 
culture media during differentiation.  Two alternative differentiation procedures were performed based 
on previously published protocols predicted to enrich for either hepatocytes or cholangiocytes.  The 
effect of Notch signalling on differentiation potential was determined through Notch signalling 
modulation. Data indicate that constitutive expression of JAGGED-1 results in a predisposition toward 
the cholangiocyte lineage.  Conversely, the percentage of hepatocyte-like cells increased with the 
suppression of Notch signalling by NUMB.  This enrichment is synergistic when used in conjunction 
with the 3-component differentiation protocol.  For in vivo experiments, various high-titer VSV-G 
pseudotyped lentiviruses containing the reporters were administered by intravascular injection to P0 
neonatal mice. This resulted in liver-restricted transduction and lifelong tolerance of the transgene. 
After establishing a bioimaging baseline, adult mice were subjected to partial bile duct ligation to 
induce a cholestatic phenotype, followed by serial bioimaging. This permitted the evaluation and 
comparison of temporal activities of a number of candidate signalling pathways involved in the 
differentiation of hepatic progenitor cells in vitro and the response to cholestatic injury in vivo.  These 
methods of longitudinal assessment are an improvement on current methodologies and can be used as 
tools to obtain mechanistic insight or as drug-screening platforms. 
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I)  Liver architecture and physiology  
a)  Structure and cell types of the liver   
The liver is a dynamic organ which plays an integral role in the homeostatic maintenance of the entire 
body.  It functions in a range of metabolic processes, acting as a store for a host of vitamins and 
enzymes, and also plays a crucial role in detoxifying the body of xenobiotic compounds.  The liver is 
composed of liver lobules composed of both parenchymal and mesenchymal cells, depicted in Figure 
1, which at a histological scale are small hexagonal subdivisions consisting of plates of hepatocytes 
radiating from the central vein.  Around the perimeter of the lobule is a distinctive cluster known as 
the portal triad composed of the hepatic artery, portal vein, and bile duct, all bound together by a 
perivascular fibrous capsule.   
 
https://cms.webstudy.com/WebstudyFileSystem/testovaci/GetFile/293875/Ch%2022/Ch22b/figure_22_25c_labeled.jpg  
Figure 1. Schematic diagram depicting the structure of the liver lobule. 
Each liver lobule consists of radiating hepatocytes emanating from the central vein. The portal vein, hepatic 
artery, and bile duct constitute the portal triad. Sinusoids act as hepatic capillaries to transport blood towards the 
central vein, while also acting as the residence for macrophagic Kupffer cells.  
 
The liver is composed of both parenchymal and mesenchymal cells that are responsible for the 
functions within the liver (Figure 2). The most abundant hepatic cell type is the parenchymal 
hepatocyte, which accounts for over 80% of the total liver mass and whose basolateral membranes 
contain microvilli utilised in nutrient intake.  Hepatocytes are hexagonally shaped, highly polarised 
epithelial cells and have an endodermal embryological origin1.  The plates of hepatocytes are 
separated from each other by the sinusoids, which serve as the primary capillaries in the liver involved 
in the transport of blood2.  Resident within the sinusoidal lumen are the hepatic immune macrophages, 
the Kupffer cells.  These cells are believed to be replenished in the liver through extrahepatic 
recruitment of bone-marrow derived monocytes that are macrophage precursors, or alternatively 
through local proliferation of mature resident Kupffer cells3. As a critical component of the innate 
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immune system, their role is to phagocytose microorganisms and other particulate matter, which are 
brought into the liver through the portal vein.  They also process and present antigens, and respond to 
such invasions through the secretion of pro-inflammatory mediators including, cytokines, nitric oxide 
and reactive oxygen intermediates4.   Between the basal surface of the hepatocytes and the sinusoidal 
endothelial cells is the peri-sinusoidal space of Disse which contains blood plasma from which the 
hepatocytes receive their nutrients.  The space of Disse also contains the hepatic stellate cells (HSCs), 
previously termed lipocytes, which amongst other roles, act as fat-storage cells and reservoirs of 
vitamin A within the healthy liver.  They also demonstrate the capacity to synthesise collagens and 
other extracellular matrix proteins involved in hepatic fibrosis5.  The region known as the canal of 
Hering has the primary role of draining bile out of the liver, and is also the site of hepatic progenitor 
cells.  More recently however, CD133+ hepatic stellate cells (HSCs) within the space of Disse have 
been demonstrated to contribute to the stem cell population.  CD133 is a cell surface protein which 
has been used as a characteristic marker of stem/progenitor cells of hematopoietic origins.  Kordes et 
al. demonstrated that these CD133+ HSCs have the ability to differentiate into myofibroblast-, 
endothelial- and hepatocyte-like cells in vitro6.  They also exhibit properties of progenitor cells in that 
they are able to grow clonally in culture and yet maintain their ability to differentiate, indicating their 
self-renewal potential7. Other parenchymal cells within the liver are the biliary epithelial cells, termed 
cholangiocytes, which line the biliary tree.  The primary function of these cells is to alkalinise the 
canalicular bile prior to its entry into the duodenum through the secretion of HCO3
- which exerts a 
protective effect against bile-acid induced cholangiocyte injury8.   
         
http://www.mdpi.com/2073-4409/1/4/1261/htm 
Figure 2.  Overview of hepatic cell types. 
The liver is organised into rows of hepatocytes with the bile flowing through the sinusoids leading to the bile 
ducts.  The bile duct (BD), hepatic artery (HA), and portal vein (PV) form the portal triad.  Blood flows from the 
portal vein to the central vein (CV).  A number of cells are also resident within the liver, each playing a 
fundamental role in hepatic homeostasis
9
.  
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b)  General functions of the liver  
The liver is the largest organ in the body and is responsible for a wide range of roles including 
metabolic, endocrine, and secretory functions (Table 1)10. 
 
  Table 1.  Table of the major functions of the liver. 
1)  Carbohydrate metabolism 
Gluconeogenesis  
Glycogen synthesis and metabolism 
2)  Fat metabolism 
Fatty acid  and lipoprotein synthesis 
Cholesterol synthesis and excretion 
Ketogenesis 
3)  Protein metabolism  
Synthesis of plasma proteins 
Urea synthesis 
4)  Hormone metabolism 
Metabolism, conjugation and excretion of both 
steroidal and polypeptide hormones 
5)  Xenobiotic metabolism Drug and foreign compound metabolism and excretion 
6)  Storage Glycogen, vitamin A, vitamin B12, iron 
7)  Bilirubin metabolism Metabolism and secretion of bilirubin 
 
Metabolic processing is one critical component of liver function.  The liver lobule is organised in 
metabolic zones such that gradients of metabolism are formed.  Periportal hepatocytes form part of 
zone 1, mainly involved in gluconeogenesis, cholesterol biosynthesis, and urea synthesis. This is in 
contrast to the hepatocytes located perivenously that form part of zone 3 and are part of xenobiotic 
metabolism, glycolysis, bile acid biosynthesis and glutamine synthesis.  The region between these 
zones has intermediate functions between the two zones and is classified as zone 2 (Figure 3)11.  
                                
http://www.mdpi.com/2073-4409/1/4/1261/htm 
Figure 3.  Hepatic metabolic zonation.  
Metabolites are processed in different regions of the liver dependent upon their location in zones 1, 2, or 3.  
Zones are concentric regions from the central vein and out towards the portal triads.  Blood flows toward the 
central vein, whilst bile flows down the sinusoids and into the bile ducts, countercurrent to the flow of blood.  
Each of the zones is responsible for specific biological functions.   
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Another function of the liver is the production of proteins, with up to 50% of total protein synthesised 
being albumin.  Albumin is essential for maintaining oncotic pressure within the capillaries.  This 
osmotic pressure is exerted by the presence of proteins within the plasma that subsequently pull water 
into the circulatory system, thereby maintaining the balance of water between the capillaries and the 
circulatory system.  Another integral role of albumin is the binding and transportation of hormones12.  
Proteins involved in the immune response are also synthesised in the liver and include the c-reactive 
protein which activates the complement cascade and complement proteins involved in the clearance of 
pathogens13.  Carrier proteins involved in transporting of molecules from the liver to other parts of the 
body are also hepatically synthesised.  An example of this is transferrin, a potent chelator involved in 
cellular iron homeostasis which maintains Fe3+ in a redox-inert state, thereby preventing the 
production of damaging free radicals14.  Tight regulation of iron through hepatic iron-sensing is vital, 
as low levels of iron result in the development of iron deficiency anaemia.  Red blood cells contain 
iron-containing haemoglobin which binds, carries, and releases oxygen to tissues throughout the body, 
a requirement for aerobic cellular respiration.  Contrastingly, iron overload in the liver results in the 
generation of excess reactive oxygen species and causes hepatic injury, particularly fibrosis, cirrhosis, 
steatohepatitis, and hepatocellular carcinoma15.   
 
c)  Bile function, production, and circulation 
Bile is the dark green fluid that is made in the liver and stored in the gallbladder.  It plays a crucial 
role in digestive processes, as it contains bile acids and pigments, phospholipids, cholesterol, and 
bicarbonates.  Firstly, the function of bile is to facilitate emulsification of fats and aid absorption of 
the fat-soluble vitamins, A, D, E, and K16.  It is also essential for the absorption of metals such as 
copper and nickel which are essential factors for haemoglobin synthesis17.  Lastly, it plays a critical 
role in the excretion of waste products, particularly end products of haem metabolism18.  
Haemoglobin originating from the destruction of senescent red blood cells is broken down by 
monocytic macrophages of the spleen, bone marrow, and the hepatic Kupffer cells to produce water-
insoluble, unconjugated bilirubin19.  This lipid-soluble form is then bound to serum albumin and 
transported to the liver.  Dissociation of bilirubin from albumin occurs at the sinusoidal interface of 
the hepatocytes20 where the bilirubin enters the hepatocyte through facilitated diffusion18.  Within the 
liver, the albumin is removed and the bilirubin is conjugated to glucuronic acid, making it water 
soluble. The conjugated bilirubin subsequently combines with bile which is synthesised by the 
hepatocytes from the products of cholesterol metabolism to form bile salts.  In the absence of disease, 
the bile flows into the bile canaliculi and subsequently flows, countercurrent to the hepatic circulation, 
towards the outside of the liver lobule where it drains from the canals of Hering and into the bile duct.  
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The bile is subsequently concentrated and stored within the gall bladder21. Figure 4 shows the bile 
flow of the biliary tree from the liver and down into the duodenum. 
 
http://gallstoneflush.com/images/biliary%20tract.JPG 
Figure 4.  Bile flow from the gall bladder to the duodenum. 
Hepatocytes synthesise bile which flows through the bile canaliculi towards the hepatic bile ducts through the 
canals of Hering.  The bile is routed through the common hepatic duct towards the gallbladder where it is stored 
until required.  Hormonally-induced contraction of the gallbladder causes bile to enter the common bile duct.  
 
The semifluid, partially digested food formed after passing through the stomach and the small 
intestine is known as chyme.  It contains a host of digestive enzymes and hydrochloric acid from the 
stomach, creating the ideal niche for the breakdown of food by protein-digesting enzymes22.  As the 
acid chyme enters the duodenum, inactive prosecretin is activated to yield the active hormone, 
secretin, which is absorbed via the hepatic portal system23.  Secretin subsequently binds G-protein 
coupled receptors of large cholangiocytes24, and activates adenyl cyclise to produce cAMP25.  An 
essential step in the extrusion of bicarbonate is the phosphorylation of the cystic fibrosis 
transmembrane conductance regulator (CFTR), a chloride channel, by protein kinase A (PKA)26.  
Dysfunction of the CFTR ion channel, as seen in cystic fibrosis, results in the insidious development 
of biliary fibrosis and periportal inflammation, characteristics also seen in individuals afflicted with 
primary sclerosing cholangitis, a highly inflammatory biliary disease27.   Secretin is responsible for 
the secretion of high concentrations of bicarbonate ions into the duodenum to neutralise the acid 
contents of the stomach28, as well as to provide the optimal, slightly alkaline or neutral pH, in which 
the pancreatic digestive enzymes are functional29.  A second hormone, cholecystokinin, is released 
from the cells in the duodenum in the presence of peptones and proteases, partial products of 
digestion, as well as long-chain fatty acids.  Cholecystokinin stimulates the secretion of pancreatic 
enzymes and causes the gall bladder to contract and release bile through the cystic duct into the 
common bile duct, and finally into the intestine through the sphincter of Oddi30 (Figure 5).  Through 
the portal venous system, approximately 95% of biliary secretions are returned to the liver to be 
reused21.    
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http://1.bp.blogspot.com/-b3xImFaEdwU/UNeuUlbbjZI/AAAAAAAAAnw/W2Os993QaFQ/s1600/digestive12.jpg 
Figure 5.  Induction of bile secretion from the gallbladder. 
The presence of acid chyme triggers the release of the hormones cholecystokinin and secretin. Cholecystokinin 
stimulates the release of enzymes from the pancreas and causes contraction of the gallbladder to facilitate the 
release of bile, while secretin induces neutralisation of the acid bile. 
 
II)  Signalling pathways involved in hepatic development  
All of the processes within the liver are regulated at the molecular level by signalling pathways which 
are tightly regulated.  These pathways have temporal activities which may be specific to the 
developmental process, while others are recapitulated during the process of regeneration and repair. 
Novel methods of monitoring pathway activity, particularly in an in vivo context, are ongoing as 
better technologies are being developed and exploited. 
 
a)  Developmental signalling pathways  
Many diseases of the liver occur as a result of deregulation of cell signalling during developmental 
processes.  Understanding developmental pathways is relevant to acquired liver diseases in adults as 
signalling expression profiles observed during embryogenesis are exploited as a mechanism of liver 
repair and the deregulation of such pathways is causative in the development of disease.  Some of the 
main cell signalling pathways involved during development, hepatobiliary disease, and regeneration 
are TGF-β, WNT, Notch, and NF-κB signalling, all of which will be discussed both in their 
developmental and disease-specific contexts. 
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i)  Transforming growth factor-β superfamily signalling pathways 
One of the key pathways in endoderm formation involves the transforming growth factor (TGF-β) 
superfamily of transcription factors. The TGF-β superfamily members can be divided into two 
branches, with TGF-βI, myostatin, Nodal, Inhibin and Lefty 1,2 activating  the TGF-β signalling 
branch, while the bone morphogenetic proteins (BMPs) are responsible for the BMP signalling 
branch, each of which phosphorylate specific R-SMAD proteins31 (Figure 6).  TGF-β receptors are 
classified into 3 different classes, with type I (TβRI) alternatively termed activin-like kinases (ALK), 
Type II (TβRII), and type III (TβRIII).  Ligand binding leads to the formation of a hetero-tetrameric 
complex of two TβRI and two TβRII receptors32.  This catalytically favourable orientation permits 
TβRII to phosphorylate TβRI which subsequently activates the cytoplasmic Ser/Thr kinase domain 
within the cytoplasm32.  There are five receptor-regulated SMAD proteins (R-SMADS), namely 
SMAD1, SMAD2, SMAD3, SMAD5, and SMAD8.  Receptor-mediated phosphorylation of the R-
SMADS induces a conformational change within the protein, resulting in its dissociation from the 
receptor complex. The R-SMADS subsequently form transcriptional complexes, which, when 
phosphorylated, have a high affinity for the coSMAD, SMAD4, and bind to it33.  This R-
SMAD/coSMAD complex subsequently translocates into the nucleus where it binds to specific 
response elements.  These response elements are short sequences of DNA within the promoter regions 
of genes which are able to bind specific transcription factors to regulate gene expression of DNA 
targets34. 
 
Figure 6.  Branches of TGF-β signalling. 
TGF-β signalling is activated through binding of an agonist to the receptor.  This induces intracellular 
phosphorylation of the receptor and subsequent R-SMADs, making them conformationally receptive to binding 
to coSMAD4.  The complexes subsequently translocate into the nucleus where they bind to their respective 
response elements depending on whether the TGF-β or BMP part of the pathway was ligand activated.   
  
CHAPTER 1 – GENERAL INTRODUCTION                                                                                         8 | P a g e  
 
 
ii)  WNT signalling 
Another critical pathway involved in both development and disease is the Wnt signalling pathway.  In 
the 1980s, Christiane Nusslein-Volhard and Eric Wieschaus performed large-scale mutant screens in 
Drosophila melanogaster and found that many Wnt genes, a family of genes, were required for axis 
determination during embryonic development35.  Wnt proteins have emerged as critical regulators of 
stem cell self-renewal and cancer, with aberrant signalling leading to tumorigenesis in a number of 
cellular contexts36.  This complex pathway is characterised by canonical WNT signalling, non-
canonical planar cell polarity pathway, and non-canonical Wnt/Calcium pathway, all of which have 
distinct ligands and downstream targets.  Wnt signalling is highly conserved across species, and is 
involved in the regulation of cell polarity37, axis determination38, cell fate determination39, 40 and a 
range of other functions during embryogenesis.   
The best characterised of these Wnt signalling pathways is canonical Wnt signalling which is β-
catenin mediated.  This pathway is highly regulated both spatially and temporally and is activated 
upon the binding of secreted Wnt proteins to the N-terminal domain of the seven-transmembrane-
spanning Frizzled (Fz) family of receptors41.  Wnt-bound Fz then forms a co-receptor complex with 
low-density-lipoprotein-related protein5/6 (LRP5/6)42.  In the absence of Wnt ligand stimulation, β-
catenin is held in a destruction complex with axin, adenomatosis polyposis coli (APC), casein kinase 
1α (CK-1α) and glycogen synthase kinase-3beta (GSK-3β).  Poly-ubiquitination of β-catenin by GSK-
3β targets it for proteasomal degradation, causing cessation of any subsequent downstream 
signalling43.  In conjunction with proteasomal modulation, Wnt target genes are kept in a repressed 
state through the association of TCF with transcriptional co-repressor complex, Groucho/transducin-
like enhancer protein 1 (TLE), a transcriptional repressor which interacts with histone deacetylases, 
thereby maintaining transcriptional inactivation44,45.  However, addition of Wnt ligand sequesters the 
negative Wnt regulator, Axin, to the cell membrane.  Binding of axin to the cytoplasmic tail of LRP-
5/646 is mediated through phosphorylation by either CK1γ or GSK-3β47.  Following LRP-5/6 
activation, Dishevelled is recruited to Fz, becomes phosphorylated, and antagonises the kinase activity 
of GSK-3β48.  The downstream affects include inhibition of phosphorylation of axin by GSK-3β, 
leading to its decreased stability and cytoplasmic levels49, as well as the inhibition of GSK-3β-
mediated phosphorylation of β-catenin, which liberates β-catenin from the destruction complex and 
halts subsequent degradation50.  The stabilisation and accumulation of β-catenin causes its 
translocation into the nucleus where it displaces groucho/TLE repressors from the TCF/LEF DNA 
binding motif and associates with CREB-binding protein (CBP)/300, a histone acetyltransferase 
involved in chromatin activation51 (Figure 7). 
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http://www.wormbook.org/chapters/www_wntsignaling/wntfig1.jpg 
Figure 7.  Regulation of canonical Wnt signalling. 
In the absence of ligand binding to the Wnt receptor, β-catenin is prevented from nuclear translocation through 
its interaction with the destruction complex consisting of Axin, APC, CKIα, and GSK-3β.  Upon ligand binding, 
Axin binds to the LRP receptor, while Dishevelled is recruited to the Frizzled receptor and is phosphorylated.  
This releases β-catenin from the repressive hold of the destruction complex, allowing its cytoplasmic 
accumulation and subsequent translocation into the nucleus where it activates downstream target genes.  
 
β-catenin also has an important role in cell-cell adhesions by complexing with E-cadherin to bridge it 
to the actin cytoskeleton at the adherens junctions.  The loss of either β-catenin or E-cadherin is 
associated with a loss of intercellular junction integrity and increased invasiveness of tumors52.  
Maintenance of these tight junctions is required for correct formation of the bile canaliculi, with the 
liver-specific loss of β-catenin resulting in intrahepatic cholestasis53.  This mobilisation of E-cadherin 
to β-catenin is regulated by the IL-6 family cytokine, oncostatin M (OSM) and is a key regulator for 
the formation of adherens junctions during liver development54. Alternatively, β-catenin can act as a 
modifier of gene expression in a Wnt-independent manner through its association with c-Met, the 
receptor for hepatocyte growth factor (HGF).  Binding of HGF to c-Met dissociates the c-MET/β-
catenin complex in a dose-dependent manner, and allows phosphorylation and the nuclear 
translocation of β-catenin independent of canonical Wnt signalling55.  
Antagonists of the Wnt pathway are crucial for Wnt temporospatial signal modulation.  A number of 
secreted proteins have been identified which prevent the interaction of Fz or LRP5/6 with their Wnt 
agonist.  These include Dickkopf (Dkk)56, soluble Frizzled-related proteins57, Frzb58, Wnt-inhibitor 
protein (WIF)59, and the Wnt inhibitor Wise60. These inhibitors act to tightly regulate signalling and 
are able to do so in a dose-dependent manner to allow the production of a morphogenic gradient 
during embryogenesis which is imperative for precise pattern formation.     
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iii)  Canonical Notch signalling 
Notch signalling between cells is carried out through direct cell-cell ligand-receptor interactions.  This 
permits signal transduction to induce transcriptional activation of genes which are involved in a 
multitude of biological activities during both embryogenesis61 and adult life62,63.  Some of the 
downstream effects include proliferation, stem cell maintenance, and cell fate determination.  Notch 
receptors comprise a large, single-pass Type I transmembrane receptor which contains both a large 
extracellular domain, and a small intracellular domain.  Following translation, the Notch receptor 
undergoes crucial modifications, glycosylation and fucosylation, to become fully functional64.  In 
mammals, there are four known Notch receptors (Notch 1-4) which have distinct transcriptional 
activities and have both redundant and unique functions65.  There are five canonical Notch signalling 
ligands belonging to either the Jagged/Serrate (Jagged 1,2) family of proteins, or the Delta-like (Dll 1, 
3, and 4) family. 
Notch signalling is one of the few pathways whose signalling is dependent upon a series of 
proteolysis events, with the final cleavage resulting in signal transduction without the need of a 
secondary messenger or signal amplification cascade. Following post-translational modification, the 
first of 4 cleavage events takes place at the S1 site by a furin like-convertase, producing a mature 
receptor which is then targeted to the cell surface66.  This cleavage converts the Notch polypeptide 
into a Notch extracellular domain and a Notch transmembrane and intracellular domain, with 
heterodimer formation retained through noncovalent interactions67.   Binding of the ligand causes a 
conformational change and exposes the S2 cleavage site to the ADAM-family metalloproteinases, 
Tumour (TACE)68 resulting in ectodomain shedding. The remaining membrane-tethered 
transmembrane domain containing the S3 and S4 cleavage sites then becomes the substrate for γ-
secretase, with cleavage resulting in the liberation of the Notch intracellular domain (NICD) and its 
subsequent translocation into the nucleus69.  In the absence of NICD, the transcription factor CSL 
(CBF1, Suppressor of Hairless, Lag-1) associates with DNA-binding recombination signal binding 
protein (RBP)-Jκ, co-repressor proteins and deacetylases, exerting a repressive signal upon target 
genes70.  Nuclear accumulation of NICD and its interaction with CSL triggers an allosteric change 
which displaces the transcriptional repressors and converts the repressive signal of (RBP)-Jκ into an 
activation signal through its association with a transcriptional activation complex which includes 
Mastermind-like-1 (MAML-1) and the histone acetyltransferase, p30071.  Recruitment of activators to 
the promoter triggers the transcription of Notch target genes such as Hes1 and Hes5 which are 
critically involved in differentiation70.  Termination of signalling is carried out through 
hyperphosphorylation of NICD on its proline-glutamic acid-serine-threonine (PEST) and transcription 
activation domain (TAD) domains by kinases such as CDK8, thereby targeting it for proteasomal 
degradation by the E3 ubiquitin ligase72 (Figure 8).   Notch signalling is exquisitely context 
  
CHAPTER 1 – GENERAL INTRODUCTION                                                                                         11 | P a g e  
 
dependent, with the timing, length, and intensity of expression all intricately controlled to provide the 
diverse array of Notch expression profiles observed within varying niches.  
 
Numb inhibition of Notch signalling 
Numb is a membrane-associated phosphotyrosine binding protein involved in regulating fate 
determination.  Its primary role within cellular differentiation is to inhibit Notch signalling which is a 
necessary component of self-renewal in stem and progenitor cells73.  Two downstream targets of 
Notch signalling are hairy and enhancer-of-split 1 (HES1) and Hes-related family bHLH transcription 
factor with YRPW motif protein 1 (HEY1), which function as transcriptional repressors of tissue-
specific transcription factors, thereby increasing the capacity for self-renewal74.  Numb biologically 
antagonises Notch signalling through association with α-adaptin, a component of clathrin-coated pits 
involved in endocytosis75. Receptor-mediated internalisation of Notch via numb is thus capable of 
repressing further Notch signal transduction. Numb also exerts is inhibitory effects by promoting 
ubiquitination of the membrane-bound Notch1 receptor.  The E3 ubiquitin ligase, Itch, and Numb act 
cooperatively to promote the degradation of NICD, leading to a loss of Notch signalling76.  A more in-
depth understanding of how the above-mentioned pathways are regulated during development and 
induce disease is highlighted below.  
 
Figure 8.  Representation of canonical Notch signalling through cell-to-cell interactions. 
Following posttranslational modifications, the mature Notch receptor resides as a single transmembrane receptor 
within the plasma membrane of the signal receiving cell.  Following binding by one of the Notch ligands, a 
series of proteolytic cleavage events results in the formation of NICD, the Notch receptor domain capable of 
binding directly to DNA binding motifs, recruiting other co-activators, and causing transcription of Notch target 
genes.  
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b)  Overview of liver development 
Over the last decade, much research has been done to further the understanding of the mechanisms of 
hepatic development.  This has led to key genes and molecular pathways being identified and used to 
produce hepatic-like cells that have therapeutic potential for a range of diseases.  Many of these 
pathways are synonymous with those involved during the process of tissue repair and regeneration.  
An overview of some of the core transcription factors involved in the differentiation of hepatoblasts 
toward hepatocytes and cholangiocytes that will be further discussed are illustrated in Figure 9.  
 
 
http://www.tankonyvtar.hu/en/tartalom/tamop425/0011_1A_Transzdifferenciation_en_book/ch01s07.html 
 
Figure 9.  Transcriptional regulation of hepatoblast differentiation. 
The differentiation of hepatoblasts to hepatocytes and cholangiocytes is dependent upon a core circuit of 
transcription factors and signalling pathways.  The temporal expression of these core transcription factors is 
crucial to their determination of cell fate.   
 
Key stages of hepatic development include competence, induction, specification, proliferation, and 
migration.  The concept of developmental “competence” is characterised by cells which have not yet 
been specified to become a particular cell type, but have the capacity to respond to molecular 
specification-inducing signals.  It has been hypothesised that the endoderm must enter a stage of 
competence prior to hepatic specification.  Mediators of hepatic competence include forkhead box 
protein (FoxA) and GATA4, both of which affect the transcriptional activity of one the earliest and 
best characterised hepatocyte markers, albumin (ALB).    The next stage of liver development is 
termed “specification”, and refers to the commitment of cells towards a specific differentiated state.   
The position of the ventral endoderm relative to the cardiac mesoderm is critical to hepatic cell fate, 
as FGF-mediated specification is concentration-dependent.   Lower concentrations induce hepatic 
specification, while higher concentrations specify lung tissue77.  Mesodermal Wnt expression 
promotes hindgut development, and its inhibition by the endoderm through the secretion of Wnt 
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antagonists is required for subsequent liver development78.    By E8.5 the liver bud is formed with 
early molecular evidence of hepatic specification seen by expression of transthyretin79, ALB, AFP80, 
and HNF4a81 in a region of the ventral endoderm.    Following specification at E9.5 or day 22 of 
human embryonic development, the liver diverticulum is formed from the primitive gut and is 
surrounded by a basement membrane composed of laminin, collagen IV, fibronectin, and heparin 
sulphate proteoglycan82.  It is here that the hepatoblasts begin to proliferate83, mediated by Hex 
signalling84. Expression of metalloproteinases (MMPs) by the hepatoblasts is required for the 
breakdown of the basement membrane, with inhibition of MMP activity resulting in the failure of the 
hepatoblasts to migrate into the septum transversum85.  By E10-15, the liver bud undergoes rapid 
growth and is vascularised and colonised by hematopoietic cells86.  From E13, the bipotent 
hepatoblasts begin to differentiate into either biliary epithelial cells (alternatively termed 
cholangiocytes), if in close proximity to the portal veins, or into hepatocytes86.   
 
 
http://www.stembook.org/sites/default/files/pubnode/1eb96f61005e0c07df780954b6df2580a1c71d6d/Liver_development/Zorn10.jpg 
Figure 10. Endodermal budding of the liver. 
i) Liver bud formation begins with the formation of the liver diverticulum containing pseudostratified 
hepatoblasts.  ii) The hepatoblasts undergo proliferation and iii) subsequently undergo EMT and migrate 
through the basement membrane and invade the adjacent septum transversum. 
 
c)  Development of the biliary tree 
The extrahepatic and intrahepatic regions of the biliary tree have discrete developmental origins.  
Genetic knockout experiments have highlighted the importance of several key transcription factors 
required for biliary development, including Hhex87, HNF688, and HNF1β89. Hepatoblast 
differentiation into cholangiocytes occurs around E13.5 in the mouse, with intrahepatic bile duct 
(IHBD) development highly conserved in humans, rats, and mice.  The first step in bile duct 
morphogenesis is the formation of the ductal plate consisting of SOX9-positive cells.  SOX9 is a 
temporally fundamental transcription factor in bile duct development and will be discussed later in 
more detail.  The ductal plate is formed from the periportal hepatoblasts which are located at the 
interface between the hepatic parenchyma and the portal mesenchyme.  This continuous, single layer 
of cholangiocytes duplicates around E16.5 and undergoes dramatic remodelling to form the bile ducts.  
Biliary differentiation occurs in a sequential but asymmetrical manner, with the cells on the portal 
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side of the ductal plate beginning differentiation earlier than the hepatoblasts on the parenchymal side.  
This differentiation asymmetry resolves with subsequent maturation of the bile duct90.  At the time of 
birth, the remainder of the ductal plate progressively regresses while the mature ducts migrate and 
integrate into the portal mesenchyme
88
 (Figure 11). This process is temporally coordinated with the 
formation of hepatic portal arteries through stage-specific communication of angiogenic factors with 
developing biliary structures91.  The cholangiocytes are responsible for the development of a vascular 
endothelial growth factor (VEGF) gradient, which subsequently determines arterial vasculogenesis 
within their vicinity91.  Progressive development of the IHBD begins from the hilum of the liver out 
towards the periphery of the liver lobes, with the ducts progressively connecting to form an 
interconnected network into which the bile can drain into the extrahepatic bile ducts92.   This means 
that neonatally, mature ducts which already possess radial symmetry can be seen near the hilum, 
while asymmetric structures are still seen at the periphery.  This is in contrast to adults which display 
mature bile ducts throughout the lobes. 
 
http://www.sciencedirect.com/science/article/pii/S0016508509004636 
Figure 11.  Bile duct development. 
At E13, hepatoblasts in direct contact with the portal vein mesenchyme begin to attain a cuboidal shape and are 
fated to become billiary epithelia.  From E17, this initial layer, or ductal plate, duplicates to form a bilayer.  This 
bilayer forms focal dilations which eventually give rise to the bile ducts, while the remainder of the ductal plate 
regresses over time.   Parenchymal hepatoblasts differentiate into hepatocytes. 
 
Transcription factor modulation of cholangiocyte differentiation 
Numerous signalling pathways are known to have a significant impact on determining the lineage of 
the hepatoblasts.  Wnt/β-catenin signalling has been shown to promote the differentiation of 
cholangiocytes through inducing expression of EGF93, which in combination with HGF, are able to 
form biliary structures from cultured hepatocytes in vitro94.  Definitive experiments have been 
performed to show the requirement of Wnt signalling in biliary differentiation.  Using embryonic liver 
explants cultured with antisense morpholino oligos to β-catenin resulted in the loss of cells positive 
for CK19, a cholangiocyte-specific marker.  Monga et al. also noted an increase in C-KIT expression, 
a marker of liver stem cells, within the β-catenin inhibited hepatocytes95.  Moreover, the treatment of 
liver explants with conditioned medium containing the well-characterised Wnt agonist, Wnt3a, was 
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able to induce biliary differentiation characterised by CK19+ staining96.  These results were further 
validated in vivo by Tan et al. who demonstrated that inactivation of β-catenin results in bile duct 
paucity.  Histologically the β-catenin knockout mice showed a reduction in overall hepatocyte 
numbers due to 1) increased apoptosis due to oxidative stress, and 2) diminished expansion capacity 
due to a decrease in cyclin-D197.  Taken together, this data shows that β-catenin plays a critical role in 
the proliferation, survival, and differentiation of the hepatoblasts and is integral to survival.  
Furthermore, recent studies have elucidated the contribution of the periportal TGF-β concentration 
gradient to biliary cell differentiation.  This activin/TGF-β gradient is regulated through the 
expression of the Onecut (OC) transcription factors, HNF-6 (OC-1) and OC-2, which inhibit TGF-β 
signalling within the hepatic parenchyma to allow hepatocyte differentiation.  High levels of TGF-β 
signalling around the portal vein, however, support the differentiation of hepatoblasts towards 
cholangiocytes98 with multiple signalling pathways acting to suppress pro-hepatocyte transcription 
factors, HNF4α99, Tbx3100, and C/EBP101, 102.  Following differentiation of the hepatoblasts to mature 
cholangiocytes, TβRII expression is repressed in a negative feedback loop of TGF-β.  Confirmation of 
the necessity of the OC transcription factors in cholangiocyte specification has been determined 
through knockout of the OC genes.   This results in a perturbation of the TGF-β gradient and the 
creation of hybrid hepato-biliary cells that exhibit characteristics of, and stain for markers of both 
biliary and hepatocyte cell lineages88.  A critical clue in deciphering the regulation of the TGF-β 
gradient is seen in the Hnf6 and Oc2 knockout mice.  It is known that these transcription factors 
modulate the expression of the TGF-β antagonists, follistatin and α-2-macroglobulin, and repress the 
expression of the TGF-β-receptor II gene.  The knockout mice see a strong downregulation in 
antagonist expression, while increasing the expression of the TGF-β type II receptor, leading to an 
increase in TGF-β signalling within these transgenic animals compared to their wildtype littermates98  
(Figure 12).  The model proposed by Antaniou et al. is that the TGF-β signalling gradient induces 
sequential differentiation of the cells on the portal side, followed by those on the parenchymal side of 
the duct90.  Further mechanistic evidence of TGF-β signalling in the development of the ductal plate is 
seen in the increased expression of SMAD5, a component of TGF-β/BMP signalling, within BECs 
that form the ductal plate.  This is in contrast to the expression of chordin, a TGF-β/BMP pathway 
antagonist, whose expression is seen throughout the liver. This gives corroborative evidence that 
TGF-β/BMP expression is limited to hepatoblasts that are in contact with the portal mesenchyme, and 
that its expression is regulated by chordin in those hepatoblasts that do not contribute to formation of 
the ductal plate103.  
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Figure 12.  TGF-β-gradient mediated restriction of hepatobiliary lineages. 
A radial gradient of TGF-β signalling is observed with high periportal expression that is gradually reduced 
towards the parenchyma.  High levels of Onecut factors and TGF-β signalling induce biliary epithelial cell 
differentiation.  Following maturation, there is a repression of TβRII expression due to TGF-β negative 
feedback.  Parenchymal hepatoblasts express low levels of the Onecut factors and are exposed to the lower 
levels of the TGF-β gradient, leading to their differentiation into hepatocytes.  Double knockout of HNF6 and 
OC-2 results in perturbation of their respective gradients leading to the generation of hybrid cells.   
 
In parallel to its modulation of the TGF-β signalling gradient, the cholangiocyte-specific transcription 
factor HNF6 has also been shown to regulate the expression of Hnf1β within cholangiocytes88.  
HNF1-β is required for cholangiocyte function, as its deficiency results in the paucity or absence of 
normal primary cilia used in cell sensory functions104.  Heterozygous mutations have been found to 
result in ductal plate malformations and cholestasis in humans105, while homozygous deletions result 
in ductopenia and bile duct dysplasia105.  Hnf6-/- mice showed the presence of hepatic bile deposits and 
increased levels of bilirubin, indicators of cholestatic syndrome induced by disrupted IHBD 
morphogenesis88.   Both HEX87 and HNF-688 also play integral roles later in development as they 
regulate HNF1-β during the process of remodelling of the ductal plate.  Furthermore, the BMP 
receptor-regulated SMAD5 has also been found to be highly expressed in those cells that form the 
ductal plate, whereas the expression of chordin, a TGF-β/BMP antagonist is highly expressed in cells 
that do not contribute to the formation of the ductal plate103.   
Another critical signalling pathway involved in the formation of the biliary tree is the Notch pathway.  
It is required for bile duct morphogenesis with biliary differentiation and tubule formation requiring 
dose-dependent signalling90. Notch has also been found to have a definitive role in the development of 
biliary tubules as a lack of biliary tubule formation is seen in Hes1 null mice at birth.  During liver 
development, expression of JAGGED-1 is restricted within the portal mesenchyme within the 
neonatal mouse, while NOTCH2 and HES1 expression is observed in cholangiocytes which reside 
adjacent to the JAGGED-1-positive cells106.  Taken together, these experiments have highlighted the 
role for several key signalling pathways in the initiation and maturation of hepatocytes and 
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cholangiocytes.  These factors and their temporal activation are tightly controlled and require 
activators, inhibitors, and the formation of periportal and perivenous gradients for normal 
development (Figure 13). 
 
Adapted from: http://www.stembook.org/node/512 
Figure 13.  Markers of biliary and hepatocyte differentiation. 
Bipotent progenitors express both hepatocytes and BEC markers.  TGF-β and Wnt signalling from the portal 
mesenchyme are suggested as promoting the expression of BEC-associated transcription factors, while 
suppressing hepatocyte-specific transcription factors.  Subsequent Notch, EGF and HGF signalling then 
reinforce the BEC lineage segregation.  Hepatoblasts within the parenchyma that are not exposed to periportal 
signalling are able to upregulate genes involved in hepatocytes differentiation.  Mature hepatocytes are derived 
through subsequent exposure to OSM, Dex, HGF, and Wnt. 
 
III)  Mortality and economic burden of liver disease  
For the body to maintain homeostasis, hepatic pathways and processes must be carefully controlled at 
the molecular level. The continual loss of homeostasis can result in the development of disease. 
According to the European Association for the Study of the Liver (EASL), approximately 0.1% of the 
European population is affected by cirrhosis, with 170,000 deaths per year, while the WHO attributes 
approximately 47,000 deaths per year in the EU to hepatocellular carcinoma.  The leading causes of 
cirrhosis and hepatic cancers are excessive alcohol consumption, hepatitis B & C, and metabolic 
syndromes consistent with obesity107.  On a global level, liver disease on the whole is on the rise.   
Therefore, distinctions at a molecular level between healthy and pathological states may give insight 
for novel pharmacological targets. The aim would therefore be to rectify aberrant signalling pathways 
and return hepatic homeostasis.  Both in vitro and in vivo models have been generated to assess and 
target relevant pathways involved in hepatic diseases.  These include the use of reporters which 
express a quantifiable marker in response to pathway activation such as β-galactosidase, 
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chloramphenicol acetyltransferase, or light-emitting luciferases.  In vivo, transgenic models have been 
invaluable in elucidating the pathogenic effects of particular genes, with more recent light-emitting 
luciferase transgenics used to study transcriptional regulation of pathways within a living organism.  
Interrogation and further investigation of these signalling pathways in vivo is important for drug 
targeting strategies for liver disease as appropriate modulation of these pathological signals may offer 
therapeutic benefit.  There is particular emphasis on increased predictability of in vitro assays prior to 
in vivo experimentation and decreasing the number of animals used within academic and industrial 
research in studies of liver disease.   
IV)  Instigators of inflammatory activation, ECM remodelling and fibrotic resolution 
a)  Role of NF-κB in liver tolerogenic responses and hepatic injury 
While particular transcription factors are required for the precise development of the liver, others are 
activated in response to various insults and are crucial to regain liver homeostasis and repair.  The 
nuclear factor-κB (NF-κB) signalling pathway is most frequently associated for its role in 
inflammation where, in the short term, it is immensely beneficial in wound-healing processes in 
response to acute injury by promoting regeneration.  Contrastingly, failed cessation of these 
inflammatory responses leads to chronic, long-term inflammation which has a negative impact upon 
the liver’s regenerative potential and results in an increased fibrotic phenotype.  The liver is unique in 
that it has a dual blood supply and not only receives blood from the hepatic arteries, but also receives 
a continuous supply of blood from the gastrointestinal tract via the portal vein.  Blood originating 
from the portal vein is therefore enriched for potential antigens108. The liver is a central 
immunological organ involved in the clearance of systemic bacterial infection as it hosts 
approximately 80% of the body’s macrophages.  NF-κB inducers include pathogen-derived molecules 
such as lipopolysaccharide (LPS), which originate from Gram-negative bacteria, and also exogenous 
DNA/RNA that stimulate Toll-like receptors (TLRs)109.  Inflammatory cytokines, tumour necrosis 
factor-α (TNF-α), and interleukin (IL-1)110, also have the capacity to activate  NF-κB signalling and in 
turn initiate the transcription of a host of genes involved in the regulation of inflammation, cell 
survival, and immune responses.   
NF-κB functions as a heterodimeric transcription factor controlling genes involved in immunity, 
inflammation, proliferation and the prevention of apoptosis.  The NF-κB family of transcription 
factors include RelA (p65), NF-κB1 (p50 and its precursor p105), NF-κB2 (p52 and p100), c-Rel and 
RelB 111.  These transcription factors are sequestered within the cytoplasm in an inactive state by an 
inhibitor of κB (IκBα) through the masking of nuclear localisation signals found on the NF-κB 
proteins.  Site-specific phosphorylation of IκBα by IKK results in IκBα proteasomal degradation and 
its dissociation from NF-κB.  Unmasking of the nuclear localisation signal allows NF-κB to 
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translocate into the nucleus, bind to NF-κB enhancer elements in gene promoters, and induce 
transcriptional expression of target genes112 (Figure 14).  
 
Figure 14.  Illustration of canonical NF-κB signalling in response to TLR agonists. 
Upon agonist binding to the TLR receptor, inhibitor of κB kinase phosphorylates IκB on conserved residues, 
thereby promoting IκBα proteasomal degradation. This exposes the nuclear localisation signal on the NF-κB 
heterodimer allowing its translocation into the nucleus and subsequent binding to its response element and 
activation of transcription of pro-inflammatory/anti-inflammatory genes. 
 
NF-κB has non-immune related roles in the maintenance of tissue homeostasis, but has also been 
implicated in the pathogenesis of many inflammatory diseases.  Dual-functioning NF-κB signalling 
not only leads to the expression of pro-inflammatory molecules, but is also capable of modulating 
anti-inflammatory signalling processes.  Kupffer cells exposed to normal physiological doses of LPS 
showed that NF-κB induces the expression of its direct target interleukin-10 (IL-10), an anti-
inflammatory cytokine, that subsequently downregulates the release of pro-inflammatory cytokine, 
IL-6 and TNFα and modulates the liver’s response to low antigenic levels113.   
b)  Kupffer cell activation  
Strong inflammatory responses may be beneficial in the short term to eradicate pathogens, however, 
long term activation of inflammatory signals may have deleterious effects.  In the context of low 
“physiological” level of LPS, Kupffer cells release anti-inflammatory cytokines such as IL-10113.  
TNF-α, IL-10, nitric oxide, and reactive intermediates all work to suppress T cell activation,  which 
may contribute to necessary hepatic immune tolerance since low levels of LPS exposure in the liver is 
ongoing114.  Inactivation of LPS is through deacylation by a lipase that removes the secondary fatty 
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acyl of LPS that is required for its recognition by the TLR4 receptor, thus preventing prolonged 
inflammatory responses in the liver115.  This state of tolerance can then be reversed by increasing 
stimulatory signalling through exposure to a sufficiently strong, pathogen-specific signal116.  In other 
contexts, such as high levels of LPS, Kupffer cells are able to secrete proinflammatory cytokines such 
as TNF-α, IL-6, IL-1β, or leukotrienes117.  These inflammatory mediators are involved in liver injury, 
since it has been shown that LPS alone does not harm hepatocytes118. This leads to the induction of 
hepatocyte apoptosis, activation of fibrogenic hepatic stellate cells, and the TNF-mediated activation 
of T-cells119.   Chronically activated Kupffer cells also produce the profibrogenic cytokines, TGF-β 
and monocyte chemoattractant protein 1 (MCP-1), which critically have the capacity to recruit 
inflammatory infiltrate in regenerating bile ducts120 and can activate quiescent HSCs and aid in their 
transdifferentiation to myofibroblasts121.  Seki et al. demonstrated using Kupffer-cell depleted mice, 
that Kupffer cells are required for HSC activation through their expression of TGF-β121.  Additionally, 
Kupffer cells produce platelet-derived growth factor (PDGF), TNF-α, IL-1β, and a host of other pro-
inflammatory and pro-fibrotic chemokines used to perpetuate the fibrotic response122.   
Kupffer cells and leukocytes have been shown to interact through intracellular adhesion molecule 1 
(ICAM-1), with ICAM-1 deficient mice having a reduced ability to regenerate after partial 
hepatectomy.  It is therefore proposed that the interaction of the Kupffer cells with leukocytes triggers 
a local inflammatory response, which subsequently leads to the Kupffer cell-dependent release of 
TNF-α and IL-6 which participate in the regenerative process123.  Gadolinium chloride is a metal salt 
known to depress the phagocytic activity of Kupffer cells through defective surface attachment and 
engulfment of debris124.  The use of gadolinium chloride to inhibit Kupffer cells was shown to prevent 
cholestasis, oxidative stress, necrosis, and fibrosis induced by the carbon tetrachloride induced model 
of hepatic injury125. 
c)  Hepatic stellate cell activation 
Within hepatic stellate cells, LPS causes the activation of IκB kinase (IKK), a crucial kinase involved 
within the NF-κB pathway that activates NF-κB signalling4.  It has been shown that LPS-mediated 
activation of the NF-κB signalling pathway within quiescent HSCs occurs specifically through TLR4, 
and not TLR2, to promote fibrogenesis.  The mechanism of fibrogenesis is two-fold.  Firstly, NF-κB 
signalling upregulates chemokine production and induces chemotaxis of Kupffer cells.  Secondly, 
LPS stimulation causes the downregulation of the pseudoreceptor, Bambi, which functions as a 
negative regulator of TGF-β signalling.  This in turn sensitises the HSCs to further TGF-β signalling 
and allows unrestrictive activation of the Kupffer cells
121
.  Cellular comparisons between the various 
cell types in healthy and injured livers are diagrammatically represented in Figure 15. 
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http://image.slidesharecdn.com/liverhistology-140827080532-phpapp01/95/histology-of-normal-liver-60-638.jpg?cb=1409126763 
Figure 15.  Cellular changes arising during liver injury. 
Within the normal liver, the quiescent stellate cells reside in the Space of Disse, however, in response to injury, 
they become activated and are the primary mediators in the deposition of extracellular matrix and the formation 
of fibrosis.  There is also a marked loss of fenestration between the sinusoidal endothelial cells
126
. 
 
d)  TGF-β-mediated ECM production and perpetuation of the fibrotic response  
The hallmark of liver disease is the excessive deposition of extracellular matrix proteins (ECM), such 
as collagen, in response to liver injury.  Recurrent/chronic injury results in deregulated wound healing 
leading to the accumulation of fibrotic tissue127.  One of the two cell types that contributes to ECM 
deposition are activated HSCs which produce the main source of matrix128, matrix metalloproteinases 
(MMPs) which are the zinc-dependent endopeptidases responsible for degradation of the ECM,  and 
MMP inhibitors responsible for regulating matrix degradation129.  Upon activation, HSCs are able to 
transdifferentiate from a vitamin A-storing cell to a more mesenchymal myofibroblastic cell whose 
phenotypic characteristics include increased cell migration, adhesion, and proliferation, expression of 
α-SMA, contractibility, increased rough endoplasmic reticulum, and the ability to secrete ECM130 
The cytokine TGF-βI is largely responsible for the transformation of hepatic stellate cells into 
myofibroblasts and is the main regulator of ECM synthesis and deposition during hepatic injury22.  It 
is synthesised as an inactive precursor that is unable to bind to its cognate receptor.  Once TGF-β is 
released from the cells, it associates with the protein, latency-associated protein (LAP), to form a 
small inactive complex.  This complex is subsequently bound to latent TGF-β binding protein 
(LTBP), a component of the ECM, which together then serve as a tissue reservoir of TGF-β131.  In 
response to injury, latent TGF-β is activated through the enzymatic processes involving plasmin132, 
integrin133, 134, thrombin135, or conformational changes, thereby liberating TGF-β136. 
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e)  Fibrotic resolution  
During the resolution phase of fibrosis however, the scar-associated macrophages become the primary 
source of MMP-13, which mediate the degradation of matrix, and a subsequent regression of 
fibrosis137, while also secreting TNF-related apoptosis-inducing ligand (TRAIL) which induces 
caspase 9-mediated HSC apoptosis138.  The remodelling of the liver matrix is reliant upon a fine 
balance of proteases and their inhibitors. Efficient wound healing requires the generation of plasmin 
from its precursor, plasminogen, by urokinase/tissue plasminogen activator (uPA).  The activity of 
uPA is regulated by the inhibitor, plasminogen activator inhibitor-1 (PAI-1).  These enzymes play a 
fundamental role in the proteolytic degradation of ECM and maintenance of organ homeostasis.  It 
has been demonstrated that TGF-β tightly regulates and increases the expression of plasminogen 
activator inhibitor-1 (PAI-1).  During the process of wound healing, PAI-1 is found to be elevated, 
leading to a decrease in uPA/tPA and plasmin-dependent MMPs.  In pathological conditions, PAI-1 is 
found to be massively increased in fibrotic tissues, while the lack of PAI-1 has been found to be 
protective against fibrosis131.   
 
Figure 16.  Regulators of ECM homeostasis. 
Degradation of ECM is regulated by plasmin and MMPs.  Inactive plasminogen, the precursor of plasmin, is 
activated by the serine proteases, uPA/tPA.  These proteases are negatively regulated by PAI-1 which in turn is 
positively regulated by TGF-β. 
 
V)  Mechanisms of regeneration  
a)  The ductular reaction 
Following initial insult and the liver’s attempt to reduce the accumulation of ECM, a number of other 
processes are initiated which are dependent on the type of injury.  For instance, in several in vivo 
models, the liver has been shown to possess immense regenerative potential following partial 
hepatectomy.  It has been demonstrated that the liver returns to exactly pre-partial hepatectomy size 
after a 2/3 partial hepatectomy, after which liver growth and cell proliferation are subsequently 
halted139.  During fulminant hepatic damage, a vast degree of regeneration occurs through the mitotic 
activity of the hepatocytes.  However, upon chronic injury, the proliferative ability of hepatocytes and 
cholangiocytes is halted by replicative senescence and the liver is no longer able to be reliant upon its 
potential to self-renew through cell division.  Instead, it relies on the capacity of a population of 
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bipotent hepatic progenitor cells (HPCs) to differentiate into either cholangiocytes or hepatocytes 
according to whether the hepatocellular or biliary compartment is predominantly damaged (Figure 
17).  This population of progenitor cells is found as a very small percentage of total liver mass within 
the normal liver; however, impaired replication of the liver parenchymal cells triggers a substantial 
activation and expansion of the HPCs as a compensatory mechanism to sustain the pace of 
regeneration that is required140.  Depending of the type of disease setting, the bipotent progenitors 
amplify to become cells which morphologically resemble cholangiocytes, hepatocytes, or 
intermediates of the two.  In general however, the hepatocyte-like cells predominantly reside along 
the parenchymal border, while the cholangiocyte-like-cells are more portally situated141.  Chronic 
activation of the HPC compartment in the liver leads to the presence of lesions, characterised by the 
presence of ductular epithelial cells along the margins of the portal tract observed histologically as 
ductular reactions (DR). The cells found within these reactions are in close contact with mesenchymal 
and inflammatory cells as well as a complex of ECM.  During the reactive process, the cells within 
the DR acquire novel functions including the ability to secrete growth factors, chemokines and 
cytokines142, which allow for integrated paracrine signalling between various cells within the reaction 
in an attempt to repair the damaged tissue. 
 
http://www.frontiersin.org/files/Articles/62272/fphys-04-00258-r2/image_m/fphys-04-00258-g001.jpg 
Figure 17.  Modes of liver regeneration in response to acute and chronic injury. 
During acute injury, hepatocytes or cholangiocytes are able to divide through mitosis to repair the damage.   The 
ability to proliferate through mitotic events is lost during chronic liver injury. Within the healthy liver, the 
hepatic progenitor cells reside in the canal of Hering.  During the process of chronic injury, these bipotent cells 
begin to proliferate and differentiate according to the hepatic compartment that is damaged, thereby regenerating 
the liver.  
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b)  The role of Sox9 during chronic liver injury 
Sex determining region Y-box 9 (Sox9) is a transcription factor known to be highly expressed within 
hepatic progenitors, with its expression seen to increase in differentiating cholangiocytes, while 
decreasing when directed down the hepatocyte lineage.   Embryonically, homozygous mutations in 
Sox9 result in early lethality while heterozygosity for loss-of-function mutations result in 
haploinsufficiency.   The lack of SOX9 expression results in campomelic dysplasia, an autosomal-
dominant disease characterised by skeletal malformation, XY sex reversal, and neonatal lethality, 
indicating a dosage requirement for Sox9 during organogenesis143.  
Sox9 has also been found to have a fundamental role in the development of the bile duct.  Duct 
formation begins with a primitive ductal structure which contains Sox9+ cholangiocytes on the portal 
side and Sox9- hepatoblasts on the parenchymal side.  Following a TGF-β-mediated maturation step, 
the biliary tube is composed exclusively of Sox9+ cholangiocytes. Liver-specific inactivation of Sox9 
in mice results in delayed duct formation and an abnormal persistence of TβRII expression within the 
portal side of ductal plate, highlighting the temporal role of Sox9 in biliary morphogenesis90.  Lineage 
tracing following multiple models of hepatic injury have shown the contribution of Sox9+ precursors 
in liver regeneration by producing a transgenic model which permanently labelled Sox9-expressing 
cells and their progeny through LacZ expression following tamoxifen induction.  In response to either 
carbon tetrachloride (CCl4) or bile duct ligation the number of X-gal lineage-labelled hepatocytes 
increased, spreading from the portal field to the central vein, as depicted in the streaming liver 
hypothesis.  Induction of either hepatic injury did not induce SOX9 expression within hepatocytes or 
endothelial cells, but rather was restricted to those cells which positively stained for cytokeratin, 
indicating their ductal cell origin.  SOX9-expressing cells were also detected in proliferating duct 
cells.  The data presented by Furuyama et al. indicates that Sox9+ precursor cells contribute to 
hepatocyte differentiation during the regenerative process in response to these models of hepatic 
disease144.  Within human fetal hepatocytes, Hanley et al. illustrated aberrant expression of SOX9 
increased the expression of several genes that encode ECM components, including COL2a1, and 
COMP1.  Inappropriate ECM deposition results in fibrosis and the role of Sox9 within the fibrotic 
environment were further interrogated.  The same authors showed that in vitro, hepatic stellate cells 
transdifferentiated to myofibroblasts in response to increased TGF-β signalling.  This led to an 
increase in Sox9 expression and caused the production of the major ECM component, Type I 
collagen, the predominant collagen type seen in organ fibrosis.  Lastly, they demonstrated that Sox9 
expression is increased during the activation of hepatic stellate cells in response to TGF-β signals145.   
More recently, in vivo models of fibrosis and in vitro experiments utilising culture-activated HSCs 
have shown that SOX9 colocalises with Osteopontin (OPN), an important component of the ECM 
used as a biomarker of fibrosis severity.  SOX9 was shown by Pritchett et al. to bind to a conserved 
  
CHAPTER 1 – GENERAL INTRODUCTION                                                                                         25 | P a g e  
 
region, upstream of OPN and regulate its expression.  This study also suggested that Hedgehog 
signalling lies upstream of Sox9 and that the loss of SOX9 resulted in a significant decrease in 
downstream OPN production146.   
 
Figure 18.  Regulation and downstream targets of Sox9. 
Sox9 has been found to be regulated by a number of molecular pathways.  Subsequently, it is able to induce 
expression of the pro-fibrotic cytokine, osteopontin.  Furthermore, it is also able to negatively regulate the Wnt 
signalling pathway and Wnt downstream targets, such as cyclin-D1 and c-myc.  
 
c)  Osteopontin as a pro-fibrotic mediator  
OPN has increasingly been of interest in the development of fibrogenic events.  It is a pleiotropic 
cytokine able to both induce cell motility and also cause persistent inflammation 147.  Within recent 
years, OPN has been implicated in the pathogenesis and progression of multiple liver diseases148, with 
marked induction observed in various biliary fibrosis models including BDL149, 150.  This 
glycophosphoprotein acts as a neutrophil chemoattractant by binding to integrin receptors, and is also 
involved in the generation of the ductular reaction.  It does this through stimulation of HPC 
proliferation and migration, while also decreasing the ability of hepatocytes to proliferate.  The cells 
within the DR, including HPCs, produce OPN and mediate the recruitment and activation of the 
hepatic stellate cells.  Evidence shows that OPN is expressed in hepatic stellate cells and is involved 
in the upregulation of collagen I production which, synergistically with activated TGF-β signalling, 
causes increased collagen deposition151.  Corroborative evidence for the involvement of OPN in the 
increased severity of DR and fibrogenesis has been shown by Coombes et al.  They demonstrated, 
through administration of OPN-neutralising antibodies, that there was a significant attenuation of the 
liver progenitor cell response, a reversal of EMT within Sox9+ cells, and a reduction in severity of 
hepatic fibrosis152 (Figure 19).  Further understanding and modulation of osteopontin and its 
regulators has the potential to be utilised as an antifibrotic therapy, and thus continues to be a topic of 
active investigation in liver fibrosis research.  
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Strazzabosco M et al. Gut 2014;63:1693-1694 
Figure 19.  Role of osteopontin in regulation of the ductular reaction. 
Chronic injury causes cells within the ductular reaction to produce OPN.  This stimulates the recruitment of the 
HSCs and their transdifferentiation to myofibroblasts which induces TGF-β signalling and subsequent matrix 
deposition.  OPN also blocks proliferation of hepatocytes.  Addition of aptamers or neutralising antibodies 
causes cessation of crosstalk between the cells in the ductular reaction and increases hepatocyte proliferation. 
 
d)  Role of WNT and Notch signalling in the regenerative response   
As the liver attempts to regain homeostasis, a number of cells and signalling pathways are activated in 
order to obtain fibrotic resolution and regenerate damaged hepatic compartments.  The cells 
responsible for the regeneration of the parenchymal cell types are the bipotent hepatic progenitor 
cells.  According to Boulter et al. who published a defining paper on the role of Wnt and Notch 
signalling during hepatic regeneration, differentiation of these hepatic progenitors is directly specified 
through their interaction with either myofibroblasts or macrophages.  HPCs have been shown to 
differentiate into cholangiocytes through their direct interaction with activated myofibroblasts 
expressing JAGGED-1, a Notch signalling ligand.  Alternatively, to facilitate hepatocyte regeneration, 
phagocytosis of hepatocyte debris after injury induces expression of Wnt3a, which subsequently 
elicits canonical Wnt signalling within the HPCs.  This signalling results in the maintained expression 
of Numb, a cell fate determinant, and promotes the differentiation of the bipotent HPCs into 
hepatocytes40.  Spee et al. have also shown in human specimens, strong activation of the Wnt pathway 
in microdissected HPCs isolated from livers which had undergone parenchymal liver disease, either 
acute necrotising hepatitis or chronic hepatitis C induced cirrhosis.  They suggest that increased WNT 
signalling is required for the activation/expansion of the progenitor cell niche.  In contrast, those 
HPCs isolated from livers which had primary biliary cirrhosis were found to have high levels of 
Notch signalling, proposed to drive the HPC cell fate towards the cholangiocyte lineage 153 (Figure 
20).  As an alternative to orthotopic liver transplantation, liver gene therapy and ex vivo differentiation 
of stem and progenitor cells is the focus of many cell and gene therapies for a host of hepatic diseases. 
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Figure 20.  Activation of WNT and Notch signalling in HPCs induces hepatocyte and cholangiocyte 
differentiation respectively. 
TGF-βI induces stellate cell transdifferentiation and the expression of the Notch activator, Jagged-1.  Through 
cell-to-cell interactions of the HPC with the activated HSC, notch signalling is activated and the cells are fated 
to become cholangiocytes.  If however, the HPCs are exposed to exogenous macrophage-secreted Wnt3a, the 
cells undergo differentiation towards hepatocytes. 
VI)   Types of biliary diseases 
Although there are a number of liver diseases, the focus of this thesis is specifically on those 
involving the biliary tract, more specifically, those that exhibit a cholestatic phenotype.  The term 
cholestasis is derived from Greek where it literally means “a standing still of bile”.  Rupturing of the 
biliary canaliculi may result in the presence of histological “bile lakes” seen amongst the liver 
parenchyma.  Disruption of bile flow can occur through impaired secretion of bile by the hepatocytes, 
or by obstruction in the intra- or extrahepatic bile ducts154.  Due to its amphipathic properties, the 
accumulation of bile within the liver due to bile duct dysfunction causes hepatocyte apoptosis and 
necrosis due to its highly cytotoxic nature when present at high concentrations, leading to fibrosis and 
eventually cirrhosis16.  Serum concentrations of conjugated bilirubin and the two liver enzymes, 
alkaline phosphatase and gamma-glutamyl transpeptidase (GGT), are typically elevated and used as 
biochemical markers of cholestatic pathology155. Clinical manifestations of cholestasis include 
jaundice, pruritus (itching), malabsorption, pale stools, dark urine, and abdominal pain.   Jaundice is 
the yellowish pigmentation affecting the skin, sclera, and mucous membranes.  Failure of bilirubin 
removal from the body leads to excess bilirubin in the blood (hyperbilirubinaemia)156. The 
development of conjugated hyperbilirubinaemia occurs during the development of biliary 
obstruction157, while unconjugated hyperbilirubinaemia is caused by a number of diseases such as 
hemolysis, Crigler-Najjar syndrome, and Gilbert syndrome158.  In both cases, however, evidence of 
jaundice is present.  Conjugated bilirubin has a lower binding affinity for albumin, and during 
obstructive cholestasis may overflow from the liver.  The kidney becomes the predominant mode of 
excretion through the urine and, due to its pigment, makes the urine dark in colour20.  Other than 
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surgical intervention, one of the most common modes of treatment for cholestatic disease is bile salt 
therapy using ursodeoxycholic acid (UDCA) which prevents or delays the progression of the 
disease159.  Evidence indicates the mechanism of action to be three-fold through 1) cytotoxic 
protection of cholangiocytes from hydrophobic bile acids, 2) stimulation of hepatobiliary secretion to 
remove excess bile salt through upregulation of transporter proteins, 3) anti-apoptotic and survival 
pathway activation in hepatocytes160.   Clinical management of cholestasis also includes vitamin 
supplementation to counteract fat-soluble vitamin deficiency due to fat malabsoption161.  Although 
many of the clinical symptoms and management of cholestatic diseases is largely uniform, the 
aetiology, comorbidities, and histopathology of these diseases varies greatly, with examples of 
intrahepatic, extrahepatic, and genetic causes of cholestasis highlighted below. 
 
a)  Primary sclerosing cholangitis and inflammatory responses  
Primary sclerosing cholangitis (PSC) is a progressive cholestatic disease resulting from chronic 
inflammation.  Inflammation of the ducts leads to obliterative fibrosis and cirrhosis ultimately ensues.  
Both the intrahepatic and extrahepatic bile ducts can be affected.  Histologically, PSC presents with 
typical periductal sclerosis seen as concentric fibrosis around the small interlobular bile ducts.  The 
layered “onion-skin” fibrosis progressively narrows and obliterates the ductal lumen.  A reduction or 
absence of bile ducts can also be accompanied by biliary hyperplasia and destruction of the limiting 
plate.  Other features include the presence of ductular reaction and mononuclear cell infiltrate162.   
 
b)  Primary biliary cirrhosis 
Primary biliary cirrhosis (PBC) is a progressive cholestatic disease with a prevalence of 40-400 per 
1,000,000, and peak incidence within the fifth decade of life163.  Interestingly, approximately 90% of 
those afflicted with the disease are woman, believed to be linked to the increased presence of 
oestrogen164.   PBC is a characterised by the presence of anti-mitochondrial antibodies (AMA) 165.  
The presence of inflammatory granulomas166 and damaged interlobular bile ducts is termed florid duct 
lesions, which are the sites of cholangiocyte proliferation167.  The destruction of the bile ducts is 
immune mediated, with cells of the immune system attacking and destroying the bile ducts, resulting 
in progressive ductopenia.  This causes scarring and subsequent obstruction of bile flow out of the 
liver. The bile thus accumulates within the liver and causes liver fibrosis which, if not resolved, may 
lead to cirrhosis168.  In contrast to PSC, however, there is no indication of bile duct dilatation or 
beaded appearance.  
 
  
CHAPTER 1 – GENERAL INTRODUCTION                                                                                         29 | P a g e  
 
c)  Biliary atresia 
Biliary atresia (BA), also known as extrahepatic ductopenia and progressive obliterative 
cholangiopathy, is a congenital disease which only occurs in infants.  Clinical presentation occurs 
within the first few weeks after birth without any gender predilection.  It is characterised by the 
discontinuity of the extrahepatic biliary system leading to biliary obstruction and end-stage liver 
disease.  BA is the most common cause of neonatal cholestasis and accounts for around 40-50% of all 
paediatric liver transplatations169.  The mean survival time without treatment is around 18 months; 
however the prognosis is substantially better in those with early diagnosis and treatment, with a 
survival rate of  90%170. Complete atresia is reliant upon liver transplantation as a definitive treatment.   
Although the aetiology of the disease is unknown, it has been hypothesised that an initiating event, 
induces apoptosis of the cholangiocytes.  In genetically susceptible individuals, exaggerated 
inflammatory response ensues, followed by an autoimmune response targeted against the 
cholangiocytes resulting in progressive injury of the bile ducts169.  The most plausible candidates of 
the initiating event, due to elevated antibody titers, appear to be reovirus type 3171, rotavirus172, herpes 
virus173, 174, human papillomavirus175, Epstein Barr virus176, and cytomegalovirus173.  Other causal 
candidates include exposure to toxins, autoimmunity, errors during liver development, or genetic 
mutations177-181. 
 
d)  Alagille syndrome  
Alagille syndrome (AGS) is an autosomal dominant disorder characterised by hepatic ductopenia, 
however there is comparatively reduced portal fibrosis, while progression to biliary cirrhosis is rare in 
contrast to most cholangiopathies182.  The occurrence of clinical abnormalities arise in cardiac, 
vascular, renal, facial, ocular, and central nervous systems183, 184.  Clinical features arising from 
hepatic disruption include cholestasis, jaundice, and pruritis. Approximately 80-90% 185, 186 of AGS 
patients have a mutation within JAGGED1, and less frequently a mutation in NOTCH2187.  Notably, 
AGS is histopathologically distinctive from other cholangiopathies in its near complete lack of HPCs 
and reactive ductular cells (RDCs).  Conversely, there is an increased presence of intermediate 
hepatobiliary cells182, which are cells that are phenotypically or morphologically intermediate between 
cholangiocytes and hepatocytes and may immunostain for markers of both188. These hepatobiliary 
cells do not express the Notch downstream target, HNF1β, a biliary-specific transcription factor, and 
are therefore unable to differentiate into mature cholangiocytes182.  Given the role of the ductular 
reaction in the fibrogenic response, it is not surprising then that the lack of this response results in 
reduced fibrosis such as is seen in AGS. 
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VII)  Animal model systems to study liver disease 
a)  Spontaneous mutation models of hepatic fibrosis 
One method of understanding the origins and progression of liver disease is by using animal models 
which manifest a similar phenotype to the one being studied.  The use of animal models has been 
instrumental in giving greater insight into disease pathogenesis, aiding the development of novel 
therapeutics.  Of particular interest have been the use of small rodents, due to their small size, 
comparatively reduced maintenance costs compared to other larger animal models, the similarity of 
organ systems in comparison to humans, and the similarity of diseases which affect both small rodents 
and humans. Some diseases within these small animal models have arisen through spontaneous 
mutation, through normal cellular processes which generate DNA-damaging free radicals as a by-
product of cellular respiration189, or through errors occurring during replication and repair.  A 
naturally occurring spontaneous mutation arose within the Cpk gene of the C57BL/6J mouse strain 
and is now a well characterised model of congenital polycystic kidney disease, which expresses a 
comorbid phenotype of hepatic fibrosis190. 
 
b)  Chemically induced models of cholestasis 
Various different methodologies allow researchers to mimic and better comprehend the 
pathophysiological and compensatory mechanisms associated with aberrant bile flow. The cholestatic 
phenotype can be induced through dietary supplementation with compounds such as the 
porphyrinogenic substance 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)191 or the xenobiotic, 
alpha-naphthylisothiocyanate (ANIT)192, which each have distinct phenotypes, but ultimately both 
lead to cholestasis.  DDC diet induced fibrotic models are widely used in the study of Mallory bodies, 
which are histopathology-determined inclusions seen within hepatocytes. These damaged 
intermediate filaments are a feature typically seen in alcoholic liver disease.  This model results in the 
presence of a strong ductular reaction within one week, and an increase in the cytokines, VCAM, 
osteopontin, and TNF-α all increased within the BECs.  The presence of mononuclear cell infiltrate, 
pericholangitis, and biliary fibrosis are characteristics of this model that are also observed within 
human primary sclerosing cholangitis191.  Another model of cholangitis is induced through the 
administration of the xenobiotic, ANIT, which is toxic and results in the loss of activity of biliary cells 
while also causes weakening of the tight junctions between hepatocytes193. Both models have been 
and continue to be extensively used to elucidate disease-associated mechanisms and possible 
therapeutic interventions. 
 
  
CHAPTER 1 – GENERAL INTRODUCTION                                                                                         31 | P a g e  
 
c)  Genetic models of hepatic fibrosis 
Although chemical induction induces a disease phenotype, underlying genetic contributions would be 
beneficial for specific drug targeting of particular aberrant pathways due to abnormal gene expression.  
Genetic technologies have been driven forward by the need for targeted gene disruption or gene 
insertion, now attainable through the use of site-specific nucleases which are able to alter the genome 
from which a transgenic animal originates. Examples of these genome-editing nucleases include 
meganucleases194, zinc finger nucleases (ZFNs)195, 196, transcription activator-like effector nucleases 
(TALENs)197, 198, and most recently engineered clustered regularly interspaced short palindromic 
repeats (CRISPR) technology199.  Genetically engineered rodents have been generated to model a 
huge diversity of human diseases including liver disease such as hepatic fibrosis200.  One such 
transgenic is the dnTGF-βRII mouse which contains a dominant-negative form of the TGF-β receptor 
whose expression is CD4-promoter regulated, restricting its expression specifically to T cells201. This 
model strongly recapitulates the inflammatory biliary disease seen in human primary biliary cirrhosis 
as it mimics the spontaneous production of anti-mitochondrial antibodies which target and interfere 
with the correct function of the mitochondria. This phenotypic hallmark of primary biliary cirrhosis 
has also been noted within the IL2Rα knockout mouse202.  A third model is the MDR2 model which 
has resulted from Abcb4 gene knockout.  This causes a decrease in the ability to excrete 
phosphatidylcholine into the bile and results in portal inflammation and the presence of ductular 
proliferation seen shortly after birth until end stage disease which occurs 3-6 months later. This model 
resembles phenotypic characteristics of sclerosing cholangitis and exhibits both biliary fibrosis and 
hepatocellular carcinoma203.  
 
d)  Surgical models of hepatic fibrosis 
Another method to induce rapid cholestatic liver injury is via surgical means. Bile duct ligation (BDL) 
is one of the most commonly performed experimental procedures used to induce obstructive 
cholestasis and fibrosis.  The most frequently used version of this model is complete ligation of the 
common bile duct, which causes a significant fibrotic response to all 4 liver lobes approximately 21-
28 days post-surgery204.  The procedure induces cholangiocyte proliferation, along with portal 
inflammation, hypertension, and deposition of ECM by transdifferentiated myofibroblasts, 
morphological changes seen in human forms of biliary cirrhosis204.   The drawback to using this 
technique is that it presents with a harsh phenotype and the mortality rate can be high due to 
infectious complications.  The procedure also requires a high degree of technical accuracy. An 
alternative version of this technique, termed partial bile duct ligation (pBDL) has been described205.  
pBDL is performed by inserting a needle into the common bile duct, followed by ligation using a 
suture. The needle is subsequently removed, resulting in a constricted lumen in the bile duct, thereby 
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allowing limited bile flow.  Heinrich et al. demonstrated histologically on 14-day post total bile duct 
ligation (tBDL) samples that there was significant portal-portal bridging fibrosis, inflammatory 
infiltrate, and ductular proliferation that was not seen in the pBDL model.  The important distinction 
between tBDL and pBDL models is that the cholestatic indicators, bilirubin and alkaline phosphatase, 
decreased to normal levels within 10 days following pBDL, but remained elevated in tBDL animals.  
pBDL is therefore a superior model, specifically of acute forms of the disease, as it causes cholestasis, 
but does so with minimal histologically-assessed tissue injury, and importantly, does not progress to 
chronic cholestasis205. A third surgical model can be used to generate a chronic cholestatic phenotype, 
but with a less severe phenotype, is achievable through ligation of the common bile duct distal to the 
right and caudal lobe (Figure 21).  This causes fibrosis in the median and left lobes, while mostly 
preserving the architecture and function of the right and caudate lobes206.  Some changes within the 
parenchyma of non-obstructed lobes has also been noted and attributed to paracrine and/or endocrine 
signalling207, 206.  This method improves the welfare of the animals, while still modelling the ductular 
reaction and proliferation of the progenitor cell niche in response to chronic injury.   
 
http://www.wjgnet.com/1948-5182/full/v4/i7/WJH-4-199-g004.htm 
Figure 21.  Schematic of ligation point for partial bile duct ligation disease modelling. 
Ligation of the common bile duct results in a severe phenotype.  Partial bile duct ligation yields the same 
fibrotic phenotype, but in only 2 of the 4 lobes.  The liver is ligated above the right and caudate lobes, 
obstructing bile flow only from the median and left liver lobes, which subsequently present with cholestasis and 
fibrosis
208
.   
 
VIII)  In vitro model systems of hepatic differentiation, disease, and pathway activation 
a)  HepaRG cells 
Prior to proceeding to in vivo experimentation, thorough in vitro analyses should be conducted.  For 
the data to be relevant, a suitable in vitro model is required.  In vitro cell lines offer a valuable 
alternative to using animals as a first-line means of experimentation.  They play a crucial role in 
elucidating molecular mechanisms of disease209, can be used in toxicity210 and xenobiotic metabolism 
screens211, and give mechanistic insight into differentiation212-214.   It is critical that the cell lines used 
  
CHAPTER 1 – GENERAL INTRODUCTION                                                                                         33 | P a g e  
 
in vitro mimic the in vivo model inasmuch as possible.  The scarcity, unpredictable availability, inter-
individual variability, and limited life-span of primary hepatocytes makes their use limited when 
continuous cell-culture material is required for experimentation215.    A vast majority of research 
involving hepatocytes has used the primary hepatocytes, HepG2 and Huh7 cell lines.  The use of 
hepatocyte cell lines circumvents the issue of availability, however basal levels of metabolising 
enzymes in HepG2216, 215, 217 and Huh7 cell lines217 are significantly lower than in primary cell lines.  
As an alternative, the HepaRG cell line has been utilised as it maintains many of the functional 
characteristics of primary human hepatocytes. This cell line was isolated from a human 
hepatocarcinoma which developed secondary to chronic hepatitis C virus (HCV) infection in 2002218, 
218 and has since been used in studies of bioartificial livers219, drug metabolism and toxicology220, 221, 
221, and HBV infection222, 223.  A unique attribute of this cell line is its ability to exist as a culture of 
hepatic progenitor cells when seeded at low density.  Upon confluence, these bipotent progenitors are 
able to terminally differentiate into hepatocyte-like cells which self-assemble into colonies222, or 
alternatively differentiate toward cholangiocytes224.  Hepatic functionality can be enhanced when the 
cells are grown to confluence in the presence of dimethyl sulfoxide (DMSO)218 and further induction 
of P450 activity is achieved through drug exposure, typically omeprazole, phenobarbital, and 
rifampicin225.  More recently it has been shown that the proportion of cholangiocytes within the 
culture could be enriched by altering the culture media224.  It is also known that HepaRG cells are 
capable of dedifferentiating and subsequently transdifferentiating into hepatocyte or biliary lineages 
via a bipotent progenitor 226. Genetic manipulation of this cell line can thus be used to determine 
which pathways affect their differentiation potential and has been employed to generate data within 
this thesis.  Using HepaRG cells could therefore be a valuable model for gaining insight into bile duct 
development, mechanistic elucidation of cellular processes, and the development of potential 
therapeutics for cholangiopathies.   
 
b)  Genetic reporters  
Once an appropriate cell line has been chosen, a quantitative method of functional output is required 
in order to study the molecular changes occurring within the cells.  This can be in the form of secreted 
growth factors or chemokines, or in the case of gene regulation, luciferase expression.  Luciferase is 
an ideal marker of transcriptional activity as it is highly sensitive and is not endogenously expressed 
within cell lines.  The firefly luciferase (FLuc) from the North American firefly, Photinus pyralis, was 
the first to be cloned and characterised 
227
 .  Since its induction into the world of molecular biology, 
it’s broad-scale applicability has seen it become a powerful tool in studies ranging from investigating 
cancer228, cardiac regneration229, neurodegeneration230, monitoring of infectious disease231, and 
tracking cell fate and function232 to name but a few.  Importantly, innovative design and diverse 
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applications utilising FLuc allow non-invasive, repeated, longitudinal collection of data that can also 
be applied to in vivo experiments.233  The use of these reporters, combined with the use of DNA 
response elements which confer particular transcription factor binding and gene regulation, has shown 
increasing applicability within biological research.  This is due to the non-invasive nature of data 
collection within animal models of disease.  This concept shall be one of the main research focuses of 
this thesis, with novel developments and proof-of-concept work detailed in subsequent chapters, with 
particular emphasis within a cholestatic disease model.  
 
i)  Properties and reaction of firefly luciferase  
The use of luminescence as a quantitative measure of gene regulation is dependent upon the presence 
of the enzyme’s substrate, D-luciferin. When D-luciferin is present, firefly luciferase is able to 
catalyse an oxidative reaction, provided there are a number of other exogenous cofactors available for 
the bioluminescent reaction to commence.  These factors include adenosine triphosphate (ATP), Mg2+, 
as well as molecular oxygen.  The first of this 2-step process involves the condensation of luciferin 
and ATP to produce luciferyl adenylate and inorganic pyrophosphate (PPi).  Subsequently, the 
reactive luciferyl adenylate is oxidised and decarboxylated to form oxyluciferin with the production of 
an electronically excited product and the release of adenosine monophosphate234 (Figure 22).  When 
the excited oxyluciferin intermediate returns to its ground state, it releases a photon of light in the 
process to produce visible light235.   
(1) D-luciferin + ATP  luciferyl adenylate + PPi 
(2) luciferyl adenylate + O2  oxyluciferin + AMP + light 
 
 
http://pubs.rsc.org/services/images/RSCpubs.ePlatform.Service.FreeContent.ImageService.svc/ImageService/Articleimage/2009/CC/b908346d/b908346d-s1.gif 
 
Figure 22.  D-luciferin oxidation reaction mediated by firefly luciferase. 
The oxidation of D-luciferin leads to the production of oxyluciferin and a photon of light, mediated by the 
firefly luciferase.   
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FLuc in particular is a good biomarker as it does not require post-translational modifications, and its 
half-life both in vitro and in vivo is approximately 3 hours, allowing adequate timing for analysis236. 
The range of light emission from FLuc is in the range of approximately 530-640 nm, with a maximal 
peak occurring at 560 nm237.  Its substrate, D-luciferin also has numerous advantages, not limited to 
having the option of several routes of administration, rapid diffusion through most tissues and cell 
types, and relative stability, all of which contribute to ease of image capture235.   Due to the varying 
contexts in which luciferases are used, development of modified and alternative luciferases has been 
crucial in the evolution of bioluminescence imaging technology within the last decade. 
 
ii) Genetically engineered luciferases  
a)  Firefly luciferase enhancements 
Since molecular methods which employ luciferase as a tool occur outside of its natural firefly host, 
many luciferase constructs have been improved for mammalian expression by a process known as 
codon optimisation. The genetic code is degenerate in nature, and this feature makes it possible to 
produce an amino acid sequence which is identical, but producing this by tRNAs that are 
preferentially used within the recipient organism. Codon usage bias results in higher levels of 
translation efficiency and accuracy due to optimised translation processes related to the relative 
abundance of particular tRNA isoforms238.  FLuc DNA has been further enhanced by removal of 
cryptic splice sites, sequence repeats, and local hairpin structures to increase mRNA stability233.  
Furthermore, Tisi et al. have developed and performed in vivo screening of luciferase mutants and 
identified a superior FLuc mutant which has improved pH-tolerance and increased resistance to 
thermal inactivation up to 45°C.  This mutant contains 5 non-synonymous mutations, substituting the 
bulky hydrophobic, solvent-exposed amino acids for hydrophilic ones, namely F14R, L35Q, V182R, 
I232K, and F465R without any accompanying loss of specific activity.  These mutations are thought 
to exert a cumulative positive effect on pH and thermostability by stabilisation through electrostatic 
interactions.  They were also shown to confer longer enzyme half-life compared to the wild-type 
luciferase239.  These improved features offer significant advantages of the TISIx5 mutant luciferase 
over its wild-type predecessor, particularly for in vivo applications.  
 
b)  Red-shifted Renilla luciferase 
Luciferases originating from the sea pansy Renilla reniformis (Rluc), and numerous other ocean-
derived organisms oxidise an imidazopyrazinone-based luciferin, coelenterazine, which releases light 
within the blue-green range of the spectrum at a wavelength of 480 nm240.  The use of RLuc over 
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FLuc has been employed in experiments where the ATP-dependence of FLuc would be a limiting 
factor or where ATP stores are lacking, since RLuc is able to catalyse the oxidation of coelenterazine 
in an ATP-independent manner241. 
The use of short-wavelength blue-green light emitted by RLuc within an in vivo environment is 
largely limited by the preferential absorption of this light by biological tissues.  One of the issues 
occurring within bioimaging of deep tissues is that the pigmented molecules, such as haemoglobin, 
readily absorb and scatter the produced light within the blue to yellow ranges, which results in 
inadequate transmission of light through the tissues.  This leads to decreased image sensitivity and 
spatial resolution242.  There is approximately a 10-fold decrease in RLU per cm of tissue243, with the 
main sources of light absorption being haemoglobin and myoglobin242.  Decreased absorption by these 
molecules occurs with light emitted at wavelengths >600 nm, in the red to infrared range of the 
spectrum.  Light emitted in this range is able to penetrate through several centimetres of tissue,  but 
with a peak spectral emission occurring at around 481 nm, only around 3% of the photons emitted 
from native RLuc are above wavelengths of 600 nm, making longer wavelength, red-shifted reporters 
an attractive alternative to unmodified renilla  for use in in vivo bioluminescence imaging, particularly 
within deep or haemoglobin rich organs237, 242, 244.  A particular red-shifted renilla (RS-RLuc) variant 
has been generated which has a 54 nm spectral redshift, allowing for an increased proportion of 
photons to be emitted over the critical 600 nm wavelength245. 
 
c)  Vargula luciferase  
Vargula luciferase is the luciferin found in the nocturnal sea ostracod Vargula hilgendorffii which 
naturally inhabits the waters of Japan where is more commonly known as “umi botaru” or the “sea 
firefly”.  Historically, vargula has also been named cypridina, owing to the fact that it belongs in the 
family Cypridinidae246.  In the presence of molecular oxygen, vargulin, its substrate, is able to be 
oxidised in the absence of ATP, and gives of light with a peak emission of around 452 nm.  
Interestingly, Thompson et al. showed through sequencing of the vargula gene, that it contains a 
signal sequence for secretion, and went on to show that vargula luciferase was secreted from 
mammalian cells into culture media and is well suited as a specific and highly sensitive reporter247.  
Vargulas’ undoubted advantage over non-secreted luciferases is its ability to permit live cell 
monitoring and longitudinal collection of gene expression profiles without the need to lyse the cells.   
 
d)  Nanoluc luciferase 
NanoLuc® (NLuc) luciferase is a small luciferase of only 19 kDa, isolated from the deep sea shrimp 
Oplophorus gracilirostris where it is used as a defence mechanism against predation.  The sequence 
has been isolated and cloned, with the aim of producing a luciferase capable of producing a sustained 
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signal with high sensitivity and low background interference.  Following multiple rounds of 
mutagenesis, this enzyme was engineered to have improved luminescence and stability, and has been 
optimised for mammalian expression through codon-optimisation.  Further optimisation was 
performed by nucleotide substitution to remove potential mRNA secondary structures, transcription 
factor binding sites, and also potential splice sites.  NLuc utilises the substrate coelenterazine, or its 
more stable derivative furimazine, in an ATP-independent reaction. The reaction produces 
luminescence with an emission maximum at 454 nm and a signal half-life of >2h.  In contrast to the 
flash luminescence produced by FLuc, RS-RLuc, and vargula, which occurs quickly within seconds 
or minutes and has a very short, intense signal, NLuc produces a glow-type luminescence which is not 
as bright, but can be sustained for hours.   Using a secretion signal from the human IL-6 protein, a 
signal sequences was appended to the N-terminus of the reporter, allowing it to be secreted out of the 
cell.  From a cell culture perspective, this allows for data collection without the necessity for cell 
lysis. The secreted NLuc has also been designed to have increased thermal stability, maintaining its 
enzymatic activity up to 55°C and for >15 hours at 37°C in culture media248.  Below are the features 
for each of the 4 luciferases, firefly, red-shifted renilla, vargula, and NanoLuc (Table 2).  The above 
mentioned reporters and models can be combined in order to generate a unique platform with which 
to perform continuous analysis of signalling pathway activity within cell culture and living animals.  
Improvement on current methodologies can therefore result in the generation of more robust data with 
a concurrent reduction of animals being used for each experiment. 
 
Table 2.  Features of the firefly, red-shifted renilla, vargula and NanoLuc luciferases. 
  LUCIFERASE   
 FEATURES Firefly  Red-shifted Vargula NanoLuc 
 Luciferase Renilla Luciferase Luciferase 
Substrate D-luciferin Coelenterazine Vargulin 
Coelenterazine or  
furimazine 
Protein half-life 3 hours 49 hours 60 hours >15 hours (in culture) 
Half-life in flash assay 
Flash-type 
Luminescence; 
>30 minutes 
Flash-type 
Luminescence; 
5 minutes 
Flash-type 
Luminescence; 
30 minutes 
Glow-type 
Luminescence; 
>2 hours 
Emission wavelength 549 nm 535 nm 460 nm 454 nm 
 
  
  
CHAPTER 1 – HYPOTHESIS, AIMS AND OBJECTIVES                                                                  38 | P a g e  
 
Hypothesis 
 
1) Tissue specific luciferase bioimaging can be used to quantify transcription factor activity in 
vivo. 
 
2) Longitudinal liver specific luciferase bioimaging will provide new insights into the temporal 
activity of transcription factors following partial bile duct ligation. 
 
3) Bipotent hepatic progenitor cell differentiation can be influenced by genetic manipulation of 
Notch signalling. 
Aims and Objectives: 
1) Design novel bicistronic luciferase vectors for in vitro and in vivo use by generating a parental 
luciferase construct containing the Gateway™ cassette upstream of luciferase-2A-eGFP. 
 
2) Validate biosensing reporter constructs in vitro by assessing luciferase expression over time 
in stably transduced cell lines in response to known agonists/inhibitors. 
 
3) Perform proof of concept somatotransgenic bioimaging using CD1 and TLR4-/- mice 
transduced with the NF-κB reporter and challenged with LPS. 
 
4) Investigate temporal signalling profiles of NF-κB, GFAP, TGF-β, Notch, and Wnt signalling 
in a mouse model of cholestasis induced by pBDL. 
 
5) Assess the effects of Notch signalling on differentiation potential in vitro using the hepatic 
progenitor cell line, HepaRG.  Cells constitutively expressing Jagged and Numb will be 
compared for their differentiation potential using qualitative and quantitative markers of 
hepatocytes and cholangiocytes. 
 
6) Assess the effects of Sox9 ablation on differentiation potential utilising CRISPR/Cas genome 
editing technology to generate a homozygous knockout cell line and assessing differentiation 
potential using qualitative means. 
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CHAPTER TWO 
DEVELOPMENT OF BIOSENSING REPORTER 
TECHNOLOGY  
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2.0  Introduction to disease modelling using genetic reporters 
2.0.1  Conventional analysis of disease 
Even though the use of animal models has proved to be invaluable for gaining greater insight into 
disease processes, pathogenesis and potential therapeutic targets, the use of biochemical markers as 
the means of determining disease status has many shortcomings. One of the greatest drawbacks is the 
necessity of generating a large cohort of diseased mice to achieve statistical significance.  Several 
animals would need to be culled at each of several time points in order to perform biochemical and 
histological analysis for determination of the extent of disease progression or regression.  This process 
not only requires the use of a large number of animals for each experiment, but a substantial amount 
of time would be required to harvest and process each of the samples (Figure 23).  Important to note 
is the discontinuous nature of such an experiment, with each data point being represented by a single 
animal.  With the large amount of inherent inter-animal variation, this would decrease the probability 
of obtaining statistical significance.  Continuous assessment of current protocols should be performed 
in line with the principles of humane animal research through improved methodologies, experimental 
design and appropriate statistical methods.  
 
 
Figure 23.  Experimental design of conventional disease model with terminal analysis. 
A subset of the animal cohort is sacrificed at each time point to perform molecular analysis and determine 
disease progression/regression. Image courtesy of Dr. Simon Waddington. 
 
2.0.2  The principle of the 3Rs of animal research  
The concept of the three Rs is a set of principles which have been set out to diminish the number of 
animals used in scientific research.  The principles were first introduced by Russell and Burch in 
1959249 and since then have become widely adopted. The three R’s are reduction, refinement, and 
replacement.  The aim when utilising animals for research purposes is to reduce the number of 
animals required by using methods which obtain the same amount of data from fewer animals, or 
obtaining more information from the same number of animals through improved experimental design, 
bioinformatics resources, or alternative techniques.  Refinement refers to the altering of current 
methodologies to ones which inflict less suffering or distress upon the animals for example through 
using less invasive techniques, while replacement aims to substitute existing experiments involving 
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animals with alternatives in which animals are no longer required250. The use of luciferase as a 
reporter for gene expression is just one example in which the 3Rs can be implemented to reduce the 
number of animals required. 
 
2.0.3  Whole-body, light-emitting transgenic animals for continual bioimaging of disease  
To address the failings of terminal analysis, various models of light-emitting transgenics have been 
developed to facilitate non-invasive monitoring of disease states in vivo251-253. This is achieved 
through the addition of a synthetic construct within the animals which consists of a response element 
containing pathway-specific transcription factor binding sites upstream of the firefly luciferase gene.  
In response to particular disease stimuli, a specific biochemical pathway becomes activated, causing 
the recruitment and binding of nuclear transcription factors to their respective response elements, the 
region of the promoter which is able to bind specific transcription factors.  This induces transcription 
factor-mediated expression of the downstream luciferase gene (Figure 24).  Bioluminescence is 
captured by a highly-sensitive charge-coupled camera able to detect the visible light emitted from the 
organs of the animals.  The bioluminescent image is then superimposed upon grey-scale photographic 
images of the animal to localise the emission signal. Therefore, quantifiable light emission can be 
used as a substitute marker of pathological molecular pathway activity without the need to cull the 
animal, a technology known as bioluminescence imaging. 
Using this novel technology, it is possible to monitor, in a continual, non-invasive fashion, processes 
in numerous disease models including bacterial infections254, arthritis255, and LPS-induced liver256 and 
brain inflammation257.  Given that mammalian cells are devoid of endogenous light, even diminutive 
quantities of bioluminescence can be detected, making bioimaging an extremely sensitive 
investigative method during even the early stages of disease.  These benefits make bioimaging a 
useful tool for investigating biological processes with the required sensitivity.  It also makes temporal 
analysis within the same animal possible, even during the early stages of disease.  
 
Figure 24.  Illustration of germline transgenic concept. 
Disease is induced in mice containing a luciferase driven by a disease-specific promoter.  Promoter activation 
results in increased luciferase expression.  Therefore, the amount of light generated is proportional to the 
amount of disease activation.   Courtesy of Dr. Simon Waddington. 
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Benefits of bioluminescence imaging within germline transgenic animals 
There are many advantages of using bioluminescence imaging to analyse disease progression and 
potential therapeutics within animal models.  Firstly, biological variation is substantially reduced 
since each animal is imaged at numerous different time points.  This means that each animal acts as its 
own internal control and can be used to normalise its own luminescent signal237.  This reduces the 
number of animals required to obtain statistical significance and is in line with upholding the 
principles of the 3Rs. This methodology is in contrast to studies in which terminal, post-mortem 
analysis is required, which limits the use of a single animal to one specific time point, resulting in the 
requirement for a large initial cohort of animals258.  Secondly, there are economic benefits in the form 
of a reduction in animal usage. Thirdly, from a technical standpoint, the ease of analysis is beneficial.  
Conventional analysis requires a high level of expertise in a wide range of molecular biology 
techniques.  In contrast, the process of bioluminescent imaging only requires the administration of 
substrate, D-luciferin, followed by the imaging of the animals within a light-tight imaging chamber, 
which requires relatively little technical knowledge.  Data is captured (usually within less than 5 
minutes), making this a rapid means of obtaining and processing data.  
 
Disadvantages of bioluminescence imaging in germline transgenics 
Despite improved ability for deep-tissue analysis using germline transgenic rodents, several inherent 
drawbacks impede the broader-scale implementation of bioluminescent technology within research.  
One of the major factors is the time required to generate the desired light-emitting transgenic animal.  
For example, the generation of the line can take as much as 8-14 months to produce, while 
backcrossing of the animals onto the preferred background strain may increase this to up to 24 
months, and is a very time consuming process.  There is also a high degree of technical expertise that 
is required in order to perform the procedures259.  The cost implications are also substantial as both 
interim and maintenance of the colony is required.  One of the more inherent disadvantages is the lack 
of tissue-specific expression, due to the fact that the luciferase construct is ubiquitously expressed 
within every cell in the body.  This can result in high background expression of the luciferase 
transgene, and may confound interpretation of the data (Figure 25).   
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Figure 25. Germline transgenic animal models used in whole-body bioluminescent imaging. 
The main disadvantages of light-emitting, germ-line transgenic animals is the time, cost, lack of sensitivity, and 
wastage of animals during the process of developing the desired transgenic.  Illustration courtesy of Dr Simon 
Waddington. 
 
2.0.4  Somatotransgenic Bioimaging (SomaBio) 
As a means of addressing the lack of organ specificity while still maintaining the prior mentioned 
positive attributes of whole-body bioluminescent imaging, several modifications to the technology 
have been developed and are presented within this thesis.  This has led to the generation of somatic 
transgenic animals which have many technical benefits over their whole-body transgenic 
predecessors.  Generation of the somatic transgenic rodents relies on administration of an HIV-based 
lentiviral vector260.  In recent years, lentiviral vectors have been developed and enhanced as gene 
delivery tools.  Using lentiviruses results in the transduction and long-term expression of a desired 
gene, with targeting of these vectors already achieved in the lung 261, neurons 262, liver, muscle 263, and 
heart 264.  In the context of somatotransgenesis, lentiviral vectors are designed to specifically deliver a 
construct containing the luciferase reporter gene into the organ of interest particularly during the late 
fetal or early neonatal period of rodent development (Figure 26).  The immune system of these 
animals is immature, facilitating tolerance towards the exogenous luciferase protein and enhancing 
transduction264. It should also be noted that due to the larger vector:body mass ratio, that a larger 
proportion of a specified organ can be transduced.  Progeny of the transduced cells will give rise to 
cells which also contain the transgene, and so the initial transducing units used is able to have a 
greater transduction potential merely due to DNA replication and cell division compared to viral 
delivery performed directly in an adult animal.  It would therefore be beneficial to target the 
expanding stem cell niche within neonatal / fetal animals.  
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Figure 26.  Illustration of the concept of somatotransgenic bioimaging. 
Somatotransgenic bioimaging is achieved through viral transduction of the animal with the luciferase reporter 
gene during the neonatal period.  Photonic output is measured over a series of time points to determine pathway- 
specific signalling activity.  Illustration courtesy of Dr Simon Waddington. 
 
Advantages of Somatotransgenic technology  
There are several advantages of using a technological platform such as somatotransgenic bioimaging, 
each of which addresses a particular drawback of prior methodologies or technologies.  These benefits 
are summarised below: 
i)  Long-term expression 
Compared to other gene transfer vectors, such as adeno-associated virus (AAV) and adenovirus, the 
lentivirus is a retrovirus that is able to reverse transcribe its RNA genome into a cDNA copy through 
the use of reverse transcriptase, the product of which then becomes stably integrated into the genome 
of the host265.   In contrast to moloney leukemia virus266, it is able to do so in non-dividing cells267.  
This results in permanent expression of the transgene, a characteristic which has seen it become a 
popular choice of viral delivery. 
ii)  Organ and tissue specificity 
Vector specificity for its target is a critical requirement for more reliable data and improved statistical 
power.  Such specificity can be conferred via two means, the first biological and the second technical.  
Enhancing transduction can be achieved through substitution of the viral coat protein for an envelope 
containing surface glycoproteins derived from alternative viruses, a process known as pseudotyping.  
Viral pseudotyping is able to expand the range of potential targets, with those viruses capable of 
infecting a broad array of tissues being referred to as having broad tropism.  One of the mechanisms 
in which tropism is conferred is through the interaction of the viral envelope protein with the cellular 
receptor on the target cell type268.   The popularly used envelope, vesicular stomatitis virus 
glycoprotein (VSV-g), proved to be pantropic due to the ubiquitous nature of the receptor with which 
it interacts with.  This receptor on the target cell is known as the low density lipoprotein receptor 
(LDLR)269.  Amongst a host of alternative viral pseudotypes, the baculovirus envelope glycoprotein, 
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GP64, is of particular importance for gene transfer to the lungs.  It has the ability to transduce the 
apical side of airway epithelia, making it a good candidate for gene therapy of cystic fibrosis261.  
The technical means of organ targeting is achieved through delivery of virus through various routes of 
administration, which is a simple method employed to control the in vivo fate of the viral vectors each 
with their own advantages and disadvantageous.  These include oral, intravenous, intra-arterial, intra-
portal, retrograde intravenous, direct injection, intraperitoneal, or organ surface methods of 
delivery270.  It is vital to keep in mind that viruses have varying affinities to a cell due to cell polarity.  
The route of administration needs to permit viral access to the basal or apical side of the cell for 
efficient transduction270.  Pseudotyping, changing of vector administration routes or a combination of 
these strategies can be immensely useful in gaining targeted expression of the transgenic construct. 
 
iii)  Ease of tissue-specific transgenesis 
In comparison to the production of a germline transgenic line, somatic transgenic animals are 
developed through neonatal or fetal administration of lentivirus.  This is technically less demanding, 
less expensive, and much quicker to implement.  The majority of time used to develop a somatic 
transgenic animals is spent on cloning of the pathway-specific response elements upstream of the 
chosen luciferase, which takes 1 to 8 weeks. Vector production and titering takes a further 2 weeks, 
and vector injection, integration and maturation of the mice approximately 8 more weeks.  Since 
generation of somatic, light-emitting transgenic mice using fetal or neonatal administration of 
lentivirus is rapid and undemanding, it serves as the ideal system to assess novel biosensing constructs 
in a range of in vivo bioimaging applications. 
 
This chapter focuses on the development of a library of transcription factor-specific response elements 
cloned upstream of a novel dual reporter.  The aim is to develop lentiviral reporters that can be used to 
analyse molecular pathway activity in response to disease progression over time in a temporal 
manner, both in vitro and in vivo, and importantly, to obtain such data non-invasively from animals. 
2.1 Results of luciferase reporter development 
2.1.1 Overlap-extension PCR and lentiviral cloning of novel luciferase constructs  
The desired constitutively expressing dual reporter vector contained the SFFV promoter upstream of a 
bicistronic firefly luciferase / GFP reporter cassette as depicted in Figure 27a.  This vector contains 
all the relevant elements including a 5’ long terminal repeat (LTR), central polypurine tract (cPPT), 
constitutive SFFV promoter, bicistronic luciferase-2A-GFP cassette, Woodchuck Hepatitis Virus 
(WHP) Postranscriptional Regulatory element (WPRE), and 3’ deleted LTR to produce functional 
lentiviral particles.  To produce this vector, primary PCR products for each of the 3 desired fragments 
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were generated using their respective primer pairs and amplified from parental vectors, a kind gift 
from Dr Martin Pule, UCL.  For each of the reactions, the expected product sizes of 125 bp, 1656 bp, 
and 907 bp were observed for 3xFLAG, FLuc, and 2A-eGFP respectively (Figure 27b).  Subsequent 
to this, a secondary fusion PCR was performed to fuse the fragments and generate a single bicistronic 
cassette comprised of 3xFLAG-FLuc-2A-eGFP (Figure 27c).  The plasmid pLNT-SEW-Asp-eGFP is 
a 2nd generation lentiviral vector containing a constitutive spleen focus-forming virus (SFFV) 
promoter which drives the expression of the Aspergillus antigen and eGFP to yield pLNT-SFFV-JDG.  
Following excision of the Aspergillus antigen- and eGFP-encoding DNA, the fused product was 
cloned into the destination lentiviral vector.  Positive clones were selected based on a restriction 
digest pattern consisting of 3 fragments of 1317 bp, 2947 bp, and 7249 bp in length,  of which there 
were 8  correct clones out of 12 (Figure 27d).  The clones which were not correct contain various 
different banding patterns, and this is believed to be a result of recombination events that occur 
around the homologous lentiviral LTRs within RecA(-) bacteria and causes part of the plasmid to be 
excised271, resulting in alternative banding patterns in the restriction digest.  The 3xFLAG-FLuc-2A-
GFP insert sequence and highlighted primer binding sites are shown in Appendix A.   
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Figure 27.  Gel electrophoresis of primary and secondary PCR, and restriction digest of pLNT-SFFV-
JDG clones. 
a)  Schematic of pLNT-SFFV-JDG lentiviral vector.  b)  Primary PCR fragments amplified from respective 
parental vectors and electrophoresed to show 3xFLAG (125 bp), FLuc (1656 bp), and 2A-eGFP (907 bp) 
fragments.  c)  Gel demonstrating secondary overlap-extension PCR products fused to produce the 3XFLAG-
FLuc-2A-eGFP insert (2614 bp).  d)  Double digested (MluI / NheI) pLNT-SFFV-JDG clones with correct 
clones (in red boxes) yielding DNA fragments of 1317, 2947, and 7249 bp, and empty backbone clones yielding 
fragments of 1686 and 7249 bp.  
 
2.1.2  Flow cytometry for presence of luciferase and eGFP 
To confirm the presence of the 3xFLAG and eGFP, flow cytometry was performed on cells which had 
been transfected with pLNT-SFFV-JDG. GFP can be detected through excitation of the fluorophore 
with a blue laser, however, since the 3xFLAG and the luciferase are not fluorophores, the addition of 
a fluorophore was required as an additional step.  To determine the auto-fluorescence within the 
HEK293T cells, untransfected cells were used to set up “gates”.  Using the forward scatter (cell size) 
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and side scatter (internal complexity) of the untransfected cells, the voltage was adjusted so that the 
untransfected cells (negative control) had an expression level of less than 102 on the 3xFLAG x-axis, 
and less than 101 on the GFP y-axis, corresponding to inherent auto-fluorescence of the cells.  These 
negative control cells were restricted to quadrant R3 (Figure 28ai).   Cells transfected with the 
positive control GFP construct were shown to be localised specifically to quadrant R1 (Figure 28aii).  
Another construct containing a well-characterised 3xFLAG tagged insert was used to transfect and 
used as the positive gating control for 3xFLAG, gated specifically to quadrant R4 (Figure 28aiii).  
HEK293T cells transfected with the novel pLNT-SFFV-JDG vector were shown to express both the 
3xFLAG and eGFP, resulting in cells being present in quadrant R2 (Figure 28aiv).  Using adequate 
gating controls resulted in less than 0.1% of non-transfected cells being seen in the GFP-positive 
quadrant, and 2.29% within the 3xFLAG-positive quadrant.  Both GFP-positive and 3xFLAG positive 
controls showed less than 0.5% cells within the double detection R2 quadrant while pLNT-SFFV-
JDG transfected cells showed 16.47% , significantly higher than the single 2.53% eGFP positive and 
single 1.52% 3xFLAG positive cells found within the sample. 
 
Figure 28.  Functional validation of GFP and luciferase expression. 
Flow cytometry on cells transfected with the pLNT-SFFV-JDG construct was performed to validate the 
expression of eGFP and 3xFLAG, which was used as a surrogate marker of the luciferase to which the FLAG-
tag is fused.  a) Untransfected HEK293T cells were used as the gating control, while cells transfected with either 
a b) well-characterised eGFP, or c) well-characterised FLAG-tag expressing vector were used as positive 
controls.  d) The pLNT-SFFV-JDG construct was positive for both GFP and 3xFLAG, indicating dual 
expression of these proteins. 
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2.1.3  Cleavage efficiency of 2A polypeptide sequence by Western Blot 
Using fluorophore-conjugated antibodies and the Li-Cor Odyssey Imaging System to quantify the 
relative amounts of fluorescence, the efficiency of FMDV-2A cleavage was determined.  Using lysate 
from cells transfected with the pLNT-SFFV-JDG construct, polyacrylamide gel electrophoresis 
(PAGE) was performed.  The Odyssey Western Blot detection system uses infrared dyes (IRDye) 
conjugated to the secondary antibody that produces near-infrared fluorescent signals that are able to 
be detected by the Odyssey fluorescence scanner.  These IRDyes emit within the 800 channel (green) 
or the 680 channel (red) and these fluorescent signals are used as a means of visualisation.  This is 
particularly beneficial in this context as the quantity of cleaved versus uncleaved product could be 
quantitatively determined. 
By applying primary antibodies for either the 3XFLAG or the GFP followed by applying a green 
fluorophore-conjugated secondary antibody, 2A cleavage efficiency could be determined.  The green 
band was used to detect the fusion protein consisting of the 3xFLAG peptide fused to the luciferase at 
65 kDa, or the eGFP with an expected molecular weight of 27 kDa.  β-actin was used as the loading 
control and probed with a red fluorophore-conjugated secondary antibody for signal detection of a 
band with an expected molecular weight of 47 kDa.  The Western blot indicates the presence of 
cleaved products as both the 65 kDa and the 27 kDa can be seen, however, there is also the presence 
of a faint band around 92 kDa (Figure 29a). 
 
2.1.4  Spectral analysis of pLNT-SFFV-JDG 
Of the 12 clones selected, 8 clones were found to contain the insert. Individual spectral analyses were 
performed to determine which of the clones expressing luciferase had the highest enzymatic activity.  
Each of the clones was transfected onto HEK293T cells, lysed after 24 hours, and spectral emission 
determined through luminometry.  An emission spectrum was generated by determining the light 
output at a series of wavelengths ranging from 450 to 750 nm.  The greatest point of fluorescent 
intensity is known as the peak photonic output, which was empirically determined to be 549 nm for 
the pLNT-SFFV-JDG vector measured as relative light units.  Analysis confirmed that luciferase 
expressed from clone 11 had the highest luciferase activity, with an output of 67293 relative light 
units (Figure 29b). The variation seen between clones may have been attributed to varying 
transfection efficiencies between wells. Ideally, a second reporter should be utilized to control for 
transfection efficiencies, or should be normalised to total protein content to account for cell numbers 
in each well.  All subsequent measurements were controlled for via the latter method.  
 
  
CHAPTER 2 – DEVELOPMENT OF BIOSENSING REPORTER TECHNOLOGY                              50 | P a g e  
 
2.1.5  Virus production and transduction validation of pLNT-SFFV-JDG 
Transient transfection of a gag-pol packaging plasmid, a VSV-g envelope plasmid, and the newly 
developed pLNT-SFFV-JDG vector, resulted in the production of virus particles that were 
concentrated using centrifugation.  In order to determine the titer, a p24 ELISA was performed to 
yield the number of vector particles per µl of supernatant.  This value was subsequently used to 
determine the multiplicity of infection (MOI), or the number of transducing viral particles per cell.  
HEK293T cells were transduced with the LNT-SFFV-JDG-containing virus and exhibited constitutive 
expression of the bicistronic cassette, clearly visualised microscopically using the GFP reporter 
(Figure 29c). Triplicate wells of LNT-SFFV-JDG transduced and untransduced cells were lysed and a 
luciferase assay performed.  A significant (p = 3.48E-4) increase in luciferase expression was seen in 
the LNT-SFFV-JDG transduced versus untransduced cells, with a dramatic 2,367,160-fold increase in 
relative light units (Figure 29d). 
 
 
 
Figure 29.  Functional validation of pLNT-SFFV-JDG.   
a)  Western blot showing protein products following 2A cleavage.  The β-actin loading control (in red) is seen in 
both blots at 47 kDa, with the 65 kDa and 27 kDa fragments (in green) indicative of 3xFlag-FLuc and eGFP 
proteins respectively.  The black-and-white version of the blot clearly shows a small proportion of uncleaved 
product at 92 kDa.  b)  Emission spectra of pLNT-SFFV-JDG transfected HEK293T cells between 450-750 nm, 
with peak emission at 549 nm.  c)  HEK293T cells transduced with LNT-SFFV-JDG lentivirus showing 
constitutive expression of GFP and d) luciferase.  
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2.1.6  Development of a rapid cloning system, the construction of pLNT-GW-JDG 
Cloning each of the transcription factor binding sites (response elements) individually would be 
labour intensive and time consuming.  Ideally, a method of rapid cloning would be employed to 
substitute the various transcription factor binding sites and generate a library of biosensing reporters.  
Gateway® cloning technology, developed by Invitrogen™, is a restriction-enzyme independent 
method of cloning.  The Gateway® cassette (GW) is flanked by recombination sites and contains the 
ccdB toxicity gene which inactivates DNA gyrase and therefore acts as a potent inhibitor of bacterial 
cell proliferation272. This cassette is cloned into the destination vector, which in the case of the desired 
vector, was upstream of the bicistronic luciferase/GFP cassette.  The accompanying recombination 
sites also flank the insert (in our case the response elements) cloned in the pENTR shuttle vector, and 
this region of homology between the recombination sites permits site-specific recombination to occur.   
This results in the Gateway® cassette being recombined out of the destination vector and into the 
pENTR vector, while the response element is recombined out of the pENTR vector and into the 
destination vector, upstream of the luciferase/GFP (Figure 30).  The increased efficiency of obtaining 
the correct recombinant clone is due to dual selection.  Only clones which contain the response 
element instead of Gateway containing the toxicity gene are able to grow in the bacteria, and a second 
layer of selection is conferred through antibiotic selection.  The pENTR vector contains only 
kanamycin resistance, and bacteria transformed with this plasmid will therefore not grow on 
ampicillin-laden agar plates.  Dual selection should theoretically result in the generation of only those 
clones which have the response element within the lentivirus backbone, grown in ccdB-sensitive 
bacteria, and plated onto ampicillin/carbenicillin agar plates. 
 
Figure 30.  Schematic of Gateway recombination cloning using the pENTR shuttle vector and the pLNT-
GW-JDG lentiviral vector. 
The ccdB-containing Gateway® is cloned upstream of the luciferase cassette.  During the recombination 
reaction, the pENTR vector, containing the disease-specific response elements undergoes site-specific 
recombination, resulting in a lentivirus containing the disease-specific response element upstream of the 
luciferase while the Gateway® cassette is shuttled into the pENTR vector. 
 
In order to generate pLNT-GW-JDG for the rapid recombination of reporter elements upstream of the 
bicistronic luciferase/eGFP cassette, the JDG insert was initially subcloned into the expression 
plasmid, pZsGreen, and subsequently cloned into its final vector, pLNT-GW-MCS, as 
diagrammatically depicted in Figure 31a. Restriction enzyme digest of positive pZsGreen-JDG 
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clones yielded inserts of 209, 1123, 1457, and 4194 bp as is observed in clones 1-5 (Figure 31b).  
Following subcloning, the JDG cassette was cloned into the final pLNT-GW-MCS vector and 
screened for a correct clone (Figure 31c).  The vector map of pZs-Green-JDG (Appendix A.iii) and 
pLNT-GW-JDG (Appendix A.v) vectors are given with relevant restriction sites. 
 
 
Figure 31.  Cloning to generate the Gateway-FLuc-2A-GFP (pLNT-GW-JDG) parental vector. 
a)  Cloning strategy to produce the pLNT-GW-JDG vector. The bicistronic JDG cassette was primarily cloned 
into a subcloning vector before being cloned into the pLNT-GW backbone.  b)  Gel of pZsGreen-JDG clones 
double digested with SapI / MluI showed bands of the correct sizes.  c)  Gel of pLNT-GW-JDG clones digested 
with BamHI / MluI with clone 5 showing a clone with the correct size digest products to confirm the presence of 
the cloned JDG insert.  
 
2.1.7  Development of  NanoLuc® and Vargula parental cloning vectors. 
While the use of firefly luciferase was the best candidate for longitudinal in vivo bioimaging due to its 
high signal intensity and stability, the necessity for cell lysis for luciferase quantification of in vitro 
assays made this vector less than desirable for temporal studies.  The preferred luciferase for 
differentiation studies would allow the determination of luciferase activity from the same sample for 
the duration of the experiment, thus requiring that the luciferase is secreted instead of remaining 
intracellular.  NanoLuc® is a newly developed luciferase that has been engineered for enhanced 
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luciferase performance and secretion of the luciferase into the media248.  This feature negates the need 
for cell lysis and permits longitudinal studies in vitro.  The use of a second secreted luciferase, such as 
vargula, under the control of a constitutive promoter, is then used to control for cell number within the 
model system.  
The cloning strategy for cloning the fused NLuc-2A-GFP product into the lentiviral backbone is 
depicted in Figure 32a.  Firstly, primary PCRs for NanoLuc and 2A-eGFP were performed and 
resulted in the expected 627 bp and 826 bp fragments respectively.  Following overlap-extension 
PCR, a fusion product of 1403 bp was generated.   This secondary fusion product was subcloned into 
the pENTR vector before being cloned into the lentiviral backbone.  A screening restriction enzyme 
digest yielded a single clone which excised the fused PCR product insert and is seen as a 1389 bp 
fragment following gel electrophoresis (Figure 32b) with the map of pLNT-GW-NLuc2 shown in 
Appendix A.vi.   
The vargula luciferase (Vluc) insert was amplified using a high-fidelity polymerase and resulted in the 
expected 1687 bp product.  This product was subcloned into the pENTR-1A vector with the 
restriction enzyme digest check demonstrating that all 4 selected clones contained the insert.  
Recombination of Vluc into the pLNT-SFFV-GW vector was performed and clones screened for the 
presence or absence of the Vluc insert.  Clone 1, 3, and 4 were positive for the insert of 1688 bp 
(Figure 32c).  The vector map is shown in Appendix A.vii. 
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Figure 32.  Restriction digest checks of pLNT-GW-NLuc2 and pLNT-SFFV-Vluc cloning. 
a)  Schematic of pLNT-GW-NLuc2 cloning strategy. b)  Primary and secondary PCR of NanoLuc and 2A-eGFP 
to create a fused product.  Clone screening digest with clone 1 shown to be positive for the NLuc2 insert.  c)  
PCR of vargula luciferase and subsequent cloning into pENTR-1A.  Positive clone selection of subcloning 
vector performed using restriction digestion.  Following recombination, pLNT-GW-Vluc clones were screened 
to detect the Vluc insert with clones 1, 3, and 4 confirmed as positive.  
 
2.1.8  In vitro validation of constitutively driven JDG, RLuc2, Vluc2, and NLuc2 
An important point of consideration when utilising various luciferases within the same model system 
is the specificity of each of the luciferases for their particular substrate.  To this end, virus was 
produced with constructs constitutively expressing either JDG (firefly), RLuc2 (renilla), VLuc2 
(vargula), or NLuc2 (NanoLuc), which were used to transduce HEK293T cells.  The lysate from these 
cells was used in a luciferase assay using each of the three luciferase substrates, namely D-luciferin, 
coelenterazine, and vargulin respectively.  Renilla and NanoLuc luciferases are both able to produce 
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photonic outputs in the presence of coelenterazine.  Data was normalised using a Bradford assay for 
total protein content, and untransduced HEK293T cells were used as the control to account for any 
background luminescence given by the substrates.  All data are represented as fold-change over 
HEK293T cells alone, with statistical significance determined using a one-way ANOVA with Tukey’s 
post-hoc test for significance.  Figure 33a demonstrates that D-luciferin is highly specific for the 
firefly luciferase found within the pLNT-SFFV-JDG vector with a 2,367,160-fold increase in RLU 
over HEK293T lysate alone (p < 0.001).  Coelenterazine showed the greatest fold-change in luciferase 
expression in cells transduced with the pLNT-SFFV-RLuc2 vector with a fold change of 12,819 RLU 
(p < 0.001) as seen in Figure 33b.  Some cross reactivity was seen with the coelenterazine substrate 
in the sample containing the firefly luciferase (fold-change of 2716 RLU), vargula luciferase (fold 
change of 12 RLU), and nanoluc luciferase (fold change of 902 RLU), but this was not significant 
after Tukey’s post-hoc testing.  Vargulin showed highly specific activation of the vargula luciferase in 
the pLNT-SFFV-Vluc transduced cells with a fold change of 24,968 (p < 0.001)(Figure 33c).   
Relative GFP expression of each of the transduced cells lines was assessed microscopically using 
fluorescence imaging.  High levels of GFP expression was detected for all constructs (Figure 33d).  
 
Figure 33.  Substrate specificity assay for JDG, RLuc2, VLuc2 and NLuc2. 
HEK293T cells transduced with JDG, RLuc2, Vluc2, or NLuc were subjected to luciferase assay using 
luciferase specific substrates, namely a) D-luciferin, b) coelenterazine, or c) vargulin.  d)  GFP expression of 
each of the constitutively expressing bicistronic vectors in HEK293T cells. Statistical significance determined 
by one-way ANOVA with Tukey’s post-hoc test. 
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CHAPTER THREE  
IN VITRO VALIDATION OF REPORTERS 
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3.0  Investigating signalling activity using transcription factor binding elements 
Once the parental pLNT-GW-JDG vector had been generated, pENTR vectors containing the 
response elements to be recombined were required.  pENTR vectors containing transcription factor 
activated response elements upstream of a minimal promoter were designed and de novo synthesised 
by Aldevron (Fargo, USA).  The following step was to produce a biosensing vector which would be 
conditionally activated by pathway-specific agonists.  Lentiviral delivery of vectors containing 
transcription factor binding elements upstream of a bicistronic reporter cassette would offer a unique 
method with which to interrogate biological pathways.  In the context of this project, the reporters for 
NF-κB, SBE, Wnt and Notch were of particular interest as they are known to be fundamental in 
regenerative responses within the liver.  Following cloning of these vectors, all constructs were 
subsequently validated in vitro prior to in vivo validation.  
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3.1  Results of reporter validations in vitro  
3.1.1   In vitro validation of the pLNT-NF-κB-JDG construct 
Following recombination of pENTR-NF-κB with the parental pLNT-GW-JDG vector to yield pLNT-
NF-κB-JDG, lentivirus was produced and a range of cell lines were transduced to produce multiple 
NF-κB stable reporter cell lines.  The hepatic cell line, Huh7, was used to assess the effect of pro-
inflammatory mediators upon NF-κB activation over several time points.  Activation of the Huh7 NF-
κB reporter line, followed by luciferase assay at 12, 24, 48, and 72 hours post activation was 
performed (Figure 34a).  Data showing fold change over non-activated demonstrated a significant 
increase of luciferase expression at T = 12, 24, and 48 hours, with the highest fold change seen at 24 
hours.   Analysis of NF-κB activation in a broad range of cell lines was performed, and these included 
the use of 2 hepatic cell lines, HepG2 and Huh7, human fibroblasts, and fibroblasts isolated from 
TLR4 knockout mice.  In all cases, significance was obtained, except for in the tlr4-/- MEFs which 
expectedly failed to reach significance (p = 0.2544) (Figure 34b). 
 
Figure 34.  LNT-NF-κB-JDG activation in response to LPS. 
a)  Time course of activation in the Huh7 cell line following 4 hours of activation with LPS. Statistical 
significance ascertained by two way ANOVA  b)  Activation of two hepatic cell lines, HepG2 and Huh7, human 
fibroblasts, and tlr4-/- MEFs 48 hours post activation with LPS.  Statistical significance was determined by 
Student’s t-test. * P <0.05, ** P <0.01, *** P < 0.001. 
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3.1.2  Time course and dose response of activin A activation of LNT-SBE-JDG in vitro  
The next reporter to be validated was the vector containing the response element activated by TGF-β 
signalling.  Primary CD1 MEFs transduced with LNT-SBE-JDG were exposed to varying doses of 
activin A for a period of 48 hours prior to lysis and luciferase assay detection for relative pathway 
activation.  The use of 1, 5, or 10 ng/ml of activin A resulted in no significant increase in luciferase 
expression in the activated versus their non-activated counterparts.  However, the use of 50 and 100 
ng/ml of activin A yielded a statistically significant difference between the activated and the non-
activated samples (p = 0.027 and 0.045 respectively) (Figure 35a). 
Lentivirus containing the LNT-SBE-JDG construct was used to transduce a host of cell lines.  These 
included 2 human stable cell lines, namely HEK293T and HeLa, human primary fetal fibroblasts 
isolated from the fetal portion of the placenta, and also mouse primary fibroblasts, from CD1 mice.  
Following viral integration, the cell lines were activated with the SMAD-2/3-specific agonist, activin 
A.  Following 48 hours post-activation, a significant increase in luciferase expression was seen in all 
cell lines, with the HEK293T (p < 0.001)  and fetal fibroblasts (p = 0.001)  showing particularly high 
levels of statistical significance (Figure 35b).   
 
 
 
Figure 35.  Validation of pLNT-SBE-JDG using the agonist, activin A, in ascending doses and in various 
cell lines. 
a)  Primary CD1 MEFs transduced with pLNT-SBE-JDG were activated with varying doses of activin A and the 
relative upregulation of luciferase expression ascertained through luciferase assay.  b)  HEK293T, human fetal 
fibroblasts, HeLas and CD1 MEFs were transduced with LNT-SBE-JDG and subsequently activated with 
activin A.  Student’s one-tailed t-test used for statistical significance.  * P <0.05, ** P <0.01, *** P < 0.001. 
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3.1.3  In vitro validation of WNT-JDG using LiCl 
WNT signalling plays a crucial role in cell fate specification, proliferation, and migration.  Within the 
context of liver regeneration, the role of WNT signalling in the lineage determination of bipotent 
hepatic progenitor cells following chronic liver damage requires further investigation. To this end, a 
WNT reporter construct containing conserved TCF/LEF transcription factor binding sites upstream of 
a luciferase cassette was generated. Three cell lines, namely HEK293T, NIH3T3, and HeLa were 
transduced with the LNT-WNT-JDG.  Stimulation of canonical WNT signalling within the stable 
WNT reporter cell lines was achieved through the addition of lithium chloride (LiCl).  Within all three 
cell lines, statistical significance was reached by 12 hours and remained elevated for the duration of 
the experiment.  Data was plotted as fold change of LiCl-activated values over non-activated, baseline 
values.  The greatest fold change was seen in HEK293T cells with a peak fold-change of 3129 noted 
at 72 hours and a significance value of p = 0.02.  Although this was the point of greatest fold change, 
the point of greatest significance across the experiment was found at the 48 hour time point in 
NIH3T3s with a significance of p = 9.6E-8 (Figure 36). 
 
Figure 36.  In vitro validation of LNT-WNT-JDG vector in various cell lines. 
HEK293T (a), NIH3T3 (b) and HeLa (c & d) cells were transduced with LNT-WNT-JDG at an MOI of 10.  The 
addition of LiCl was shown to upregulate WNT signalling in all cell lines, seen microscopically as the increase 
in GFP expression, and statistically as enhanced luciferase expression.  Data analysed using two-way ANOVA 
with Bonferroni post-hoc test for significance.  * P <0.05, ** P <0.01, *** P < 0.001. 
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3.1.4  In vitro validation of Notch using co-culture with Jagged-1 overexpressing cells 
Notch signalling uses juxtacrine signalling for signals to be transduced from one cell to the signal-
receiving cell where it can modulate gene expression.  A co-culture method was employed as an in 
vitro model in which the luciferase reporter could be validated by means of said contacts. The 
SGHPL5 trophoblast isolated cell line was transduced with both the LNT-Notch-JDG lentivirus, and 
also with the LNT-SFFV-RLuc vector, a constitutively expressed renilla construct used to normalise 
luciferase light units in each well of the experiment. Separately, HEK93T cells were transduced with 
the constitutive LNT-SFFV-Jagged-1-IRES-GFP vector. Cells were co-cultured at initial densities of 
10, 30, 50, and 70% of HEK293T cells containing Jagged-1.  The dose response curve indicates a 
significant increase in luciferase expression can be seen between each of the doses of HEK293T cells, 
with the highest level of significance seen when co-culturing with the maximum number of HEK293T 
cells at 70% (Figure 37a).  Within the time-course experiment, Notch signalling was shown to be 
significant at 48 and 72 hours post continuous incubation with constitutively expressing Jagged-1 
HEK293Ts (Figure 37b).  
 
Figure 37.  In vitro validation of pLNT-Notch-JDG using Jagged-1 dose response curve and time course. 
a) SGHPL5 cells transduced with the Notch reporter were incubated in increasing doses of Jagged-1 
overexpressing HEK293T cells and displayed dose-dependent signalling. Analysed using one-way ANOVA and 
Tukey post-hoc analysis b) A time course of the Notch reporter incubated with 70% Jagged-1 overexpressing 
HEK293T cells exhibited increasing luciferase expression over time with significance reached at 48 and 72 
hours. Analysed using two-way ANOVA and Bonferonni post-hoc test. * P <0.05, ** P <0.01, *** P < 0.001.
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Somatotransgenic bioimaging to assess pathway activity in chronic liver diseases 
The TGF-β, NF-κB, WNT and Notch pathways function to activate relevant cell types required for the 
initiation and termination of the wound-healing response.  They also have key roles in the liver’s 
response to chronic injury through the activation of the normally quiescent progenitor cell 
compartment, instigating their proliferation and subsequent differentiation.  Therefore, the use of 
somatotransgenic animals containing luciferase reporter cassettes/genes under the control of disease-
specific response elements has the capacity to offer insight into the activity of these pathways during 
disease induction and progression within an in vivo context.  Currently, analysis of liver disease 
consists of serial bleedings for analysis of serological biomarkers of liver function, particularly liver 
enzymes and total serum bile acids.  Terminal analysis of animals for histological assessment of 
disease pathology also restricts temporal disease profiling within a single animal.  The aim of the 
work described in this chapter is to present data on the in vivo validation of the aforementioned 
biosensors, before assessing the role of these pathways within a model of chronic biliary injury 
induced by bile duct ligation. 
4.1  Results of reporter validations in vivo 
4.1.1   Monitoring of LPS-mediated inflammatory responses in vivo using a NF-κB reporter 
Using a constitutively expressing construct, LNT-SFFV-JDG, and an NF-κB pathway activated 
biosensing construct, LNT-NF-κB-JDG, lentivirus containing each of these constructs was targeted 
for the liver in outbred CD1 and tlr4-/- mice.  Administration of ultra-pure LPS resulted in a significant 
increase (p = 0.016) in luciferase expression within the CD1 mice after 4 hours, whereas no 
significant effect was seen within the TLR4 knockout animals (p = 0.498) (Figure 38a).  Examining 
fold change over baseline, mice expressing the constitutively active LNT-SFFV-JDG showed no 
significant change in expression over time in the CD1 or the tlr4-/- mice (Figure 38b). Luciferase 
activity data is visualised in pseudocolour scaling format.  This pseudocoloured heat map quantifies 
photonic output as photons/s/cm2 with blue showing the least expression and red showing the highest 
photonic output. 
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Figure 38.  Validation of NF-κB using CD1 and tlr4-/- mice. 
CD1 and tlr4-/- mice injected with LNT-NF-κB-JDG virus and imaged at 0 and 4 hours post LPS exposure.  
When expressed as fold change, only CD1 mice challenged with LPS showed a significant fold change in 
luciferase expression over baseline. b)  Graphs showing outbred CD1 or tlr4-/- mice injected with either 
constitutive LNT-SFFV-JDG or LNT-NF-κB-JDG virus.   
 
4.1.2   Antagonistic abrogation of inflammatory NF-κB responses by dexamethasone 
In order to show the utility of somatotransgenic bioimaging as a powerful tool for use in drug 
screening and efficacy testing, the NF-κB signalling pathway was used.  This well-established model 
of inflammation was used in conjunction with a well-characterised anti-inflammatory steroid, 
dexamethasone.  Animals were subjected to either LPS alone, or pre-treated with dexamethasone prior 
to LPS exposure.  A significant NF-κB-mediated upregulation of luciferase in response to LPS was 
seen within 24 hours in those animals which received LPS alone, however, in stark contrast, the 
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animals that were pre-treated with the anti-inflammatory steroid prior to exposure were found to be 
protected from NF-κB-induced inflammation  (Figure 39a).  Pre-treatment with Dex resulted in a 
significant decrease in LPS-mediated response (p = 0.0047) (Figure 39b). 
 
Figure 39.  Response of NF-κB signalling when challenged with the glucocorticoid, dexamethasone. 
a)  LNT-NF-κB transduced animals experience a marked increase in luciferase expression within 24 hours after 
receiving LPS alone, however, complete abrogation of this response was seen in those animals pre-treated with 
the corticosteroid, dexamethasone.   b)  Statistical analysis using a one-tailed t-test to compare the two groups. 
 
4.1.3   Exogenous activation of the LNT-SBE-JDG construct in vivo using activin A 
At P0, neonatal CD1 outbred mice were injected with LNT-SBE-JDG virus.  At 68 days post-birth, in 
vivo validation of this construct was performed through intravenous injection of exogenous activin A.  
Using this direct agonist of the SMAD 2/3 signalling pathway, there was an overall increase (p = 
0.053) in SBE-mediated luciferase expression in the animals that were given the activin A compared 
to those which received LPS, which is not an agonist of smad2/3 signalling. The greatest difference in 
photonic output was seen between the groups at 24 hours, with a t-test assuming unequal variances 
showing statistical significance (p = 0.020).  There was a steady decrease in expression over the 
following days, and a return to baseline levels 5 days post-activation. 
 
Figure 40.  Activation of pLNT-SBE-JDG in vivo using exogenous activin A. 
Mice injected with LNT-SBE-JDG virus underwent either direct agonist activation using exogenously added 
activin a. Significant activation was obtained in activin A treated mice (p = 0.05) 
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4.2  Molecular analysis of fibrosis and virus cell-type targeting 
4.2.1  Haematoxylin and eosin and Lilly’s trichrome staining for liver morphology and fibrosis 
To study signalling pathways in vivo, an animal model of liver fibrosis was employed.  Fibrosis was 
induced by surgical means, with Dr. Simon Waddington performing all partial bile duct ligations.  
Prior to embarking on bioimaging experiments using the reporters, the development of ductular 
reactions and fibrosis following pBDL was confirmed. 
Conventional haematoxylin and eosin (H&E) staining was performed to observe gross histological 
differences between the sham-operated and pBDL samples.  Within the control liver sample, the large 
portal vein is clearly visualised, with a bile duct, containing distinctive cuboidal epithelial cells seen 
adjacent to the vein. Below this, the small hepatic artery is seen, completing the last part of the portal 
triad (Figure 41i).  The pBDL sample showed dilation of the bile duct, the beginning of biliary 
hyperplasia, and the presence of ductular reactions comprised of mild mononuclear cell infiltrate and 
proliferating biliary cells.  The periportal limiting plate, hepatocytes that usually lie adjacent to the 
portal tract and separate it from parenchymal hepatocytes, has been disrupted.  This feature is termed 
piecemeal necrosis and refers to the loss of the hepatic limiting plate in response to liver damage.  It is 
associated with lymphocytic infiltrate intruding into the adjacent parenchyma (Figure 41ii). 
Successful pBDL results in the development of biliary fibrosis, beginning with periportal fibrosis, and 
progressing toward bridging fibrosis between the portal triads.  Liver samples of mice 3.5 months 
post-pBDL were embedded, sectioned, and Lily’s trichrome staining performed to detect collagen 
deposition, synonymous with liver fibrosis/cirrhosis following BDL surgery.  This staining technique 
uses selective dyes of varying sizes to achieve differential staining of the tissue sections and to 
distinguish histological changes in the samples.   The control liver showed no collagen deposition 
around the portal tract or within the liver parenchyma (Figure 41iii and v), and each of the central 
veins were morphologically normal.  Occlusion of the bile duct is expected to result in fibrosis of the 
ligated lobe.  Trichrome staining of the fibrosed left lobe demonstrates periportal collagen deposition 
in blue. Furthermore, a strong proliferative response seen as extensive biliary hyperplasia was noted 
by the presence of multiple biliary ductules.  Portal expansion was observed with severe dilation of 
the bile duct and significantly increased amounts of peribiliary fibrosis seen as concentric layers of 
collagen deposition around the bile duct (Figure 41iv).  Lower magnification of the liver lobe showed 
interlobular porto-portal bridging fibrosis along the liver septa surrounding the lobules, connecting the 
hepatic triads with collagenous deposits, indicative of advancing fibrosis (Figure 41vi).    
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Figure 41.  H&E and trichrome staining of sham operated and pBDL livers. 
Mice livers sectioned and stained with H&E (i and ii) for histological architecture and Lilly’s trichrome (iii-vi) 
to show the deposition of collagen (blue), nuclei (black), and cytoplasm (red). Control livers were sham 
operated animals while the left and right lobes were isolated from the left fibrosed lobe of a LNT-SBE-JDG 
injected mouse.  bile duct (BD), hepatic artery (HA), portal vein (PV), biliary hyperplasia (BH), ductular 
reaction (DR). 
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4.2.2  Immunohistochemical analysis of lentiviral targeting of hepatic cell types  
One critical aspect of the biosensing technology is the ability to target and transduce particular organs 
and cell types.  Immunohistochemical analysis was performed to determine the cell types being 
targeted in the liver when utilising VSV-g-pseudotyped lentivirus.  Firstly, the levels of transduction 
and green background fluorescence were assessed by comparing an uninjected control to a liver that 
was transduced with the constitutive SFFV-JDG vector.  The uninjected control showed low levels of 
green auto-fluorescence following 0.3% Sudan Black treatment which was used to decrease 
fluoroscein-mediated  autofluorescence known to be problematic in liver samples.  The GFP-specific 
signal was distinct in the SFFV-JDG transduced sample and could clearly be distinguished from its 
uninjected counterpart (Figure 42a).   The most prominent colocalisation was between the GFP 
transduced cells and the hepatocyte-specific marker HNF4α.  The merged image shows that a 
majority of the GFP positive cells contain purple nuclei produced from the dual overlay of nuclear 
HNF4α (red) and DAPI (blue)(Figure 42b).  Within a normal liver, α-SMA is localised to the lining 
of the portal vein where it marks the smooth muscle of the vasculature.  However, in the context of 
disease, it is a marker of activated myofibroblasts.  In pBDL samples, α-SMA was localised along the 
portal tracts in the stroma adjacent to the proliferating biliary cells (Figure 42c).  Glial fibrillary 
acidic protein (GFAP) is also a marker of activated stellate cells.  It can clearly be observed within the 
parenchyma adjacent to hepatocytes (Figure 42d).  The cholangiocyte marker CK7 was seen to be 
expressed within the proliferating bile ducts, and GFP was limited to the region directly adjacent to 
this (Figure 42e).  Pyruvate kinase isoform M2 (PKM2) is a marker of hepatic progenitor cells and 
stains both the cytoplasm and the nucleus where it associates with chromatin.  This marker is clearly 
localised periportally, the region where the progenitors reside and proliferate in response to chronic 
cholestasis.  GFP clearly does not colocalise with PKM2 as observed in the overlapping merged 
image, indicating a lack of progenitor cell targeting (Figure 42f).   Confirmation of largely hepatocyte 
targeting of the virus was of particular importance for subsequent biosensing experiments, as the 
signal generated would be informative for a specific cell type and would offer an increased level of 
sensitivity compared to whole-organ signalling profiles. 
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Figure 42.  GFP colocalisation with hepatic cell types using cell-type specific markers. 
Uninjected controls were used to assess background fluorescence and GFP antibody specificity.  Transduction 
efficiency was assessed in livers injected with the constitutive SFFV-JDG virus with GFP immunofluorescence 
used as a marker of transduction (a).  GFP was colocalised with the hepatocyte marker, HNF4α (b), while it 
showed negative colocalisation with the activated stellate cell makers, α-SMA (c) and GFAP (d), the 
cholangiocyte marker, CK7 (e), and the progenitor cell marker, PKM2 (f). 
 
4.3  Analysis of critical pathways involved in chronic liver injury 
Once each of the reporters had been successfully validated both in vitro and in vivo, their use within a 
biological context was assessed.   The pBDL model was employed as it is a well-established model of 
cholestatic liver disease. Within the pBDL model, animals would express physiological levels of 
agonist and would require a high level of reporter sensitivity.  These vectors could subsequently be 
developed to assess disease progression and pharmacological interventions in a host of diseases, 
including other types of liver disease. 
 
4.3.1  SFFV-mediated luciferase expression is unaffected by pBDL surgical procedure 
Firstly,  to verify that the signalling profiles obtained following pBDL were not due to the loss of 
signal transducing cells in response to pBDL, mice were injected with lentivirus containing the 
constitutively expressing LNT-SFFV-JDG vector and subsequently underwent either sham or pBDL 
surgery.  No significant difference between the groups was noted (Figure 43a), indicating that 
deviations from basal luminescence using the biosensing reporters would be due solely to a change in 
luciferase signalling, and not due to the loss of cells during injury progression.   
 
Figure 43.  Mean luminescence intensity of LNT-SFFV-JDG transduced mice with or without BDL 
surgery.   
Mice transduced with liver-specific LNT-SFFV-JDG virus were subjected to either BDL (red) or sham (black) 
surgery.  Mean fluorescence intensity over baseline was plotted over time. No significant change in luciferase 
expression was found. 
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4.3.2  NF-κB activity monitoring during the acute phase of cholestasis 
NF-κB signalling was assessed in vivo by injection of LNT-NF-κB-JDG virus into neonates.  Fifty 
days post-birth, half of the animals underwent partial bile duct ligation surgery to induce chronic 
cholestasis, while the other half of the cohort underwent sham surgery, where the surgery was 
performed but the bile duct was not ligated.  Bioimaging of the animals was assessed for 50 days 
during which a 33.7-fold increase in luciferase expression was seen 14 days post-surgery in the pBDL 
animals.  Area under the curve (AUC) analysis of total photonic flux for each cohort was assessed.  
The mean area AUC for non-pBDL animals was 84.4 units and 621.2 units for pBDL animals.  The 
difference in luciferase activity between the two groups was statistically significant and assessed as a 
t-test for the AUC analysis (p = 0.011).  Interestingly, a peak was also observed in the animals which 
had undergone the sham surgery, but this peak was more transient and had decreased to baseline 7 
days post-surgery. 
 
Figure 44.  NF-κB reporter activation in response to partial bile duct ligation model of cholestasis. 
CD1 mice transduced with LNT-NF-κB-JDG virus underwent either pBDL (red) or sham (black) surgeries. 
Bioluminescent output was measured as a fold-change of the median of 3 triple time points (baseline) taken 
prior to disease induction.  Area under the curve analysis revealed a significant increase in luciferase expression.  
 
4.3.3  Smad 2/3 activation in vivo using fibrosis-inducing partial bile duct ligation  
Another cohort of CD1 mice transduced with the LNT-SBE-JDG vector underwent pBDL or sham 
surgeries.  At 60 days post-birth,  10 of the 21 injected mice underwent partial BDL surgery, followed 
by 15 imagings at several time points during the progression of chronic fibrosis (day 2, 4, 8, 11, 14, 
17, 21, 24, 28, 31, 35, 38, 49, 56, 63, 71). Novel temporal TGF-β signalling profiles were observed 
with the SMAD2/3 response element. Partial bile duct ligation resulted in a small, non-significant 
increase in light emission compared with non-operated controls (Figure 45a).  However, a greater 
oscillatory amplitude was observed in pBDL mice, indicative of more dynamic TGF-β signalling in 
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those animals that underwent fibrotic induction.  This variation (standard deviation) was found to be 
significant between the two groups when analysed using a Student’s T-test (p = 0.009) (Figure 45b).  
 
Figure 45.  Activation of pLNT-SBE-JDG in vivo following pBDL surgery. 
a) Mice injected with LNT-SBE-JDG virus underwent partial bile duct ligation, exacerbating fibrosis-inducing 
TGF-β signalling within a biological disease model.  No significant difference in means was noted.  b) A 
difference in standard deviation was determined, indicative of the greater amplitude of luciferase signalling 
within the pBDL animals. 
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4.3.4  In vivo assessment of GFAP expression in response to biliary injury 
The activation of hepatic stellate cells results in their transdifferentiation to a myofibroblastic 
phenotype that expresses increased levels of glial fibrillary acidic protein (GFAP).  However, 
immunohistochemical data indicated that the hepatic stellate cells were not be targeted by the virus, 
and thus would not contribute to the luciferase expression.  Therefore, we determined to assess the 
activity of GFAP and produce a temporal profile originating specifically within hepatocytes.  
Neonatal mice were transduced with lentivirus containing the LNT-GFAP-JDG construct.  The 
hepatic GFAP somatotransgenic animals were monitored for basal GFAP expression before 
undergoing partial bile duct ligation or sham operations 45 days post birth.   From the earliest imaging 
time point at day 48, an increase in GFAP expression was noted (p = 0.06).  The levels of GFAP-
induced luciferase expression exhibited a steady decrease over the following 3 weeks.  Sham-operated 
animals exhibited only minimal variation for the duration of the experiment, and in contrast to NF-κB, 
did not show any signs of activation in response to the surgical procedure. 
 
Figure 46.  GFAP activation in response to pBDL. 
CD1 mice transduced with LNT-GFAP-JDG virus underwent pBDL or sham surgeries.  Animals that received a 
pBDL showed a fold-change increase in luciferase expression over baseline.   
 
4.3.5  In vivo evaluation of WNT signalling during chronic cholestasis  
Using CD1 mice transduced at P0 with LNT-WNT-JDG high-titer lentivirus, partial bile duct ligation 
or sham surgeries were performed on 13 mice 50 days post-birth.  Both sets of animals showed a 
decline in mean fluorescence intensity over time up to 40 days post-surgery.  There was no 
statistically significant difference between the two cohorts at any particular time, however, from the 
mean graph, it appears that WNT signalling shows a trend toward being decreased within pBDL 
animals.  The most significant point was at day 76, 24 days post BDL, with a decrease in Wnt reporter 
activity compared to sham operated animals (p = 0.094) (Figure 47a).  Terminal analysis was 
performed on 3 individual ligated and non-ligated bile duct livers. Gross localisation of active β-
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catenin (non-phosphorylated) was assessed by immunohistochemistry.  Interestingly, both hepatocytes 
and cholangiocytes expressed active β-catenin at the plasma membrane.  The bile duct stained bright 
red in both samples, however, due to the biliary hyperplasia seen in bile duct ligated samples, a 
number of biliary ductules are stained, giving the appearance of increased β-catenin.  Close inspection 
reveals that cells within the hyperplastic lesion of the biliary tree do not show nuclear accumulation of 
β-catenin.  Levels of hepatocyte-associated β-catenin demonstrated no distinctive difference in 
expression levels periportally or perivenously (Figure 47b). 
 
Figure 47.  Effect of pBDL on β-catenin signalling in vivo.   
a)  Graph of mean fluorescence intensity of LNT-WNT-JDG transduced mice with pBDL (red) or sham (black) 
surgery.  b)  Immunofluorescence for active β-catenin on three individual sham and pBDL liver samples. 
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4.3.6  In vivo assessment of pLNT-Notch-JDG using BDL 
To elucidate the temporal profile of Notch signalling during the course of chronic biliary obstruction, 
the LNT-Notch-JDG virus was injected into CD1 PO neonates.  At 52 days post injection, partial bile 
duct ligation surgery was performed on 10 mice and sham operation carried out on 5 mice followed 
by assessment of luciferase expression in response to chronic bile duct obstruction over time.  pBDL 
animals showed a trend of decreased luciferase expression over time (Figure 48a).  Histologically, no 
visual difference in the levels of activated Notch intracellular domain (NICD) expression levels was 
observed between the two groups (Figure 48b).  NICD expression appears to be localised to the 
plasma membrane within the biliary epithelia, while expressing low levels of nuclear staining within 
the hepatocytes.  
 
Figure 48.  Mean fluorescence intensity and immunofluorescence of LNT-Notch-JDG transduced mice 
with or without BDL surgery.   
a)  Mice transduced with liver-specific LNT-Notch-JDG virus were subjected to either BDL (red) or sham 
(black) surgery.  Mean fluorescence intensity over baseline was plotted over time. b)  NICD-specific antibody 
staining in 3 individual livers from sham or pBDL operated mice.  
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Introduction 
Following the in vivo interrogation of various pathways, further investigation into the role of Wnt and 
Notch signalling was performed in vitro.  While the in vivo data demonstrated that Wnt and Notch 
signalling in mature hepatocytes was not affected during acute cholestatic disease, the role of these 
pathways within the differentiation process was subsequently interrogated using an in vitro model.  
Genetic and chemical manipulation of a progenitor cell line was predicted to give more insight into 
the role of these pathways as progenitor cells differentiate into cholangiocytes and hepatocytes.   
Progenitor cells are the unique cells that reside within the Canal of Hering and are activated to 
massively increase their proliferative capacity in response to chronic injury.  Their attractiveness in 
regenerative medicine is their ability to differentiate into either hepatocytes or cholangiocytes, 
dependent on the mode of injury.  Expression of WNT signalling within the progenitors has been 
proposed to drive them toward a hepatocyte lineage, whereas increased expression of Notch signalling 
determines their biliary lineage.  The therapeutic potential of these bipotent cells is further increased 
by the ability of these particular pathways to be modified, thereby harnessing a patient’s own 
regenerative capabilities to assist hepatic regeneration.  To further investigate the pathways involved 
in the differentiation of hepatoblasts an in vitro model is required.  The bipotent HepaRG cell line, 
capable of differentiating into both cholangiocytes and hepatocytes can be used as a platform in which 
to study both differentiation potentials using defined media protocols.  Furthermore, genetic 
manipulation of this cell line can give further insight into triggers which could affect each of the 
cellular lineages.   In 2014, Dianat et al. published a protocol to differentiate HepaRG cells along the 
cholangiocyte lineage using 3 components, IL-6, sodium taurocholate, and sodium butyrate224.  Their 
data suggest that the use of this differentiation protocol results in an enrichment of cholangiocyte-like 
cells from bipotent HepaRG cells.  Using this novel described differentiation protocol, the aim of the 
subsequent experiments in this chapter was to determine whether cholangiocyte and hepatocyte 
populations could be enriched for using culture conditions and genetic manipulation of the HepaRG 
cell line.  This enrichment was compared to the industry standard of hepatocyte differentiation of 
HepaRG cells using the addition of 2% DMSO to the culture medium. 
5.1  Results of HepaRG differentiation through media composition and genetic modulation 
5.1.1  Temporal reporter gene expression during alternative differentiation protocols 
Progenitor HepaRG cells were transduced with lentivirus containing either LNT-α1AT-NLuc, LNT-
Notch-NLuc, or LNT-WNT-NLuc.  To control for cell number, a second lentiviral vector was used to 
transduce the cells, namely LNT-SFFV-Vluc, that constitutively expresses the secreted luciferase 
vargula.  The α1AT reporter contains a hepatocyte-specific response element and would be 
informative for relative levels of hepatocytes in each of the cultures.  Protocol 1 was the standard 
  
CHAPTER 5 – HEPATIC PROGENITOR DIFFERENTIATION                                                          80 | P a g e  
 
differentiation protocol for hepatocytes using 2% DMSO, while protocol 2 used the Dianat protocol 
that included IL-6, sodium taurocholate, and sodium butyrate in the differentiation medium.  Using 
the dual secreted luciferase system, media was harvested and analysed every 2 days.  For all reporters, 
both the cholangiocyte-associated Notch reporter and the hepatocyte-associated reporters showed 
increased levels of expression in the 3-component protocol compared to day 0.  By day 4, prior to 
dual treatment with sodium taurocholate and sodium butyrate, all protocols showed a peak in 
expression for protocol 2.   Using protocol 1, generally known as a hepatocyte-inducing protocol, 
α1AT did not show an increase in expression, but rather decreased after day 4 to a final value of 8% 
of the starting expression.  Notch reporter activity showed a modest peak early on at day 4, but this 
decreased over time and also decreased to 15% of its initial value.  Lastly, WNT expression mimicked 
α1AT expression with relatively stable expression until day 4, after which there was a rapid decrease 
to a quarter of  its expression 2 days later at day 6, which further declined to 9% of its initial value.  
 
Figure 49.  Reporter gene analysis during protocol 1 and protocol 2 differentiation. 
The Notch, α1AT, and WNT reporter cell lines all showed an increase in expression levels using protocol 2 over 
protocol 1.  All protocols exhibited a peak at day 4. 
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5.1.2   Phenotypic, qualitative, and quantitative assessment of differentiation protocols 
Despite basal culture conditions of protocol 1 and protocol 2 being different, in that protocol 2 has 
lower levels of serum, zinc, and hydrocortisone in comparison to protocol 2, the cells appeared 
morphologically similar at the start of the experiment and no distinct differences could be seen.  
Following 2 weeks of differentiation, the cells treated with DMSO showed an elongated morphology, 
while the cells that had undergone protocol 2 were more densely packed and more triangular in shape.  
Within the second culture using protocol 2, there were some sparse collections of denser cell colonies 
which appeared smaller in size, presumably consisting of hepatocyte-like cells (Figure 50).  These 
hepatocyte-like cell clusters were absent from the protocol 1 culture, and thus a more in-depth 
analysis using immunohistochemistry and qPCR was carried out (Figure 51).   
 
Figure 50. Microscopic phase images of HepaRG cells using protocol 1 and 2. 
HepaRG cells were morphologically the same prior to differentiation.  Following differentiation, protocol 1 
resulted in morphologically distinct cells which were elongated in comparison to those which had undergone 
differentiation using protocol 2.  
 
Immunohistochemical staining for the cholangiocyte marker, CK19, and the hepatocyte markers, 
HNF4α and albumin all showed an increase in protocol 2 compared to protocol 1 (Figure 51a).  To 
determine the relative amounts hepatocyte- and cholangiocyte-like cells in each of the cultures and to 
corroborate the data obtained from the immunohistochemical analysis, qPCR was performed for cell-
Protool 2 – 3 component 
20x 
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type specific markers.  Albumin is a well-established marker of hepatocytes, while osteopontin and 
HNF-1β are cholangiocyte markers.  The average fold change for triplicate values for protocol 1 was 
22.36, 0.34, and 0.53 for albumin, osteopontin, and HNF-1β respectively, indicating an increase in 
hepatocyte marker expression and a decrease in cholangiocyte markers compared to undifferentiated 
HepaRG progenitor cells.  The relative fold-change for the same markers using protocol 2 were 32.86, 
5.20, and 2.29 indicating that both hepatocyte and cholangiocyte markers were increased utilising this 
protocol (Figure 51b).  
 
Figure 51.  Immunohistochemical and qPCR analysis of protocol 1 and protocol 2. 
a) The cholangiocyte marker CK19, and the hepatocyte markers HNF4α and albumin were all comparatively 
higher expressed in protocol 2 than protocol 1. b) Relative expression of albumin, osteopontin and HNF-1β were 
assessed, with protocol 2 showing increased hepatocyte and cholangiocyte markers compared to protocol 1.  
Statistical significance determined by one-way ANOVA. * P <0.05, ** P <0.01, *** P < 0.001. 
 
5.1.3   Assessing the modulation of Notch signalling on differentiation potential 
Notch signalling plays a fundamental role in the differentiation of cholangiocytes during liver 
development and its activation within hepatic progenitor cells via cell-to-cell interactions with stellate 
cells has been proposed to induce cholangiocyte differentiation.  The effect of Notch modulation on 
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differentiation potential was assessed through Jagged-1 and Numb overexpressing HepaRG cell lines, 
termed HepaJag and HepaNumb respectively.  Following their growth to confluence, the cells 
underwent differentiation protocol 1 or 2, with phase microscopy used to assess gross morphological 
and whole-culture differences (Figure 52).  HepaNumb using protocol 1 yielded the least hepatocyte-
like clusters, while interestingly showed the most hepatocyte clusters within protocol 2.  The HepaJag 
culture using protocol 1 displayed increased levels of hepatocyte-like clusters when compared to its 
HepaNumb counterpart.  A further increase in colony formation was noted when HepaJag cells 
underwent protocol 2 differentiation.  These experiments further confirm that protocol 2, utilising IL-
6, sodium taurocholate, and sodium butyrate results in more hepatocyte-like cells over the 
conventionally used DMSO protocol.  Moreover, the cells surrounding the hepatocyte-like cells 
appear phenotypically more like cholangiocytes.  Given the poor induction potential of protocol 1 for 
cholangiocytes, all further studies were conducted using protocol 2 as it is a far superior model for 
studying progenitor cell differentiation in response to cholestatic liver disease where the progenitor 
cell niche is primed for cholangiocyte differentiation and regeneration. 
 
Figure 52.  Differentiation potentials of HepaJag and HepaNumb cell lines in response to variable 
differentiation protocols. 
Jagged-1 and Numb overexpressing HepaRG cell lines were subjected to each of the protocols.  The HepaNumb 
cells in protocol 1 yielded the lowest hepatocyte differential potential, while the same cells in the second 
protocol yielded the highest potential to form hepatocyte-like cells.  
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Comparison of the differentiation propensities of HepaJag (Figure 53a) and HepaNumb (Figure 53b) 
cell lines that had undergone protocol 2 differentiation was performed.  Cells were subjected to 
immunohistochemistry for key markers of cholangiocytes and hepatocytes.  While data presented was 
not quantified, a general qualitative analysis of the cultures as a whole was undertaken. 
Representative images are presented for each marker for each condition.  HepaJag showed increased 
intensity staining for the cholangiocyte markers CK19 (I) over HepaNumb, while CK7 (II), a marker 
of more mature cholangiocytes appeared to show little difference between the cultures.  This indicates 
that the cholangiocytes within this culture may still be immature.  Conversely, HNF4α (III) and 
albumin (IV) showed decreased levels of staining within the HepaJag compared to the HepaNumb 
sample which contained many more positively stained cells outside of the colony structures.  Albumin 
expression within the HepaJag culture showed almost mutually exclusive staining of GFP and 
albumin, indicative of a lack of JAGGED1 expression within the albumin-expressing colony. 
Interestingly, SOX9 (V) expression was found to be highest within colony like structures in both cell 
lines, with lower expression seen in JAGGED expressing cells, as indicated by low levels of 
colocalisation of GFP and SOX9.  The differentiation of bipotent progenitors towards hepatocytes is 
usually associated with an increase in NUMB expression, resulting in decreased accumulation of 
nuclear NICD.  However, it appears that the hepatocyte colonies exhibited increased NICD staining 
(VI) compared to the cholangiocytes on the periphery of these colonies. Active β-catenin staining 
(VII) resembled that seen within the immunohistochemistry samples obtained from pBDL mice, with 
distinct plasma membrane staining that was significantly more intense within the hepatocyte colonies.  
There was also punctate nuclear staining of cells within the colonies that was not observed in the 
cholangiocyte cells.  Lastly, acetylated α-tubulin (VIII), a marker of primary cilia seen on 
cholangiocytes and not hepatocytes, did not detect ciliary structures.  However, since acetylated 
tubulin also stains cytoskeletal acetylated tubulin and the level of acetylation differs in cell types 
dependent on tubulin deacetylase activity, it was intriguing to note that the cholangiocytes stained 
poorly for acetylated α-tubulin, while the hepatocyte-like colonies exhibited intense staining.  
Furthermore, the colonies within the HepaJag culture displayed strong perinuclear staining, while 
those colonies within the HepaNumb culture displayed more dispersed cytoplasmic staining. 
Overexpression of JAGGED1 was confirmed through qPCR analysis of the downstream target, HEY1.  
HepaJag cells showed a 655.20 fold increase over undifferentiated HepaRG cells, while HepaNumb 
showed a fold-change of only 3.29 over undifferentiated cells.  This is a decrease in expression from a 
fold-change of 243.04 seen in unmodified HepaRG cells which underwent protocol 2 differentiation, 
indicating that Numb decreases Notch signalling. Furthermore, qPCR of HepaJag cultures for the 
cholangiocyte markers Sox9, Osteopontin, and HNF1-β, all showed increased levels over the 
HepaNumb cell line.  Contrastingly, albumin was shown to be increased in the HepaNumb cell line 
compared to the HepaJag cell line (Figure 53c). 
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Figure 53.  Immunohistochemical and qPCR analysis of HepaJag and HepaNumb cell lines in response to 
protocol 1 and 2. 
a)  Immunohistochemistry of HepaJag showed increase CK19 expression, while b) HepaNumb immunostaining 
showed increased staining for the hepatocyte markers HNF4α and albumin. c)  Although no points were 
statistically significant, qPCR analysis confirmed a trend towards increased cholangiocyte expression in Jagged 
overexpressing cells using Sox9, osteopontin, and HNF-1β markers, while HepaNumb demonstrated an increase 
in hepatocyte expression using albumin.  HEY1 exhibited increased levels of expression in HepaJag cells.  All 
samples expressed as fold change ± SD over undifferentiated HepaRG cells.  Statistical significance determined 
by two-way Anova corrected for multiple testing using Bonferroni.  
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Introduction  
The determination of factors which trigger hepatogenic differentiation is necessary for future 
development of liver cell therapies. In the previous chapter, media composition and Notch modulation 
were shown to definitively affect the differentiation potential of HepaRG cells, however, data 
increasingly suggests that Sox9 also plays a pivotal role in differentiation following hepatic injury.  
The role of Sox9 during embryogenesis and ductulogenesis is now well established, but its role in the 
process of differentiation following biliary injury is still under investigation.  The use of HepaRG 
cells in vitro is used to mimic the ductular reaction in which the hepatic progenitors proliferate 
expansively and differentiate. Understanding the mechanistic role that a pathway contributes to a 
biological process is achievable through target gene validation.    One of the most valuable means of 
validation is through disruption or overexpression of a gene within a cell culture setting or within a 
whole organism.  This enables the elucidation of the role of a particular gene with regard to 
developmental processes and disease initiation, perpetuation, and resolution. Many advances in 
technologies have facilitated the way in which genetic manipulations are achieved. The use of 
overexpression vectors using transient transfection or viral delivery for long-term expression offers 
insight into gain-of-function roles of a gene.  The use of short-interfering RNAs (siRNAs) or short 
hairpin RNAs (shRNAs), which reduce the expression levels of a protein through RNA interference, 
have also been used with much success273.  The efficacy, however, is extremely variable, and levels of 
knockdown may not be sufficient for phenotypic or functional perturbation, and complete knockout is 
even less feasible.  Therefore, modification of expression levels at the genomic level remains the 
method of choice to overcome the difficulties of gene function abolition.   
Endonucleases are molecular “scissors” which have the ability to cleave DNA and cause the 
formation of insertions or deletion which, in the absence of suitable template DNA, results in gene 
disruption and knockout. Alternatively, double-stranded DNA breaks can be repaired by homology-
directed repair. Site-specific nucleases can be used to cleave the DNA and permit exogenous template 
DNA to be substituted for genomic DNA. The latest, and undoubtedly mostly widely-used genome 
editing tool currently, is the CRISPR (clustered regularly interspaced short palindromic repeats)-Cas 
(CRISPR-associated) system. The ease of development of a targeting construct, specificity of 
targeting and efficiency of cleavage274 has seen this technology come to considerable prominence in 
molecular research.  Modifications of the CRISPR/Cas system are constantly being evaluated to 
increase the utility of this revolutionary technology for use within translational medicine275.  
Given the advantages of genome editing, a CRISPR/Cas genomic knockout strategy was employed to 
determine the effect of SOX9 ablation on progenitor status and differentiation potential.  Given that 
SOX9 is expressed in progenitors, with its expression further induced upon cholangiocyte 
differentiation, it is hypothesised that the knockout of this gene would further promote HepaRG cells 
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toward a hepatocyte phenotype, synergistically with the prior mentioned protocol 2 and HepaNumb 
modifications.  This hypothesis was tested and is the topic of the following chapter of research.  
6.0  Introduction to RNA-guided CRISPR/Cas9 genome editing 
The CRISPR/Cas9 system forms part of the bacterial adaptive immune system based on self/non self-
discrimination.  CRISPR-Cas imprints genetic material into the host genome as a form of memory in 
the event of future invasions by phages, plasmids and other mobile genetic elements276.  The system 
has been further modified and exploited for molecular biology use.  There are three types of 
CRISPR/Cas systems277, with type II being the most widely used for genome editing.  This system 
requires the formation of a secondary structure comprising the trans-activating (tracrRNA) with the 
pre-crRNA through complementary base pairing.  This secondary structure triggers further processing 
of the crRNA by RNase III and silencing of foreign DNA by Cas9278.  DNA targets are determined by 
the guide RNA (gRNA) finding regions of complementarity within the genome.  The caveat to Cas9 
cleavage is that a protospacer adjacent motive (PAM) sequence is required to be juxtaposed to the 
tracrRNA:crRNA secondary structure on the 3’ end.   The PAM motif is species specific, but in the 
case of genome editing, the Streptococcus pyogenes Cas9 requires an 5’-NGG-3’ consensus sequence 
immediately following the region of complementarity to the gRNA278. The crRNA is required for 
target sequence recognition while the transencoded tracrRNA forms a duplex with the crRNA to form 
a stem loop, and in the presence of Cas9, this ribonucleoprotein complex is able to mediate specific 
double-stranded cleavage of the target DNA279 ( 
Figure 54). Using this system, Jinek et al. engineered an RNA chimera vector composed of a dual 
tracrRNA:crRNA-guided Cas9 protein and showed that, in the presence of the Cas9 and the PAM 
motif,  the construct could target and cleave any double-stranded DNA sequence of interest280.  This 
RNA chimera is now routinely used to facilitate the use of the CRISPR-Cas9 system as a RNA-
programmable genome editing tool.    
 
 
Figure 54. Genome editing using CRISPR/Cas9. 
Cas9 nuclease targeting is mediated through a 20 
nucleotide guide sequence that forms part of the 
gRNA and binds to its complementary genomic 
counterpart. The remainder of the gRNA is 
comprised of the tracrRNA and crRNA which form 
a secondary structure required for crRNA 
processing of and activation of the Cas9 nuclease. 
The NGG PAM site is required for S. pyogenes 
Cas9 to recognise its target and initiate a site-
specific DSB. 
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http://www.transomic.com/getattachment/0c3a5b99-05eb-43ee-a253-892eaf34b018/transEdit.aspx?maxsidesize=800 
Upon the introduction of a double-stranded break (DSB), natural cellular repair mechanisms are 
activated and attempt to repair the lesion and continue transcription.  In the absence of a suitable 
repair template, the DSB is repaired through ligation of the two cleaved ends by the error-prone 
system of Non-Homologous End Joining (NHEJ).  Since there is an absence of template, random 
nucleotide bases are either inserted or deleted leading to DNA sequences which differ from the 
wildtype sequence.  These insertions/deletions (InDels) may alter the reading frame of the target gene 
either through significantly altering the amino acids within the transcript, or alternatively, through the 
introduction of a stop codon which would cause premature transcription termination281, 282.  It is these 
alterations to the genome that makes the CRISPR-Cas9 system such a revolutionary tool within the 
laboratory, as any target gene can be “knocked-out” simply through the introduction of Cas9 with a 
gRNA loaded with a target sequence for the gene of interest274.  
6.1  Results of genome editing of HepaRG cells 
6.1.1  Cloning of guides into the px330 CRISPR/Cas9 vector 
To determine the role of SOX9 during the differentiation two constructs were developed, one that 
contained the SOX9-specific guide, and a second which contained a guide which theoretically had no 
region of complementarity within the human genome.  Following genome-editing, indels result in the 
formation of mRNA transcripts that contain a nonsense mutation resulting in the presence of a 
premature stop codon that would be degraded through nonsense-mediated decay.  Therefore, the 
earlier the interruption, the increased probability of the mutation producing a non-functional protein, 
and to this end, the guide RNA was designed within the first bases of exon 1.  The spCas9 is predicted 
to cut 3-4 bp upstream of the PAM sequence, and was therefore predicted to result in early 
termination of the SOX9 protein.   
The Sox9 guide RNA and a negative guide RNA, with no known binding sites within the human 
genome, were annealed and cloned into the px330 vector upstream of the human Pol III promoter.  
When designing the guides, particular parameters as outlined in the seminal genome editing 
CRISPR/Cas paper by Cong et al. were adhered to in order to increase the probability of gene 
knockout199.  To ensure that a gene is knocked out, it is preferable to design oligos corresponding to 
the N-terminus of the protein so that a truncated, but functional protein is not formed.  Downstream of 
the guide was the chimeric tracrRNA:crRNA which contains the modified tracrRNA that is 85 
nucleotides longer than the originally described versions has been found to have more efficient 
cleavage when compared to shorter tracrRNA sequences used in some other vectors283.  Below is the 
genomic region amplified using the specified PCR primer sequences (aqua) with the guide strand 
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indicated (grey) adjacent to the PAM site (blue).  Cas9 cleavage is expected to occur between the 3rd 
and 4th base from the PAM sequence, and is denoted by the▼ symbol (Figure 55).  
 
Figure 55.  Sox9 knockout genomic location and Cas9 cleavage site. 
The guide binding site is highlighted in grey with the highlighted cccggg site corresponding to the SmaI 
restriction site.  The arrow represents the predicted cleavage site of the Cas9 nuclease between the 3rd and 4th 
base upstream of the PAM motif, highlighted in blue.  Aqua highlighting represents the primer binding 
sequences used for amplification of the Sox9 target sight with 274 bp upstream and 420 bp downstream of the 
nuclease site. 
 
The spCas9 is flanked by nuclear localisation signals, causing nuclear import of the Cas9 protein.  
Lastly, the Cas9 transcript is terminated with the presence of the bovine growth hormone 
polyadenylation signal (bGHpA) (Figure 56a). Following cloning of the Sox9 and negative control 
guides into the px330 vector, several clones were restriction enzyme digested in order to validate 
whether the insert was successfully ligated into the backbone.  Upon ligation of the insert into the 
BbsI restriction site, the restriction site is destroyed, but the AgeI restriction enzyme site 
approximately 1 kb upstream remains intact.  Therefore, ligation of the insert is expected to yield a 
single band due to only digestion of one of the sites, AgeI, and failure of ligation will leave the BbsI 
site intact, thereby causing cleavage at both the BbsI and the AgeI sites and excising the 1 kb band.  
From the gel in Figure 56b, all 4 clones for both the Sox9 and the negative control clones contained 
their respective inserts, while the empty px330 backbone showed an excised band of approximately 1 
kb.  Sequencing validation was performed on the correct clones to ensure clone sequence integrity.   
 
6.1.2  HepaRG knockout of Sox9 using CRISPR/Cas9 technology 
Efficient transfection of the vectors into the target cell line was required, as the higher the 
transfection, the greater the probability of achieving bi-allelic knockout and the fewer clonal colonies 
would be required to be screened.  To achieve higher transfection efficiency, electroporation of the 
plasmid was performed, whereby an electric field is applied to the cells to increase the permeability of 
the cell membrane and enhance the uptake of plasmid DNA into the cell284.   
The culture was initially heterogeneous following electroporation due to the lack of antibiotic 
resistance or fluorescent marker genes within the px330 vector.  Following nucleofection of the 
HepaRG cells with the px330-Sox9 and px330-ng ctrl vectors, genomic DNA was extracted from the 
cells.  Primers flanking the guide RNA site were used to amplify the target followed by a T7 
gtgcaagcgcccccacttttgctctttttcctcccctcctcctcctctccaattcgcctccccccacttggagcgggcagctgtgaactggccaccccgcgccttcctaag
tgctcgccgcggtagccggccgacgcgccagcttccccgggagccgcttgctccgcatccgggcagccgaggggagaggagcccgcgcctcgagtccccgagccgc
cgcggcttctcgcctttcccggccaccagccccctgccccggg▼cccgcgtatgaatctcctggaccccttcatgaagatgaccgacgagcaggagaagggcctgt
ccggcgcccccagccccaccatgtccgaggactccgcgggctcgccctgcccgtcgggctccggctcggacaccgagaacacgcggccccaggagaacacgttccc
caagggcgagcccgatctgaagaaggagagcgaggaggacaagttccccgtgtgcatccgcgaggcggtcagccaggtgctcaaaggctacgactggacgctggt
gcccatgccggtgcgcgtcaacggctccagcaagaacaagccgcacgtcaagcggcccatgaacgccttcatggtgtgggcgcaggcggcgcgcaggaagctcgc
ggaccagtacccgcacttgcacaacgccgagctcagcaagacgctgggcaagctct 
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endonuclease I assay for confirmation of genome editing within the population.  This assay is 
dependent on the formation of heteroduplexes which contain mismatches during the process of PCR 
product melting and slow re-annealing.  These mismatches occur due to some of the DNA containing 
a mutation, while other fragments contain the wildtype allele.  When the wildtype and mutated strands 
anneal, they form a base mismatch.  The T7 endonuclease is a junction-resolving enzyme that 
recognises these mismatches and cleaves the DNA at the first, second, or third phosphodiester bond 5’ 
to the mismatch285.  Digestion of the PCR product with T7 results in multiple bands following gel 
electrophoresis. The presence of the additional band within the Sox9-guide transfected cells was 
confirmation of successful population-wide genome editing of the cells.  HepaRG and negative guide 
PCR products showed a single band of 300 bp, while the Sox9 guide PCR product resulted in the 
presence of 3 bands, 300 bp, 250 bp, and 50 bp in size (Figure 56c).  To obtain a homogenous 
culture, the cells were clonally amplified and genomic DNA extracted from each of the clones.  PCR 
amplification of a larger target region was performed and should have resulted in the production of a 
700 bp fragment. Clone 3, showed only a single band around 2kb in size, while all other clones 
contained the correct size insert of 700 bp (Figure 56d).    
A T7 endonuclease assay was then performed on the samples in order to determine whether the clones 
were heterozygous for an indel.  Heterozygotes would result in the formation of heteroduplexes 
during denaturing and re-annealing of the PCR product, whereas homozygous wildtype and 
homozygous mutants would only yield a single band as they would anneal perfectly, and not giving 
access to the T7 enzyme to cleave the annealed product.  A Sox9 bi-allelic knockout cell line was 
desired for the differentiation protocol, and thus all heterozygote clones detected by T7EN I were 
discarded.   
A restriction enzyme digest method of mutation analysis was employed in order to assess the presence 
of an indel within a particular location.  The predicted Cas9 cleavage site is between the 3rd and 4th 
base from the PAM sequence, and corresponds to the SmaI recognition sequence (CCC▼GGG).  
Therefore, using the SmaI restriction site, the remaining clones underwent restriction digestion and 
subsequent gel electrophoresis to determine whether they contained a bi-allelic Sox9 mutation.  Any 
mutations in the SmaI recognition site where the predicted cleavage site is located, would result in the 
abolishment of the recognition sequence, and would produce a single band on the gel.  This is in 
contrast to the wild type amplicon which would be digested into two fragments by SmaI. All digests 
contained the same amount of DNA as measured spectrophotometrically and digested for only 1 hour 
to ensure that the DNA was not overdigested which result in star activity and the production of 
multiple bands on the gel.  Using this strategy, it was found that 2 clones no longer contained the 
predicted SmaI site, and had therefore been mutated (Figure 56e).  Furthermore, they did not show 2 
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alleles (3 bands on the gel, 1 for the mutant and 2 for the wildtype alleles), and were therefore 
predicted to be bi-allelic Sox9 knockouts.   
 
Figure 56.  Cloning and validation of the px330-Sox9 genome editing vector. 
a)  BbsI guide-RNA cloning site in px330.  b) Positive clones for Sox9 and negative guide clones in the px330 
vector.  c) T7EN1 assay using DNA from the HepaRG cell line and heterogeneous populations of negative and 
Sox9 guide nucleofected cell lines. d) PCR amplification of target region for clonally amplified populations of 
HepaRG Sox9 knockout clones. e)  SmaI digest of individual clones with 3 bands indicating heterozygosity. 
 
Sox9 DNA from clones 3 and 31 were sequenced to confirm bi-allelic mutations.  Sequencing results 
revealed that clone 3 contained a large insertion mutation between the 3rd and 4th base upstream from 
the PAM site (Figure 57a).  The misaligned sequence was analysed by BLAST and did not yield any 
positive hits, indicating that the inserted sequence is not from a coding region of the genome.  Clone 
31, interestingly, did not contain a large insertion like clone 3, but instead contained only a 6 bp 
deletion at the 5’ end of the guide, with the sequence 5’-CCCGGG-3’ (Figure 57b).  Interestingly, the 
6 bases which had been deleted corresponded exactly to the SmaI recognition sequence detected 
through failed digestion of this clone by SmaI. 
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Figure 57.  Sequencing of 2 clones following CRISPR-Cas genome editing of the Sox9 locus. 
a)  Sequencing of 2 individual clones containing a large insertion and b)  a 6 bp deletion. 
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6.1.3  Analysis of Sox9 knockout clones 
The validated clones were subsequently amplified as a homogenous HepaRG Sox9-/- cell line to be 
used within the 3-component differentiation protocol.  A total of four Sox9 knockout clones were 
found.  A number of phenotypic observations were made between the wildtype HepaRG cells (Figure 
58a) and all four of the Sox9 knockout cells (Figure 58b) during their amplification.  Firstly, the rate 
of proliferation was dramatically reduced compared to the wildtype cells with only a sparse number of 
cells seen compared to the wildtype cells which had become confluent during the same period of time.  
Secondly, upon proliferation, the cells displayed decreased cell-to-cell contacts, increased motility 
and a decreased propensity for colony formation following a series of cell divisions.  Thirdly, the 
Sox9-/- cells appeared morphologically distinct with their elongated, spindle-like phenotype.  A higher 
proportion of Sox9 knockout cells also contained extending processes (arrow head).  Following a 
month of culturing, the Sox9-/- knockout cells showed growth arrest, a flattened cellular morphology, 
and exhibited increased cytoplasmic mass and a distinctly large nucleus (arrow), indicative of cellular 
senescence.  Passaging of these cells resulted in the loss of the cells as they did not adhere when 
replated. 
 
Figure 58.  Phenotypic differences in wildtype and Sox9 knockout HepaRG cells. 
a)  Clonally amplified wildtype and b) Sox9 knockout cells exhibited decreased proliferation and cell-to-cell 
contacts and appeared phenotypically distinct to the wildtype cells at the same magnification.  
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7.0  Discussion 
Animal models have been employed to gain insight into the evolution of pathological phenotypes. 
Many of these phenotypes arise due to altered signal transduction pathways at the onset and during 
the progression of disease.  While these models provide invaluable information, there is a growing 
need to reduce the number of animals required for such studies by improving upon current 
methodologies.  One innovative refinement has been the generation of whole-body reporter mice 
which have been generated within the last decade. Disease-mediated activation of a signalling 
pathway yields a quantifiable measure of luciferase activity in vivo to produce a temporal readout of a 
biological process. While this non-invasive methodology has greatly reduced the numbers of animals 
used by providing longitudinal imaging/data capture, the generation of these transgenic lines is 
immensely costly and time consuming.  The research presented within this thesis illustrates the 
development and proof-of-concept work using somatotransgenic bioimaging.  This is followed by the 
application of the reporters within a relevant in vivo liver disease model and in an in vitro culture 
system used to assess pathways implicated in chronic liver disease.  The exceptionally high sensitivity 
of luciferase allows for the detection of small changes in gene expression.  Importantly, there is no 
endogenous activity of the luciferase within host cells, so interference in quantification is absent, 
making this an ideal gene regulation reporter system.  While these reporters have shown great promise 
for in vivo applications, the development of various luciferase vectors, including secreted versions for 
temporal in vitro purposes provides limitless possibilities of using such reporters within a wide range 
of applications. 
7.1  Dual reporter vectors can be successfully used within in vitro and in vivo model systems  
7.1.1  Development of a bicistronic firefly luciferase / GFP lentiviral construct  
For the purposes of this project, a bicistronic lentiviral vector containing dual reporters, namely firefly 
luciferase and GFP, was produced.  The firefly luciferase was developed in the lab of Dr James 
Murray239.  This engineered luciferase mutant was codon optimised for mammalian expression 
through base substitutions which result in synonymous mutations and thus do not alter the amino acid 
sequence.  It also contains the non-synonymous mutations, without an accompanying loss of specific 
or kinetic activity relative to the wild-type version of the enzyme.  These attributes make this 
luciferase a far more desirable candidate for both in vitro and in vivo applications.  The foot-and-
mouth disease virus (FMDV) 2A cleavage peptide fused to the GFP codes for a peptide that 
undergoes spontaneous post-translational peptide-bond cleavage, generally resulting in equimolar 
amounts of the transgenes upstream and downstream of the 2A sequence286.  Other elements within 
the lentiviral cassette include the cPPT, the WPRE, and the 5’ and 3’ deleted LTR. The cPPT is 
required for positive-strand DNA synthesis following reverse transcription, and also enhances 
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transduction efficiency through increased nuclear import of the vector genome287, while the WPRE 
has been shown to enhance expression of the transgene within target cells288.  The LTRs facilitate the 
integration of the payload area contained between them, into the host genome.  The 3’ LTR contains a 
disabling self-inactivating mutation that removed the LTR promoter activity through deletion of the 
TATA box, and renders the lentivector replication-incompetent289.   
 
7.1.2  Validation of the pLNT-SFFV-JDG vector 
Expression of the FLuc and GFP proteins was determined using 3xFLAG and GFP-specific 
antibodies.  Results indicated that the vector expressed both transgenes in vitro.  Using lysate from 
LNT-SFFV-JDG transduced HEK293T cells, it was established that 2A cleavage was 90% efficient as 
determined densitometrically using Western blot, which was more than adequate for the proposed 
work and well within the published cleavage efficiencies of 76-88% for various 2A sequences290, 291.  
This indicates that the bicistronic reporter cassette reliably cleaves the 2A peptide which should 
theoretically yield two individual proteins of equimolar quantities. 
The development of novel luciferase vectors requires complete analysis of the luciferase enzymatic 
kinetics.  Since the luciferase used has multiple modifications, it was necessary to determine the peak 
fluorescent output of this vector in vitro.  The empirical peak was determined to be at 549 nm, almost 
the same peak wavelength expected for wild-type Phontinus pyralis (firefly luciferase), which has 
been shown to have a peak photonic emission around 560-562 nm292, 293.  A 10 nm spectral shift was 
not predicted to be large enough to affect in vivo luciferase expression since the quantum yield 
(brightness) of the vector was exceptionally high and a significant amount of photons were being 
expressed above 600 nm, the region of the spectrum where the photons are not absorbed by 
haemoglobin, and are therefore more readily detectable from within haemoglobin-rich tissues such as 
the liver.  Importantly, enzymatic activity was also assessed, as cleavage of the 2A sequence results in 
19 residual amino acids remaining attached to the upstream protein on the carboxy terminus, while the 
downstream protein retains the remaining 2 amino acids on its amino terminus following cleavage294.  
The data confirmed that the 2A sequence did not result in any accompanying loss of enzyme activity 
post-cleavage. Transduction potential was visually assessed by fluorescence microscopy for the 
presence of GFP, while luciferase activity was detected by luciferase assay. 
 
7.1.3  Development of a library of reporters using Gateway cloning 
The development of a parental vector that has the capacity to quickly and efficiently generate a library 
of alternative vectors was a highly desirable feature.   Thus, the JDG insert was directionally cloned 
into the pLNT-GW-MCS vector to create pLNT-GW-JDG.  This vector has the ability to mediate 
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ligation-independent Gateway® recombination to clone transcription-factor binding response 
elements upstream of the dual reporter insert with a high degree of efficiency.  Response elements 
were cloned into the pENTR shuttle plasmid containing a mouse minimal promoter that contains 
sequences that specify the transcriptional start site, however does not strongly recruit RNA 
polymerase, thus only giving basal levels of transcriptional activation.  Signalling specificity and 
strong transcriptional activity is then conferred through the binding of specific transcription factors to 
their unique response elements.   The rapid generation of these lentiviral reporters has immense 
broad-scale applicability within the biomedical sciences, as they can be used as a quantitative measure 
of transcription factor activity, particularly in models of inflammation, fibrosis, cancer, and metabolic 
processes. These signalling profiles will further contribute to our understanding of the ways that 
particular signalling pathways are involved in normal development and also the pathogenesis of 
disease. 
 
7.1.4  Dual secreted luciferase platform permits longitudinal in vitro analysis of signalling  
Following the successful development of the Gateway® firefly luciferase vector, the NanoLuc® 
(NLuc) vector was subsequently cloned.  This luciferase is secreted into the media, thus allowing 
longitudinal studies using luminescence as the output without termination of the experiment. This 
mode of analysis is particularly useful in differentiation experiments where pluripotent or bipotent 
progenitor cells are specified toward a particular lineage through the addition of particular agonists, 
antagonists and/or growth factors. These differentiation experiments are typically of longer duration 
than most drug activation/inactivation studies.  The quality of the data is also improved since the same 
samples can be analysed at several time points throughout the course of the experiment, thereby 
decreasing the amount of inter-experimental variability.  The ideal vector for such temporally 
extended studies would contain the secreted NanoLuc that could be assayed without the need for cell 
lysis and also contain GFP as a visual reporter of signalling activity that could be monitored 
microscopically.  To this end, the Gateway-NanoLuc®-2A-eGFP (pLNT-GW-NLuc2) vector 
(Appendix A.vi) was synthesised to create a parental construct into which an array of response 
elements could be rapidly cloned using Gateway technology.  
Vargula luciferase is a naturally secreted luciferase that uses vargulin as its substrate and can be used 
in conjunction with NanoLuc® as the constitutive control to normalise expression.  Transcription 
factor activity can then be determined using the biosensing NanoLuc® readout.  The generation of 
this non-terminal luciferase assay system, and the ease with which libraries can be generated in order 
to obtain longitudinal readouts, is a significant development for in vitro bioluminescent assays, 
particularly with respect to differentiation experiments295.  
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7.1.5  Constitutively expressed luciferases confirm substrate specificity  
Substrate specificity of luciferases is critical for combining reporter constructs for dual quantitation 
either in vitro or in vivo.  Validation studies confirmed that firefly luciferase was highly specific for 
its substrate, D-luciferin, while the other luciferases were unresponsive.  Interestingly, even though 
renilla showed the highest fold change in luciferase activation with coelenterazine as the substrate, 
firefly luciferase also showed an increase in luciferase activity, but this was not significant following 
correction for multiple testing using the Tukey’s post-hoc test.  NanoLuc is known to utilise 
coelenterazine as a substrate, and so its photonic output in response to coelenterazine is not 
unexpected.  However, the signal is relatively modest in comparison to other luciferases to their 
specific substrates.  An enhanced substrate, known as furimazine, has recently been produced.  This 
substrate is an analogue of coelenterazine and shows improved luminescent output compared to RLuc 
and FLuc with their respective substrates, making it an attractive alternative for luminescent-based 
assays248.  Lastly, vargulin was tested and exhibited the greatest fold increase in the vargula luciferase 
sample with all other luciferases having no activity in the presence of vargulin, indicating a high 
degree of substrate specificity.  The use of the two secreted luciferases, Vluc and NLuc, within the 
same well is desirable, and thus there should be minimal cross-reactivity of the NLuc vector with 
vargula and the Vluc vector with coelenterazine.  The presented data confirms the suitability for 
simultaneous use of these secreted vectors within a single-well system.   In vivo comparisons have 
also been conducted with Tannous and colleagues inoculating tumor cell lines expressing firefly, 
renilla, or vargulin luciferase into different regions of the same mouse.  Following sequential (1 day 
apart) administration of their respective luciferins, namely D-luciferin, coelenterazine, or vargulin, 
only the tumor location corresponding to the paired luciferase showed an increase in luminescence296.  
This shows the specificity of these luciferases within an in vivo context and offers the potential to 
perform dual or even triple bioluminescence imaging analysis of cellular processes. 
7.2  Biosensing reporters as monitors of transcription factor activity 
7.2.1  NF-κB reporter cell lines respond significantly to agonist administration in vitro 
Coupling of genetic reporters with particular synthetic response elements facilitates the detection of 
pathway-specific gene activation in contrast to constitutive expression which is stimulus independent.  
Reporter gene expression has been increasingly used to determine the impact of relative expression 
levels on the phenotype of an organism or culture assay.  To this end, the NF-κB-JDG vector was 
used within the proof-of-concept in vitro assay of the biosensing reporters using the hepatic Huh7 cell 
line.  This cell line is a human hepatoma-derived cell line, and has been used extensively to study 
many hepatic processes and pathways, including mechanisms of HCV infection and replication, 
xenobiotic responses, and the effects of potential therapies297.  A significant proportion of hepatic 
insults result in an increase in inflammation, thus, the Huh7 cell line was considered a suitable model 
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to validate the NF-κB reporter using agonists that incite inflammatory responses that mimic natural in 
vivo responses.  Huh7 cells were activated by ultra-pure LPS, a TLR4-specific agonist.  LPS not in its 
ultra-pure state contains other bacterial components, such as lipopeptides, which not only stimulate 
TLR4, but also TLR2298, an undesirable result in the context of our experiments as this would cause 
NF-κB signaling within the tlr4-/- mice transduced with the vector.   
Several NF-κB transduced cell lines showed a significant increase in luciferase expression over their 
inactivated counterparts in response to LPS. All cell lines were assayed at 48 hours post-activation, as 
this was the time of highest activation within the aforementioned time course.  Huh7 cells showed 
significance at 48 hours with a mere 1.8 fold change, while a 4.6 fold change seen at 12 hours within 
the time course was not deemed significant.  This is due to the number of samples that are being 
compared.  Due to the fact that a change in expression over time was used for the time course, a two-
way ANOVA was applied to determine statistical analysis.  This takes into account multiple testing 
and corrects for it using the Bonferroni.  This is in contrast to the cell line comparisons, in which a 
Student’s t-test was performed, which does not require correction for multiple testing.  A significant 
response was noted in HepG2, Huh7, and fibroblast cell lines.  This response was specifically TLR4 
mediated, as LPS failed to instigate an NF-κB-mediated increase in luciferase activity in tlr4-/- MEFs.  
This observation has also been published by Chow et al. who determined that NF-κB signalled 
specifically through TLR4299.  NF-κB signalling has been found to be a driving force in EMT, with 
LPS induction resulting in an increase in expression of EMT-associated transcription factors such as 
SNAIL300.  It has been previously shown that cholangiocytes exposed to high levels of LPS, are able 
to undergo EMT and contribute to the fibrogenic phenotype or even the development of 
hepatocellular carcinoma301.  In vitro NF-κB reporters are therefore a useful tool for the continued 
assessments of the effects of LPS and NF-κB signalling on tumour cell characteristics such as 
invasion and survival in HCC cell lines302, 303.     
 
7.2.2  Activin A induces a temporal and dose-dependent increase in Smad2/3 signalling in vitro 
In the context of in vivo fibrosis, activation of the TGF-β pathway is largely due to TGF-βI, enhancing 
the transcription of fibrosis-promoting target genes, most notably collagen, fibronectin, and the 
protease inhibitors PAI-1and TIMPs304.  The SBE binding sequence CAGACA, also known as a 
CAGA box, is a TGF-β-inducible DNA element found in the regulatory regions of fibrosis-associated 
genes.  Using the LNT-SBE-JDG construct, a concentration of 10 ng/ml or less of activin A resulted 
in failure of reporter activation, while higher doses demonstrated a positive correlation with luciferase 
expression.  Activation of the reporter was confirmed in a number of cell lines including the immortal 
human cell lines, HEK293T and HeLa, a human primary fibroblast cell line, and a CD1 mouse 
primary fibroblast cell line.  All luciferase activity was normalised to total protein content.  While all 
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cell lines were transduced with the same MOI of virus, they may not all be transduced with the same 
efficiency oweing to cell-surface receptor availability for viral entry.  All cell types were known to 
have intact SMAD 2/3 signalling pathways.  However, it is known that there is significant variation in 
downstream affector abilities between of signalling pathways within different cell types due to 
adaptor protein305 and transcription factor abundance306 and the regulation of gene expression via 
distal enhancer elements307. These factors may account for some of the variation of expression 
observed between cell types.     
Benus et al. utilised TGF-β stimulation of the SBE-Luc reporter which resulted in a 7-(HepG2) to 18-
fold (A549) increase in reporter activity308.  These wide-ranging effects of reporter activity between 
different cell lines and in response to different agonists indicates that this response element has a 
broad activation range and has the capacity to become activated with nanogram concentrations of 
agonist which is essential in a physiological context.  
 
7.2.3  LiCl activates Wnt signalling and increases WNT-JDG reporter activity in vitro 
WNT signalling is crucial in the development of the liver amongst other organs, and has increasingly 
been shown to be imperative in the differentiation of hepatic progenitors to hepatocytes in response to 
chronic liver disease.  Specifically, Forbes et al. have shown ex vivo data showing that in response to 
hepatocyte injury, macrophages secret the Wnt ligand, Wnt3a, initiating canonical Wnt signalling 
within the adjacent hepatic progenitor cells40.  The use of a Wnt signalling biosensor in vitro and in 
vivo therefore has the potential to offer further insight into the temporal behavior of this complex 
pathway during the disease progression using different disease models.   
LiCl is an inhibitor of GSK-3β, and thereby prevents the destruction of β-catenin via the destruction 
complex309.  The TCF/LEF reporter was significantly activated in response to LiCl in HEK293T, 
NIH3T3 and HeLa cell lines.  Canonical Wnt signalling is heavily activated during multiple processes 
during development, and thus the in vitro differences are expected with the embryonic human kidney 
HEK293T and embryonic murine fibroblast NIH3T3 cell line demonstrating the highest level of 
activation.  The WNT pathway plays a critical role in the development of hepatocellular carcinoma. 
TCF/LEF-Luc expressing HepG2, Huh7, and Hep3B cell lines were used to demonstrate that omega-3 
polyunsaturated fatty acids such as decosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) 
inhibited β-catenin through the activation of GSK-3β.  This resulted in dose-dependent reduction in 
hepatocellular cell viability via caspase-3/9 activity310.  This indicates the powerful utility of this 
reporter for in vitro drug evaluation for the treatment of human HCC. 
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7.2.4  Jagged-1 overexpression induces Notch signalling in an in vitro co-culture assay  
Notch signalling not only has a critical role in biliary tree development during embryogenesis, but 
also functions as a cell fate-determining “switch” within hepatic progenitors.  The temporal kinetics of 
Notch signalling during in vitro differentiation and in vivo regeneration is not yet fully elucidated, and 
thus warrants further investigation.  To this end, a Notch reporter construct containing the RBPJκ 
binding site was developed as a tool to better understand the activity profile of Notch during 
differentiation processes in vitro using the HepaRG cell line, and in vivo using the pBDL model of 
chronic cholestatic liver disease.  
Using an in vitro co-culture model, the Notch luciferase reporter construct was validated.  SGHPL5 
cells are a first trimester extravillous trophoblast cell line that have been validated to ensure intact 
Notch signalling components, a critical factor for biosensing reporter validation studies.  Inhibition of 
the Notch2 receptor within this cell line, using Notch2-specific blocking antibody or siRNA, results in 
increased migration of these cells311.  Furthermore, the activity of Notch signalling within SGHPL5 
cells, specifically the inhibition of proliferation through activation of RBPJκ, has been shown to aid in 
differentiation toward more mature trophoblasts within the developing human placenta312.   
Expression of the Notch1, Notch2 and Notch3 receptor, coupled with known biological effects of 
Notch signalling within this cell line made it an ideal candidate for subsequent validation studies prior 
to in vivo validation. 
The transduction of HEK293T cells with a constitutively expressing JAGGED-1-IRES-GFP enabled 
the expression of Notch pathway ligand within the cell line since HEK293T cells express no313 or very 
low levels314 of endogenous JAGGED-1.  The co-culture system exhibited a dose-dependent increase 
in SGHPL5 luciferase expression, which is expected as there are increased cell-to-cell contacts. This 
data illustrates the sensitivity of the reporter, with increasing levels of agonist showing a positive 
correlation on the amount of activation.   
For all reporter assays presented in this thesis, a significant increase in luciferase expression was 
observed in response to agonist.  While these and a whole range of other reporters are highly sensitive 
and versatile tools for the study of gene regulation, they show varying degrees of transcriptional 
activation and basal expression315.  Taking this into account, it is important to be aware of such 
variation when using lentiviral reporters.  Firstly, transduction of cells with lentivirus containing the 
transgene may result in variable levels of expression which may arise from either 1) varying number 
of viral integrations between cells, 2) inherent cell-to-cell variability which has been shown to have a 
discrepancy of protein expression of up to 15%-30%316, or 3) the genomic location of insertion which 
may enhance or repress expression of the transgene. With regards to the variable number of 
integrants, a more homogenous culture can be achieved through clonal amplification of cells followed 
by subsequent qPCR in order to detect the number of integrated viral copies within the clonal 
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population. Dual reporters can be utilized to reduce the variability that is observed due to varying 
transduction efficiencies of the virus between experiments.  For this dual reporter approach, one 
reporter is driven by a biosensing response element while the second is constitutively expressed.  
Signal from the biosensing vector can then be normalized to the expression of the constitutively 
expressed reporter.   
It is a well known phenomenon that transgene expression of integrated retroviruses has the capacity to 
be transcriptionally silenced, mainly via trans-acting factors which bind and restrict expression from 
the viral LTRs, or though promoter silencing317.  Integrating lentiviruses, however, have been shown 
to have a decreased propensity for transgene silencing318, 319.  Although some data has shown that 
silencing occurs more frequently when using vectors containing a wild-type HIV-1 LTR, silencing 
has been shown to  be decreased by 50% when utilizing self-inactivating (SIN) vectors containing a 
deletion in the U3 region of the 3’ LTR320.  These vectors should therefore be considered as an 
alternative vector backbone, particularly for reporters transduced into stem cells.  Another mechanism 
in which such silencing can be controlled is to flank the transgene with chromatin insulator elements.  
These elements have the ability to block interactions between enhancers and repressors from adjacent 
chromatin and promoters within the vector.  In so doing, they are able to reduce position and 
methylation effects on transgene expression levels321.  While most cell lines do not cause transgene 
silencing, it should always remain a consideration and should be controlled for inasmuch as possible 
through suitable vector design. 
 
7.2.5   Intravenous injection of VSV-g lentivirus predominantly targets hepatocytes in vivo  
Pseudotyping of viral vectors has been extensively used to target particular organs.  VSV-g is known 
to be pantropic due to the highly ubiquitous receptor, LDLR, which it uses to gain entry into the 
cell269.  Broad or cell-specific targeting of the biosensing vectors is dependent on the experimental 
context and will thus determine the choice of pseudotype.  To give the in vivo bioluminescent imaging 
data context dependence, it is important to know the specific cell types that are targeted and are 
responsible for the bioluminescent output.  This insight is important as it adds another layer of 
sensitivity to the technology by acquiring information at a cellular level as opposed to a whole-organ 
level. Liver samples transduced with the constitutive SFFV-JDG vector underwent colocalisation 
assessment using GFP as a marker of viral transduction and other cell-type specific markers of 
hepatocytes (HNF4α), cholangiocytes (CK7), activated myofibroblasts (α-SMA and GFAP), and 
hepatic progenitor cells (PKM2).   
Firstly, an uninjected control liver was analysed for background levels of green autofluorescence.  
The liver is particularly problematic with regards to autofluorescence mainly due to the high 
lipofuscin content within the tissue.  Lipofuscins are lipid-containing granules that autofluoresce 
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particularly within the green emission spectrum.  Background fluorescence was significantly 
decreased by incubation of the samples with Sudan Black stain322.  The uninjected control contained 
only very low levels of autofluorescence, while the GFP positive sample showed high intensity GFP 
signal.  This was particularly observed in the GFP alone, HNF4α, GFAP and PKM2 samples which 
were retrieved with sodium citrate at pH6 as opposed to Tris buffer at pH9 which is suboptimal for 
the GFP antibody with higher background and lower specific signal, but was required for dual 
staining of α-SMA and CK7. A large proportion of the cells were GFP positive, particularly around 
the central vein.  Some hepatocytes failed to stain for GFP, adding further confidence that the green 
was a true signal and not merely due to autofluorescence.  GFP was notably absent from regions of 
ductular proliferation. Confirmation of hepatocyte targeting of the reporter vector was achieved 
through nuclear localisation of HNF4α within GFP-positive cells.  
The α-SMA antibody typically stains vascular smooth muscle cells of the portal vein and the hepatic 
artery that would also be seen within a healthy liver.  However, the defining observation in cholestatic 
liver injury is the presence of α-SMA positive myofibroblasts found surrounding the hyperplastic bile 
ductules with the amount of injury shown to be positively correlated to the amount of α-SMA 
staining323.  Quiescent stellate cells do not express α-SMA, and only do so once they become 
activated and acquire a myofibroblastic phenotype.  It has been suggested that peribiliary fibroblasts, 
and not only hepatic stellate cells, are able to transform into myofibroblasts and contribute to portal 
collagen accumulation in chronic cholestatic models, and will also stain positive for α-SMA324.  GFP 
staining failed to merge with the α-SMA marker, indicating that quiescent stellate cells are not 
targeted with the VSV-g pseudotyped lentivirus within the neonate prior to disease induction and 
myofibroblast activation.  
GFAP staining was shown to be localised to the biliary epithelia in some sections, which has also 
been shown by others, but is mainly localized adjacent to the hepatic plates.  Mederacke et al. 
demonstrated colocalisation of GFAP and CK19, indicating that biliary cells do express GFAP325.  
GFP localisation with CK19 indicates that our VSV-g luciferase vector does not target the 
cholangiocytes, and therefore, does not contribute to their bioluminescent output.  Thus, even though 
there is a significant biliary hyperplasia during cholestatic injury, our GFAP model exhibited an initial 
burst of GFAP expressivity, followed by a decline in expression over the following 3 weeks.  This 
offers a further benefit of utilising somatotransgenic mice over many other existing GFAP-transgenic 
mice that may be expressing GFAP non-specifically325, and therefore limits interpretation of the data.  
Of specific interest is the perisinusoidal expression of GFAP, which is clearly seen and has previously 
been described as GFAP+ activated stellate cells326.  The merged image shows a distinct lack of 
colocalisation of GFAP with GFP, indicating that these cells are also not responsible for the 
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upregulation of GFAP within the pBDL liver bioimaging, as vector targeting using the GFP marker 
has been confirmed to be localized to HNF4+ hepatocytes.  
The cholangiocyte-specific marker, CK7 was used to determine if the VSV-g vector was targeting 
these cells.  Strong CK7 staining was seen in the proliferating ductal cells lining the portal tract.  
These cells did not colocalise with GFP.  The level of green autofluorescence within the samples was 
relatively high, however, a firm distinction between the GFP-positive stained hepatocytes lining the 
portal tract can clearly be seen.   
Furthermore, there was the distinct lack of colocalisation seen between GFP and PKM2.  The samples 
assayed originated from the left lobe of a pBDL animal in order to visualise the proliferation of the 
progenitor cell niche, as the proportion of progenitor cells residing within the healthy liver is minimal.  
The image clearly illustrates that the GFP positive cells lie on the periphery of the ductular reaction.  
The mass of DAPI stained cells indicate proliferating biliary cells and immune-related cells around 
the portal injury.  The progenitor cells reside at the terminal end of the Canal of Hering where they 
undergo expansion and differentiation when the regenerative capacity of either the hepatocytes or 
cholangiocytes is severely compromised due to chronic injury. The lack of colocalisation would 
suggest that the progenitor cells are not being targeted within the neonates, as proliferation of the 
progenitor cell niche during chronic injury would give rise to clonal GFP positive cells.  Instead, GFP 
immunohistochemistry strongly indicates that the majority of targeted GFP
+
 cells are hepatocytes as 
indicated by the colocalisation of GFP with the hepatocyte marker, HNF4a. 
 
7.2.6  In vivo NF-κB signalling following ultrapure LPS treatment is TLR4 mediated 
One of the more specific aims of developing the biosensing reporter vectors was to analyse pathways 
in vivo, both developmental and in response to disease induction, and also as a drug-efficacy platform.  
Following in vitro validation of the LNT-NF-κB-JDG vector, it was subsequently validated in vivo.  
Neonatal injection of the virus containing the LNT-NF-κB-JDG or control LNT-SFFV-JDG cassettes 
into CD1 or tlr4-/- mice via the temporal orbital vein resulted in liver-specific expression of the 
reporters.  Four hours post-LPS administration in adult mice, the tlr4-/- mice failed to elicit an LPS-
mediated NF-κB response, while the CD1 mice showed a significant upregulation of luciferase 
expression.  In vivo fold-change values were significantly higher in CD1 biosensing mice than in in 
vitro cultures, highlighting the impact of cellular context in signalling activation.  Constitutive 
expression using the SFFV promoter is inherently agonist independent permitting continual 
transcription of its associated downstream gene, which in this scenario is luciferase.  This is in 
contrast to regulated promoters that require a specific stimulus in order for transcription to commence.  
Thus LPS was not expected to result in an increase in luciferase expression in CD1 or tlr4-/- mice 
when using the SFFV promoter, as the levels of expression would be continuous, irrespective of the 
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presence of NF-κB agonist.  Indeed, the control SFFV-JDG-injected mice showed no biosensing 
activity, with levels of luciferase expression remaining stable over time.   
It is important to note that the use of somatotransgenesis within this experimental model further 
verified the broad applicability of technology through overlaying the biosensing platform upon an 
already existent germline transgenic, the tlr4-/- mice.  This introduces a new method of non-invasively 
obtaining more data from existing models of disease and assessing which biological pathways may be 
potential therapeutic targets. Moreover, organ specificity is higher when using somatotransgenic 
animals compared to whole-body NF-κB-Luc mice327-329. The luciferase within our vectors is also 
optimised for in vivo applications compared to the pGL3 luciferase from Promega used within the 
commercial NF-κB-Luc transgenic mice developed by Caliper Life Sciences. 
 
7.2.7  Dexamethasone-induced abrogation of NF-κB signalling  
The NF-κB-JDG vector showed a significant response to LPS-mediated NF-κB signalling, indicating 
its utility as a surrogate marker of inflammatory responses.  However, in a pharmacological context, 
the abrogation of such responses is of importance in the management of acute and chronic 
inflammatory diseases.  Proof-of-concept work was performed using the conventional anti-
inflammatory steroid, dexamethasone.  This glucocorticoid exerts a dual-mechanistic, anti-
inflammatory effect to diminish pro-inflammatory responses.  The first mode of action is induced 
through the binding of dexamethasone to the glucocorticoid receptor. This permits functional 
antagonism of the GR with p65, excluding activated NF-κB from the nucleus and decreasing the 
expression of pro-inflammatory genes, particularly IL-6330.  The second mode of action is through the 
direct binding of the activated glucocorticoid receptor to its own response element (GRRE) as a 
transcription factor that induces the expression of a host of anti-inflammatory mediators as well as 
negative regulation of other genes331.  Activated GR also causes the transcriptional upregulation and 
synthesis of IκB-α through binding of GRRE motifs within its regulatory regions332.  The upregulation 
of IκBα increases cytoplasmic retention of the NF-κB heterodimeric complex through masking of the 
nuclear localisation signal on p65, and maintains it in its inactive state333.   
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Figure 59.  Dual mechanism of anti-inflammatory activity of glucocorticoids. 
Glucocorticoids exert their anti-inflammatory effects firstly through their inhibition of the p65 subunit of 
activated NF-κB, and secondly through acting as a transcription factor binding to response elements of anti-
inflammatory genes, as well as increasing the expression of IκBα at the transcriptional level.  
 
The utility of NF-κB reporter mice as a platform for drug-efficacy testing was evaluated using 
dexamethasone to modulate NF-κB in an LPS-induced model of inflammation.  The NF-κB 
biosensing mice exhibited a substantial decrease in luciferase output when LPS was preceded by a 
single dose of dexamethasone.  These results validate the use of somatotransgenic bioimaging as a 
means of temporally analysing effects of drugs in vivo without the need for culling.  Moreover, the 
same animals can be used for numerous studies as the NF-κB luminescence returns back to basal 
levels over time, as can be seen by day 74 post birth.  A “washout” period is required to return the 
readings to baseline levels prior to subsequent experimentation, and is would be dependent upon the 
excretion and pharmacokinetics of the drug previously tested.  Triple imaging for baseline 
luminescence should also be performed before any subsequent experiments. 
Screening of compounds for anti-inflammatory activity in vitro is currently performed by using cell 
lines such THP-1, a human monocytic cell line, which secretes proinflammatory cytokines such as IL-
1, IL-6, and TNF-α when challenged with LPS.  Thus, various compounds can be screened within the 
model system to determine their potential anti-inflammatory effects334.  Unfortunately, the efficacy 
and doses that are used in vitro may not necessarily be recapitulated in an in vivo pre-clinical scenario 
as the difference in biochemical environments may alter the kinetic profile of the potential anti-
inflammatory drug335. To circumvent this problem, animal models such as the zebrafish have been 
used as an in vivo anti-inflammatory drug screening platform.  Experiments by Yang et al. 
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demonstrated that the administration of LPS followed by a dose of anti-inflammatory compounds 
such as chlorogenic acid, or the well-established corticosteroid, dexamethasone, resulted in a 
decreased inflammatory phenotype, such as the reduction of macrophage and neutrophil 
recruitment336.  Although this model clearly and significantly illustrates the efficacy of chlorogenic 
acid against endotoxin-induced inflammation, the number of animals required was in the region of 34 
to 300 animals per experiment with the mortality experiment requiring 6 groups each containing 50 
animals.  From an NC3Rs perspective, there is scope for improved and refined methodologies in order 
to reduce the numbers of animals required to determine drug efficacy, particularly within longitudinal 
studies. 
Larger animals such as mice have also been utilised for in vivo anti-inflammatory screening.  Several 
transgenic lines containing luciferase reporter genes have been described, including those using the 
inducible nitric-oxide synthase .  The iNOS-luc transgenic mouse is used as a model for rheumatoid 
arthritis, septic shock, contact hypersensitivity autoimmune diseases, and myocardial ischemia.  
Administration of the known iNOS inhibitors, epigallocatechin-3-gallate, α-phenyl-N-tert-butyl 
nitrone, ebselen, and dexamethasone all exhibited a decrease in iNOS induction when challenged with 
IFN-γ and LPS337.  The LPS-mediated induction of the iNOS reporter is quite variable, and though 
undesirable, may be unavoidable due to the fact that the bioluminescent transgenic founders that were 
screened for luciferase activity showed varying induction of the reporter, and thus offspring arising 
from different mating pairs showed variability.  The use of somatotransgenesis overcomes this 
problem by having tissue-restricted expression while also being more cost-effective as generation of 
somatic transgenic animals is not reliant upon backcrossing in order to obtain the transgenic reporter 
colony. 
 
7.2.8  Activin A induces upregulation of SBE-mediated luciferase expression in vivo   
Just as activin A was used for in vitro validation of the SBE-JDG construct, it was important to 
validate the construct in vivo using an exogenous agonist, prior to using it within the pBDL disease 
model.  Somatotransgenic mice transduced with SBE-JDG-containing lentivirus demonstrated a TGF-
β-mediated increase in luciferase expression that remained above basal levels for 6 days following 
activin A administration.  LPS stimulation showed a minor decrease in luciferase expression 2 days 
post administration, but did not show any deviation from baseline for any subsequent time points.  
LPS has been shown to antagonise TGF-β signalling through decreased expression of TGF-β 
receptors, TβRI and TβRII, and concurrently the expression of SMAD2 within rat primary 
microglia338. Other studies show contradictory data showing that within the liver LPS-mediated 
activation of TLR4 is able to downregulate the TGF-β pseudoreceptor, BAMBI121.  This 
pseudoreceptor lacks the intracellular kinase domain required for TGF-β signal transduction, and the 
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interaction of BAMBI with type I receptors inhibits the formation of receptor complexes required for 
normal signalling, and in this way acts as a negative regulator of TGF-β signalling339.   The 
downregulation of BAMBI with activation of TLR4 subsequently was shown to enhance TGF-β 
signalling through increased sensitisation of the hepatic stellate cells to TGF-β signalling121.  More in-
depth mechanistic data has recently been published using chromatin immunoprecipitation analysis.  
This demonstrated that the NF-κB p50:p50 homodimer, in conjunction with a histone deacetylase, 
associated with transcriptional silencing, was bound to the promoter region of BAMBI, resulting in its 
transcriptional repression in hepatic stellate cells340.  The observed decrease in TGF-β signalling in 
response to LPS during the initial phases, may therefore be a cell-specific response.   
 
http://www.nature.com/nm/journal/v13/n11/images/nm1107-1281-F1.jpg 
Figure 60.  NF-κB-mediated enhancement of TGF-β signalling in HSCs via BAMBI downregulation. 
LPS signals through TLR4 to increase NF-κB signalling.  P50 homodimers subsequently bind to the BAMBI 
promoter, resulting in increased TGF-β signalling within the HSCs through sensitisation of the TGFβIR. 
 
7.2.9  Increases in NF-κB signalling are observed during the acute phases of pBDL  
Following confirmation of fibrosis development and the presence of reactive ductular reactions within 
mice subjected to pBDL, analysis of signalling pathway activity in response to chronic cholestasis 
was undertaken.  pBDL was performed through occlusion of the common bile duct between the 
left/median and the right/caudate lobes, inducing fibrosis largely only in the left and median lobes.  
This was the preferred method of fibrosis induction as total bile duct ligation is highly associated with 
severe hepatic injury and accompanying mortality.  More importantly, indicators of cholestasis are 
present within this model without the tissue-damage associated with total occlusion of the bile duct205, 
making this a more NC3Rs acceptable model of acute cholestasis.  Using mice that had been 
transduced with viruses containing reporter under the control of an NF-κB response element, pBDL 
resulted in a significant increase in an acute NF-κB-mediated response seen as a transient peak in 
luciferase expression at day 14 post surgery, before returning almost to baseline over the subsequent 7 
  
CHAPTER 7 – DISCUSSION                                                                                                               112 | P a g e  
 
weeks. The sham-operated animals also exhibited a transient increase in expression, albeit for only 4 
days, before decreasing to baseline, indicative of a degree of “sham effect” immediately following the 
surgical procedure. 
In vivo experiments have shown that particular bile acids have the capacity to activate NF-κB 
signalling in cultured hepatocytes341.  This has implications for cholestatic diseases where chronic 
retention of cytotoxic bile acids causes oxidative stress and apoptosis of hepatocytes.  The increase in 
bile acids induces proapoptotic signals within the hepatocytes through the activation of Fas signalling.  
Specific bile salts such as taurochenodeoxycholate have the capacity to activate survival-inducing 
phosphatidylinositol 3 kinase (PI3K) signalling and downstream NF-κB signalling341, thus responding 
as an adaptive mechanism to prevent hepatotoxicity while permitting the hepatocytes to function in 
spite of the development of cholestasis.  This is consistent with other studies which determined that a 
reduction of hepatocyte apoptosis during regeneration occurs with the administration of TNF-α342, 
which causes the loss of IκBα, resulting in the activation of NF-κB110. 
To determine the role of NF-κB during the acute phase of cholestatic liver disease, Miyoshi et al. 
induced cholestasis in mice by means of common bile duct ligation.  Terminal analysis of liver 
disease was performed by culling of the animals, liver sample extraction, and molecular analysis.  
Electrophoretic mobility gel shift assay of nuclear extracts and immunohistochemistry of livers 3 days 
post-BDL exhibited increased levels of nuclear NF-κB localisation within hepatocytes.  Furthermore, 
the same authors demonstrated increased liver injury in response to the administration of an 
adenovirus containing inhibitor of kappa B (IκB), proposing that NF-κB functions to reduce the extent 
of liver injury following acute biliary injury343.  This study confirms the data collated in our NF-κB 
somatotransgenic model with a dramatic increase in NF-κB signalling during the initial phases of 
cholestatic induction.  Comparative assessment of the number of animals used, however, shows that 
6-12 animals were used in the control and the treated groups within their experiment, with data 
obtained being restricted to a single time point.  This is in contrast to the 13 BDL and 8 sham NF-κB 
biosensing animals used in order to assess NF-κB signalling over a series of 25 time points during 
chronic injury within our model.  The guidelines given by the NC3Rs recommends that fewer animals 
should be used to obtain the same amount of data, or that the same number of animals should are used 
in order to obtain more information compared to conventional methodologies.  Somatotransgenic 
bioimaging is therefore the preferred method of transcription factor activity interrogation.  
In contrast to the beneficial role of NF-κB signalling during the initial hepatic “wound-healing” 
response, maladaptive continuous activation of NF-κB promotes chronic inflammation, and is 
strongly linked to the development of fibrosis, subsequent cirrhosis, and hepatocellular carcinoma344.  
This has been shown using the chemical compounds, pyrrolidine dithiocarbamate and sulfasalazine, 
potent NF-κB inhibitors.  Both compounds exerted a therapeutic effect on BDL-mediated liver 
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damage in Sprague-Dawley rats terminally assessed 10 days post-BDL345.  However, the long term 
inactivation of components of the NF-κB pathway, such as TGF-β-activated kinase (TAK1), an 
upstream modulator of NF-κB activity, results in the spontaneous development of pathological injury, 
including fibrosis and carcinogenesis
346
.  A second study, observing NF-κB signalling during a 
chronic state of obstruction confirms the signalling profile seen within the somatotransgenic animals, 
but utilising classical technologies involving termination of the animals.  Lin et al. quantitated the 
levels of the NF-κB downstream targets, TNF-α and IL-6, in rat hepatic macrophages following BDL, 
and showed they were increased during the initial 2 weeks, followed by signal attenuation by the third 
week.  As further confirmation of the sensitivity of somatotransgenic bioimaging, data from the same 
authors noted increased NF-κB binding activity within Kupffer cells using a gel mobility shift assay, 
with NF-κB binding enhanced by 2.9-fold in the first week, 4.2-fold in the second week and 1.9-fold 
by the third week347.  An increase was noted not only in the BDL-induced animals, but also within the 
sham-operated animals with a 2.6-fold increase in NF-κB binding over non-operated controls. This 
effect was also seen using our biosensing platform with the sham-operated animals exhibiting a 
transient 16-fold increase in NF-κB signalling, highlighting the improved sensitivity of the 
bioluminescent imaging over alternative molecular techniques.  This “sham-effect” is most likely due 
to the inflammation caused by the surgical procedure. 
NF-κB is a key modulator of hepatic homeostasis and the regulation of disease progression through its 
role during inflammation, cell death, and wound healing. It is therefore critical from a therapeutic 
perspective to fully understand the signalling profile of NF-κB and other pathways involved in the 
fibrotic response, as therapeutic intervention may be required at defined time-points.  Ideally, NF-κB 
signalling should allow initial phases of inflammation to aid in the healing response, while therapy 
should prevent signalling from continuing indefinitely and permitting exacerbation of the original 
injury.  Furthermore, the targeting of biosensing vectors to specific cell types through differential 
pseudotyping and the use of alternative viruses has the potential to be invaluable in understanding NF-
κB signalling profiles in specific cell types that could prove useful for molecular targeting of 
therapeutic interventions for chronic liver disease.  
 
7.2.10  Novel Smad2/3 expression profiles are observed using SBE somatotransgenic animals  
In order for somatotransgenic bioimaging to successfully be used in disease modelling applications, 
the biosensors should be responsive to physiological concentrations of agonists and antagonists within 
a biological model.  Interestingly, the levels of TGF-β signaling in LNT-SBE-JDG transduced mice 
did not increase over time, but rather showed an oscillatory signalling output.  Significant differences 
in luminescence, however, were not found at any one particular time point. Assessment of 
luminescence shows inherent variation even when basal levels for each animal are taken into account, 
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yet the experimental cohort exhibited a significant increase in the amount of variation over the control 
group.  This difference in variation means that that the amplitude of the luminescent output for the 
pBDL group was greater in the positive and negative direction than for the sham-operated group.  
This variation was statistically significant, and when averaged across all animals, showed a novel 
temporal TGF-β signalling profile that would not have been seen using serial culling methodologies.  
The fluctuation of TGF-β-mediated luciferase expression is most likely due to the liver’s propensity 
for re-equilibration following disruption of normal homeostasis.  Whole-body SBE-Luc transgenic 
mice have been developed in order to study the temporal and spatial patterns of Smad2/3-dependent 
pathway signalling in vivo.  These animals were utilised to show TGF-β signalling in response to 
kainic acid model of neuronal degradation and inflammation of the CNS.  The usefulness of 
bioluminescent imaging as a drug platform was further shown with the amelioration of TGF-β 
signalling using a glutamate receptor antagonist, MK-801348.  The time and resources required for 
generation of these whole-body transgenics, however, limits its broader applicability and encourages 
the use of more continual imaging methodologies. 
 
7.2.11  Induction of cholestatic liver injury results in a significant increase in GFAP expression 
Within the normal liver, quiescent hepatic stellate cells are vitamin A-storing cells that play a 
fundamental role in the regulation of retinoid homeostasis349.  There have been publications indicating 
that GFAP is a marker of quiescent HSCs, and that liver injury downregulates the expression of 
GFAP within these cells350, however, the majority of publications have shown GFAP as a marker of 
activated HSCs351, 352.  Upon hepatic injury, these cells have the capacity to transdifferentiate into 
more mesenchymal, ECM-producing myofibroblasts that are known to express both α-SMA and 
GFAP upon activation.   A whole-body transgenic GFAP reporter mouse has been generated, with ex 
vivo GFAP expression shown to be highest in the brain, with detectible luciferase expression also seen 
in the heart.  The lung, muscle, and kidney exhibited undetectable levels of luciferase353.  Therefore, 
targeting of the liver with high specificity using our lentiviral reporters was performed in order to 
determine whether the use of our novel biosensing platform would perform better due to the enhanced 
luciferase and lack of background signal arising from the remainder of the animal.    
Bioluminescent imaging was used as a quantitative measure of GFAP expression during the acute 
response of cholestasis, and as far as is known, is the first known GFAP reporter mouse used to non-
invasively monitor its activation in a temporal manner.  The sharp increase in luciferase expression 
within 3 days following surgery was expected as terminal molecular assessments have shown that 
stellate cells become activated by day 3 of injury, with persistent upregulated α-SMA expression seen 
for the duration of the experiment until day 21 using the CDE model of chronic cholestatic injury354.  
Since stellate cells that undergo activation to myofibroblasts secrete an array of modulatory molecules 
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that have a role in inflammation and fibrosis during liver disease, their inhibition has been suggested 
as a therapeutic target.  A murine model depleted of hepatic stellate cells has been developed by 
Puche et al. in order to determine the contributions of hepatic stellate cells in response to acute liver 
damage.  In this model, the GFAP promoter was used to selectively express the herpes simplex virus-
thymidine kinase (HSV-Tk), making the stellate cells susceptible to death through administration of 
the antiviral agent, ganciclovir, specifically during proliferation.  In response to bile duct ligation, 
these mice showed marked attenuation of liver fibrosis, while displaying an increase in IL-10 
expression355.  Although the mechanism of fibrotic attenuation is not yet fully elucidated, it is 
hypothesised that this cytokine plays a significant role.  The treatment of Sprague-Dawley rats with 
IL-10 has been shown to suppress the growth factors, TGF-β1, EGF, and HGF within hepatic stellate 
cells in response to chronic CCl4 liver injury and has anti-inflammatory and anti-fibrogenic activity
356.  
Others have debated the use of GFAP as a marker solely of stellate cells, and have instead found its 
expression within cholangiocytes in untreated mice and in both cholangiocytes and oval cells in 
response to CDE-induced liver damage352.  Exposure of the liver to the hepatotoxicant, thioacetamide 
also induces bile duct proliferation, and showed colocalisation of GFAP with CK19-positive ductular 
cells351.  This has further been confirmed by others using an alternative GFAP-driven transgenic 
mouse in response to BDL325.  So although HSCs are the most prominent cell type within the liver to 
express GFAP in response to hepatic injury, it appears that it is by no means the only cell type to do 
so.  
Within my current work, colocalisation assessment has shown that VSV-g pseudotyped lentivirus 
does not target hepatic stellate cells or cholangiocytes, but rather hepatocytes and possibly Kupffer 
cells.  Previous sections of rat liver were negatively stained for GFAP in hepatocytes, however, these 
were in normal liver samples without any injury induction357.  Other studies have also noted that 
GFAP is absent in endothelial cells, hepatocytes, and Kupffer cells326, making the bioimaging results 
even more intriguing. Furthermore, it is known that VSV-g pseudotyped lentivirus has a propensity 
for targeting Kupffer cells within the liver when administered via portal vein injection358.  The F4/80 
antibody, the most common marker of Kupffer cells, however failed to stain the liver samples in 
various conditions, and requires further optimisation and investigation.  Kupffer cells cannot be 
disregarded as the GFAP biosensing cells until colocalisation studies are performed.  Thus, the 
bioimaging results offer an interesting insight into the expression profile of GFAP in response to 
fibrosis that is not stellate or biliary cell mediated.  There is a possibility that in vivo luciferase 
expression may be upregulated within hepatocytes by the truncated GFAP promoter, but that post-
translational regulatory mechanisms may be involved in the stability of the protein, causing a loss of 
protein expression.  This would account for the loss of GFAP expression within the hepatocytes 
within immunohistochemical samples, even though virus-targeted hepatocytes are showing a 
significant increase in GFAP-mediated luciferase expression at the transcriptional level.  The data 
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indicates that GFAP within hepatocytes or possibly Kupffer cells may have a role to play within the 
acute phase of cholestasis, and requires further interrogation within the BDL model of fibrosis.   
GFAP somatotransgenic animals offer a new platform with which to study cell-type specific GFAP 
activity in various models of liver disease, while also being used as a platform for inhibition assays 
for anti-fibrotic therapy.  
7.3  The role of WNT signalling in cholestatic liver disease 
7.3.1  Hepatic β-catenin localisation is not changed in vivo during BDL 
The role of Wnt signalling within the progenitor cell niche has been characterised, with nuclear β-
catenin accumulation occurring within the progenitors to direct their hepatocytic fate in response to 
chronic damage.  However, since my data has clearly demonstrated that there is no colocalisation of 
GFP with the liver progenitor marker, PKM2, the contribution of Wnt signalling output from these 
cells will not confound the data generated when assessing the role of Wnt signalling in hepatocytes in 
response to chronic biliary injury.  
pBDL mice did not show a significant decrease in TCF/LEF-mediated luciferase expression compared 
to sham-operated animals.  The overall median fold change of bioluminescence did not deviate from 
the basal levels, however, there was a high degree of variation seen at days 43 (pBDL) and 48 (sham), 
but in both cases, this was due to the signalling of a single animal, which increased the standard 
deviation. Liver enzymatic zonation is β-catenin dependent, with nuclear β-catenin shown to be 
expressed within 1-2 cell layers adjacent to the perivenous zone359, 360.  Following 
immunohistochemical staining, however, this perivenous β-catenin boundary was not observed in my 
samples.  Immunohistochemistry of sham 1 and 3 shows periportal sections with strong staining of the 
bile ducts, however, this staining was not nuclear and therefore not indicative of activated canonical 
Wnt signalling.  Sham 2 clearly shows the central vein without any enhanced nuclear β-catenin 
staining within cells limited to the region surrounding this region.  Strong plasma membrane staining 
was observed in hepatocytes and cholangiocytes.  It is known that β-catenin is a component of 
adherens junctions.  It is here that it binds to the cytoplasmic tails of various different cadherins, most 
notably E-cadherin which it tightly interacts with361.  It has been hypothesised that seeing as there are 
many mutations within the cadherins within epithelial tumours, that this perhaps releases β-catenin 
from the adherens junctions and allows it to become part of the cytoplasmic Wnt signalling pathway.  
This permits β-catenin to interact with Tcf transcription factors and activate downstream Wnt target 
genes implicated in oncogenesis362, a comorbidity often featured in chronic forms of liver disease.  
During the initial phases of regeneration, the Wnt/β-catenin signalling pathway has a fundamental role 
in ensuring proper G1 to S transition of hepatocytes through expression of cyclin-D1, a Wnt target
363.  
However, the hyperactivation of β-catenin through mutations in Axin364 and Dishevelled365 have been 
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associated with the development of hepatocellular carcinoma, a risk factor in cholestatic liver disease.  
The Wnt ligands Wnt3, 4, and 5a have been found to be overexpressed in hepatocellular carcinoma366.  
Yang et al. determined, through a series of cell-type specific knockouts of genes involved in Wnt 
secretion, that hepatocytes are not the source of Wnts secreted for canonical Wnt signalling.  Rather, 
they produce Wnt5a, a Wnt protein involved in the termination of β-catenin signalling following late 
liver regeneration in a partial hepatectomy model.  Wnt5a thus acts as a negative regulator of β-
catenin and hepatocyte proliferation367.  Chronic biliary damage also results in low levels of 
hepatocyte loss due to bile acid-induced hepatotoxicity, requiring regenerative intervention.  It is very 
likely that the luminescent data obtained from the Wnt analysis during the development of cholestasis 
is signalling from the most abundantly transduced cells, namely the hepatocytes.  Data from 
somatotransgenic animals indicate that Wnt signalling within targeted hepatocytes generally remains 
lower within the latter period of injury, and this may be due to the ensuing Wnt5a signalling in 
animals undergoing hepatocyte regeneration.   
7.4  The role of Notch signalling in cholestatic liver disease 
7.4.1  Notch signalling displays a trend in decreased expression during acute phase of pBDL 
In vivo monitoring of hepatic Notch reporter activity during chronic cholestasis was assessed. The 
hypothesis is that an increase in Notch signalling would be seen through activation of Notch in two 
cell types in particular, the progenitor cells and hepatocytes.  Firstly, during chronic cholestatic injury 
resident hepatic stellate cells would become activated, causing their transdifferentiation. These 
myofibroblasts express Jagged-1 ligand, and their subsequent interactions with the Notch receptor on 
the progenitors would be expected to increase Notch signalling40.  Secondly, within a culture setting, 
Jagged-1 was found to be mitogenic for hepatocytes, with siRNA knockdown of either Notch or 
Jagged-1 resulting in a decrease in hepatocyte proliferation368.  The activated Notch receptor, NICD, 
acts as a transcription factor that mediates the expression of several genes involved in cellular 
proliferation and cell cycle regulation, including Cyclin D1 and CDK2369.  BDL is known to induce 
Fas-mediated hepatocyte apoptosis through the accumulation of toxic bile salts370, therefore, Notch-
induced mitogenic signals within hepatocytes would be expected to increase hepatocyte proliferation 
during the regenerative process.    
In vivo bioluminescence data using the pBDL model indicated a significant decrease in overall hepatic 
Notch reporter activity at several time points compared to the sham operated animals when each of 
the time points were analysed individually (t-tests without correction for multiple testing), however 
this failed to reach significance when analysed over time.  This trend towards decreased expression 
was noted during the very early stages of disease and continued for the duration of the experiment.  
This result was unexpected as alternative liver disease models have definitively indicated increases in 
  
CHAPTER 7 – DISCUSSION                                                                                                               118 | P a g e  
 
Notch expression following injury in both hepatocytes and cholangiocytes dependent upon the injury 
type.  Within the partial hepatectomy model, Notch and Jagged are known to be upregulated within 
hepatocytes for up to 4 days, and initial nuclear accumulation of NICD has been observed within 15 
minutes following partial hepatectomy, with downstream target expression of HES1 seen within 30-
60 minutes368.   Köhler et al. demonstrated that increased nuclear accumulation of activated NICD 
began 5-15 minutes following partial hepatectomy, with non-significant fluctuations of NICD seen 
between the control and operated group at times between 30 minutes and 7 days post hepatectomy, in 
acute injury368.  The Notch signalling components, Jagged-1 and Notch3, and the downstream target, 
Hes1, have been noted to be significantly upregulated in response to chronic, fibrosis-inducing CCl4 
treatment371.   DDC-induced biliary injury mirrors these results with an increase in periportal Notch 
signalling components and downstream targets, Hes and Hey40. 
Neonatal mice containing immature hepatocytes remain responsive to Notch signalling and have the 
capacity to switch fates and become BECs upon ectopic Notch pathway activation372.  Notch 
signalling is switched off within hepatocytes or is present at very low levels in order to resist 
transdifferentiation toward a biliary phenotype.  Aberrant function of the Notch pathway results in 
pathogenesis, with a number of malignancies associated with its activation373.  Experiments have 
indicated that Notch-mediated conversion of hepatocytes to BECs is able to induce intrahepatic 
cholangiocarcinoma, with the intensity of Notch signalling within the hepatocytes showing a positive 
correlation with malignancy and disease progression374. 
Immunohistochemistry revealed no differences in pBDL versus sham groups, with both groups 
staining intensely for NICD within the biliary epithelia.  This result is unexpected as 
immunohistochemical evidence from previous studies have indicated that the Notch receptor is found 
within biliary epithelial cells, hepatocytes, and endothelial cells, while its ligand, Jagged-1, is 
expressed within biliary epithelial cells and hepatocytes368.   Since it is known that these cell types 
express the required receptors for signal transduction, it was hypothesized that the levels of Notch-
mediated luciferase expression would increase from the signal-producing hepatocytes in response to 
mitogenic signals, but this was not found to be the case.  One possibility for a reduction in signaling 
may be the increased expression of the Notch antagonist, Numb, which has the ability to decrease 
downstream Notch signaling. Further interrogation into the effects of exogenous and genetic factors 
was subsequently assessed within the bipotent HepaRG cell line.  This permitted the manipulation of 
Notch signaling components and the subsequent assessment of these modifications upon the 
differentiation potential used as a model of in vivo regeneration.  
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7.5   Modulation of media composition and Notch signalling results in differential capacities of 
hepatic progenitors to differentiate into hepatocytes and cholangiocytes in vitro 
7.5.1  Notch, WNT, and α1AT reporters show increased activity in response to protocol 2  
Treatment of HepaRG cells with 1.7-2.0% DMSO is the standard protocol to programme the cells to 
undergo hepatocyte differentiation in order to perform functional assays222, 375, 226.  The seeding of 
HepaRG cells at a low cell density enables maintenance of their bipotent progenitor phenotype and 
aids in their rapid proliferation.  Cells grown to confluence undergo spontaneous differentiation, albeit 
with low hepatocyte functionality.  An alternative protocol in order to stimulate the presence of 
cholangiocytes from HepaRG cells has also been described through the addition of 3 components, 
namely IL-6, sodium taurocholate hydrate, and sodium butyrate224.  The difference between these two 
protocols on cell-type differentiation was assessed. 
Using lentiviral transduction of the Notch, WNT, and α1AT reporters, the relative contribution of 
each of the cell types can be compared between the two protocols.  As already stated, Notch pathway 
activation is associated with progenitors destined for a biliary lineage, while Wnt pathway activation 
is associated with the hepatic lineage according to Boulter et al40.  In contrast to the data describing β-
catenin signalling as a driver of hepatocyte differentiation, Cerec et al. describe an early and transient 
expression of active β-catenin during biliary differentiation within HepaRG cells226, highlighting the 
temporal complexity of this signalling pathway in hepatic differentiation.  Such a peak was also noted 
on day 4 of differentiation using protocol 2, followed by a reduction of WNT activation for the 
duration of the experiment.  
The alpha-1 antitrypsin (α1AT) promoter element is hepatocyte-specific within this context.  The 
promoter drives expression of the human alpha-1 antitrypsin gene which encodes a serine protease 
inhibitor, and is the prototypic member of the serpin superfamily.  Its role is to protect tissues from 
the enzymes of inflammatory cells, particularly neutrophil elastase released from leukocytes, which 
functions to eliminate bacterial infection while concurrently causing host tissue destruction376.  
Hepatocyte-specificity is conferred through the presence of a distal non-specific control element, and 
a proximal hepatocyte-specific response element containing HNF1 and HNF4 response elements, 
proteins which are both enriched within hepatocytes377.  Thus, the reporter vector contains the 
hepatocyte-specific 5’ cis-acting element specifically designed for cell-specific expression378 and has 
been utilised to assess hepatocyte differentiation. 
Comparison of pathway activation during the process of differentiation resulted in a significant 
increase of the biliary-associated Notch pathway, and interestingly also the α1AT and WNT 
hepatocyte-associated pathways under protocol 2 conditions.  This indicates that both cell types are 
being enriched for within this culture and are expressing these pathways as they terminally 
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differentiate.  This preliminary data prompted a more comprehensive investigation of the culture 
using alternative molecular techniques. 
 
7.5.2  Verification of increased hepatic and biliary markers using protocol 2 
Immunohistochemical staining of the cultures clearly indicated that the cholangiocyte marker, CK19, 
and the hepatocyte markers HNF4α and albumin were increased in protocol 2 cultures.  Furthermore, 
the cultures contained clusters of small, binucleated cells that resembled primary hepatocytes.  It is 
these colonies that stained intensely for HNF4α and albumin and were surrounded by HNF4α- cells.  
The CK19+ cells surrounded these clusters and possessed a flattened morphology.  Protocol 1 samples 
stained weakly for all of the markers, indicating a decrease in their lineage specification. Moreover, 
these cultures contained no colony-forming structures.   
Using qPCR, quantitative validation further verified the relative abundance of hepatocyte and 
cholangiocyte cells within protocol 2.  Since protocol 1 is a hepatocyte-specifying protocol, it is not 
surprising that the smallest difference is seen in albumin expression, even so, protocol 2 outperformed 
protocol 1 in producing cells expressing hepatic markers.  
Protocol 2 was established by Dianat et al. to largely induce cholangiocyte differentiation.  Given the 
constituents of the medium and the role that they play within a physiological context, it is not that 
surprising that the results presented here were found to enrich both cholangiocytes and hepatocytes.  
Day 0 indicates the day that the pleiotropic cytokine, IL-6, was added to the cells in protocol 2.  IL-6 
is known to be an initiator of quiescent cell re-entry into the cell cycle during the acute phase response 
during regeneration.  IL-6-/- mice show a reduced ability to undergo hepatocyte regeneration following 
partial hepatectomy379, 380.  This was further corroborated by Ezure et al. who used IL-6-/- mice, in 
conjunction with bile duct ligation, to confirm the reduced ability to sustain compensatory liver mass 
even though the rate of apoptosis was shown to be the same between WT and IL-6-/- animals.  The 
lack of IL-6 was also associated with increased mortality rates discovered to be due to the decrease in 
gp130/STAT3 cell signalling381.  These in vivo models highlight the integral role that IL-6 has in 
hepatocyte response to liver damage.   Hepatocytes require IL-6 for their proliferation, and it is 
therefore not surprising that the addition of IL-6 to the medium would enhance hepatocyte 
differentiation potential.  IL-6 is also crucial in the regenerative process of cholangiocytes.   In situ 
analysis of human biliary disease samples exhibited increased IL-6 within the biliary cells and 
damaged ductules, particularly those originating from patients afflicted with primary biliary 
cirrhosis382.  Moreover, corroborative in vitro data has demonstrated that primary intrahepatic BECs 
express IL-6 and secrete it within the culture medium, presumably to enhance their own 
proliferation382.  Other studies, have shown that SOX9 expression was downregulated following the 
treatment with IL-6, however this was in articular chondrocytes and the effects may be cell-type 
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specific383.  The decrease in SOX9 expression in response to IL-6 would thus be expected to increase 
the differentiation of cells toward a hepatocyte cell fate as opposed to a cholangiocyte one. 
On day 2, sodium taurocholate hydrate, the sodium salt of taurocholic acid, was added to the media.  
In vivo cholic acid is synthesised from cholesterol to form bile taurocholic acid within the 
hepatocytes.  It subsequently undergoes biotransformations by microorganisms in the intestinal lumen 
during enterohepatic circulation to form a number of secondary bile acids.   These secondary bile 
acids are reabsorbed by the liver, and are subsequently conjugated to either glycine or taurine within 
the hepatocytes before being secreted back into the bile ducts384.  Thus, during normal bile synthesis, 
both hepatocytes and cholangiocytes are immersed in a pool of bile acids, with the unconjugated form 
of taurocholic acid, namely cholic acid, being one of the most abundant385.   
Lastly, on day 4 and subsequently every second day, sodium taurocholate hydrate and sodium 
butyrate were added to the media.  According to Dianat et al, the addition of sodium butyrate was for 
the prevention of spontaneous differentiation of the HepaRG cells down along the hepatocyte 
lineage224.  Sodium butyrate functions as a histone deacetylase (HDAC) inhibitor.  Histone acetylation 
is an epigenetic modification that is associated with a more relaxed DNA conformation surrounding 
the nucleosomes, thus assisting in increased levels of gene expression386.  Studies have shown 
enhanced differentiation potential of cells in response to HDAC inhibitor treatment.  The effect of 
HDAC inhibitors on hepatic progenitor differentiation has been assessed through isolation of rat 
hepatic progenitor cells following chronically induced cholestatic disease and in vitro culturing and 
treatment with sodium butyrate.  Subsequent Western blot and gross morphological assessment 
revealed a substantial increase in albumin expression, decreased nucleus:cytoplasmic ratio, and a 50% 
increase in the percentage of binucleated cells, indicative of hepatocyte-like cells387.  Thus, sodium 
butyrate may function to retain the epigenetic signature of cells already primed to become hepatocytes 
through treatment of IL-6 and sodium taurocholate.  
 Methods of increasing the level of these cells from hepatic progenitors is immensely useful as a tool 
for disease modelling and drug testing as primary cells have a finite lifespan and are challenging to 
obtain.  Instead specific populations of cells can be isolated using cell-type specific markers and using 
FACS analysis, thereby offering an unlimited supply of cells for research and therapeutic 
investigations. 
 
7.5.3 JAGGED-1 overexpression increases cholangiocyte differentiation while Numb 
overexpression results in increased hepatocyte differentiation using protocol 2 
Since Notch signalling is integral in cell-type specific differentiation, this pathway was an intriguing 
candidate for genetic modulation.  To this end, constitutive Notch pathway activation was achieved 
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through overexpression of JAGGED-1, while its expression was inhibited using overexpression of 
Numb, a downstream target of Wnt signalling.  A constitutive pLNT-SFFV-Numb vector was initially 
used to create HepaNumb cells that were hypothesised to generate an increased number of 
hepatocyte-like cells.  Alternatively, a pCMV-Jagged-IRES-GFP vector was also used to generate 
HepaJag cells.  Importantly, the expression of the CMV promoter is known to be silenced within 
hepatocytes through the action of methyltransferases and acetylases388, and therefore, the expression 
of Jagged and its associated GFP marker gene would thus be limited to cells fated to become 
cholangiocytes.  Cells which were already primed to become hepatocytes would thus naturally silence 
the CMV promoter, thus restricting the expression of JAG1 to cells which had the capacity to 
differentiate to cholangiocytes only.   
HepaJag cells exposed to protocol 2 appeared visually more abundant in CK19 and CK7 expression 
than HepaNumb cells, indicative of an increased proportion of cholangiocytes within the culture.  The 
culture, however, was not homogenous with Numb overexpression correlating with an increase in 
cells positively stained for hepatocyte markers within the culture.  HNF4α and albumin were seen at 
lower levels in HepaJag than in the HepaNumb cells, in which over 50% of the cells were HNF4α+ 
and albumin staining was significantly more intense.  SOX9 is a downstream target of Notch 
signalling and one of the earliest markers of biliary fate determination from hepatoblasts90.  It is 
interesting then that the cells that do not express JAGGED1 and are within the hepatocyte colony 
stain higher for SOX9 than the cells outside.  This is in contrast to other studies which have shown 
that knockdown of expression using a SOX9-specific shRNA results in the hepatogenic differentiation 
of human liver progenitor cells. The same publication, however, reciprocally revealed that in human 
samples, SOX9 expression, specifically within the hepatocytes of diseased livers, including biliary 
atresia, were significantly increased389.  These results indicate the need for further investigative 
analysis into the role of SOX9 within hepatocytes during the regenerative process, as it may have an 
alternative expression profile than during development.  NICD expression was also unexpectedly 
higher within the hepatocyte colonies within both HepaJag and HepaNumb cultures, and perplexingly 
in the cells that were shown to be GFP/JAGGED1 negative.  This is in contrast to the mostly widely 
published paper regarding Notch signalling in progenitor cell differentiation towards the 
cholangiocyte fate by Boulter et al40.  As expected, expression of β-catenin was only found within the 
hepatocyte clusters of both cell lines.  However, this expression was mainly localised to the plasma 
membranes of hepatocyte-like cells, with only low levels of punctate nucleolar staining also seen 
within the colonies.  This suggests that β-catenin is not active within these hepatocyte clusters 
following 2 weeks of HepaRG differentiation.   
The marker acetylated α-tubulin is ordinarily used as a marker of primary cilia, which are localised to 
cholangiocytes and function as osmo-, mechano-, and chemosensory regulators of bile acid levels390, 
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391.   Terminally differentiated hepatocytes lack primary cilia and therefore this marker is proposed to 
be cholangiocyte-specific392.  Interestingly, and in stark contrast to that seen by Dianat et al., primary 
cilia could not be detected on either hepatocytes or cholangiocytes.   This may be due to the lack of 
maturity of the cholangiocytes which would require subsequent culturing or due to the low resolution 
of the microscope compared to confocal microscopy which would make the cilia more difficult to 
visualise.  The hypothesis that the cholangiocytes are still immature at 2 weeks following induction is 
based upon the concomitant low levels of CK7 seen within the culture.  This cytokeratin is associated 
with later biliary development in humans, while CK19 is present at low levels in hepatoblasts and 
increases within duct cells during development393, 394.  Intense staining of microtubules, centrioles, and 
mitotic spindles within the hepatocytes, however, were clearly visualised.  The centrioles and spindles 
play a critical role within mitosis, while the cytoskeleton has a mechanistic role in a number of 
cellular processes including intracellular protein trafficking395.  Post-translational modification of the 
microtubules has been termed the “tubulin code”396. This code is known to be modulated within 
alcoholic liver disease, with α-tubulin being highly susceptible to post-translational modification, 
specifically via acetylation, due to the presence of reactive oxygen species and other reactive 
metabolites397.   The cellular consequence of altered microtubule formation has the potential to disrupt 
the binding of microtubule-associated proteins and enhance steatosis395. 
Cytoskeletal staining was mostly perinuclear within the HepaJag cells, while the staining was more 
dispersed within the entirety of the cytoplasm within the HepaNumb cells, indicative of enhanced 
acetylation of the tubulin in the HepaNumb cells.  The acetylated tubulin staining of the HepaNumb 
cells was similar to cells treated with the histone deacetylase 6 inhibitor, trichostatin A (TSA), which 
results in the acetylation and increased stability of the microtubules, while reducing membrane 
trafficking398.  The surrounding cholangiocytes within both cultures exhibited only modest staining.  
The direct contrast seen within the two different cell types warrants further investigation of the role of 
acetylation within the differentiation of the HepaRG cells, with the Notch modulated cells intriguingly 
hinting that the activation or inhibition of this signalling pathway might be involved in the altered 
acetylation status and possibly the stabilisation of the microtubules within these cells399.  Modulation 
of acetylation status has been proposed as a possible therapeutic strategy for liver disease, and thus 
future in-depth analysis within Notch-modulated HepaRG cells might prove to be a useful tool to 
assess the role of altered microtubule polymerisation within hepatocytes. 
Utilising qPCR, expression of the Notch downstream target, significant HEY1 expression was 
confirmed in HepaJag cells.  Although HEY1 expression increased in HepaNumb cells compared to 
progenitors, this was lower than unmodified cells that had undergone differentiation using protocol 2, 
confirming Numbs repressive effect upon Notch signalling.   
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SOX9 expression is low within progenitors and is shown to be upregulated in HepaJag cells. The 
forced overexpression of Notch signalling in HepaJag cells also led to an increase in cholangiocyte 
markers and a decrease in hepatocyte markers compared to HepaNumb.  This confirms that Notch 
signalling is increased in HepaRG cells during protocol 2 differentiation.  Furthermore, the expression 
of JAGGED-1 in conjunction with protocol 2 results in a synergistic increase in cholangiocyte-
specific markers.   
HepaJag cells that underwent protocol 2 differentiation resulted in an unexpected increase in albumin 
expression (158.69-fold over HepaRG) when compared to differentiated HepaRG cells alone (32.86-
fold over HepaRG).  This may initially seem counter-intuitive; however, it has been shown by Köhler 
et al. that the addition of recombinant JAGGED-1 to primary hepatocytes induces DNA synthesis368.  
Furthermore, the same authors showed that both Notch-1 and Jagged-1 peaked within 15 minutes and 
remained upregulated for up to four days within hepatocytes following partial hepatectomy368.  This 
indicates its involvement in the natural regenerative response during the early stages of acute hepatic 
injury368.  There is a possibility that some of the cells within the culture are already “primed” to 
become hepatocytes as HepaRG cells have the capability to spontaneously differentiate upon 
confluence, albeit with significantly lower hepatocyte functional activity.  Thus, the presence of 
JAGGED-1 may increase the proliferation of those cells which had already begun to differentiate into 
hepatocytes.  Interestingly, YFP lineage-labelled hepatocytes that underwent forced expression of 
NICD over 6 weeks in an in vivo model triggered hepatocyte to cholangiocyte reprogramming.  This 
reprogramming only occurred in a subset of hepatocytes, indicating that the forced expression of 
Notch signalling is not enough for cells to develop into biliary epithelia400.  It has also been 
demonstrated that HepaRG cells, differentiated in vitro and subsequently transplanted into uPA/SCID 
mice, are able to undergo transdifferentiation via reversion to a bipotent progenitor phenotype, 
particularly upon induction of biliary injury226.  Thus this Notch modulated culture system may be a 
useful model to elucidate the effect of Notch signalling on other signalling pathways during hepatic 
reprogramming events and gain more insight into what other factors are involved in the subset of 
Notch-expressing hepatocytes.   
Overexpression of Numb in HepaNumb cells resulted in a further increase in albumin expression 
compared to both HepaRG (255.90-fold) and HepaJag (1.61-fold) cells.  Data from a 2014 publication 
has noted that inhibition of Notch signalling utilising Notch2-specific siRNA and also the γ-secretase 
inhibitor L-685,458 promoted hepatic differentiation from isolated hepatoblasts from E14.5 livers. 
This was followed by a decrease in HNF-1β expression.  The converse experiment looking at Notch 
upregulation resulted in an increase in HNF-1β expression, accompanied with a downregulation of the 
hepatocyte-specific markers HNF-1α, HNF4α and c/EBPα.  This data strongly implicates HNF-1β in 
hepatoblast lineage specification through altering of liver-enriched transcription factors involved in 
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the core signalling network401. There was a moderate increase of HNF-1β expression in HepaJag 
(5.10-fold over HepaRG) compared to HepaNumb (2.72-fold over HepaRG).  This lack of HNF-1β 
upregulation within the HepaNumb cell line may therefore also be a contributing factor to the increase 
in hepatocyte-like cells within the culture.  This data confirms that Numb overexpression in 
conjunction with protocol 2 resulted in a synergistic increase in hepatocyte-specific markers.  Thus, 
Notch modulation can be exploited as a means to enrich for hepatocyte or cholangiocyte lineages 
using HepaRG progenitor cells.  In conclusion, protocol 2 is able to generate both BECs and 
hepatocytes, however, both have been shown to be immature as indicated by the low levels of CK7 
seen in BECs and high SOX9 staining observed in hepatocytes.  The overexpression of JAGGED-1 
within the culture results in the most mature phenotype of both cell types and indicates that Notch 
signalling plays a critical role in the maturation of hepatic parenchymal cell types. 
7.6  HepaRG knockout of Sox9 using CRISPR/Cas9 technology 
7.6.1  Sox9 site-specific genome editing using a cas9-expressing vector 
HepaRG cells were selected to be genome edited, as these bipotent hepatic progenitors are expected to 
express SOX9 as progenitor cells and also as cholangiocytes, indicating that it may be required for the 
progenitors to differentiate into cholangiocytes.  Knockout of SOX9 was therefore hypothesised to 
induce differentiation toward the hepatocyte lineage, which could potentially be enhanced by protocol 
2 and Numb overexpression to produce a more homogenous culture of hepatocytes.   
 
7.6.2  Bi-allelic Sox9 knockout results in a mesenchymal phenotype that is non-viable 
Unfortunately, following serial passaging of genome-edited HepaRG cells, a number of phenotypic 
features became apparent including a decrease in proliferative potential.  The decrease in proliferation 
followed by a senescence-appearing phenotype is believed to be attributed to the inhibition of the G1 
to S progression within the cell cycle.  This has previously been validated in primary cells devoid of 
SOX9402.  Building on this, Bellido et al. illustrated that a decrease in SOX9 expression resulted in an 
increase in the cycle-cycle regulator, p21.  Taken together, this would indicate that the enlarged, 
flattened Sox9-/- cells had indeed undergone senescence. Ideally, the senescence phenotype would 
have been confirmed at the molecular level using the cell cycle inhibitors, p16INK4a and p21CIP1, as 
they have been shown to also be upregulated during growth arrest.  The p21 tumour suppressor has 
also been known to be upregulated in response to several growth factors and cytokines that are 
involved in the process of liver regeneration and differentiation particularly by mediating the anti-
apoptotic effects of IL-6-type cytokines like OSM403.  The knockout data strongly suggests that SOX9 
may indirectly have a role in cell-cycle regulation, and may account for the non-viability of cells 
which do not express it.   
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Furthermore, prior to senescence, Sox9-/- cells appeared more elongated (spindle-shaped), 
mesenchymal-like, and more motile compared to the more polarised stationary epithelial cells.  This 
would suggest that epithelial to mesenchymal transition (EMT) had taken place.  This data is also in 
line with other studies which have shown that the loss of SOX9 in vivo is associated with increased 
risk of cholangiocarcinoma and poorer prognosis.  EMT is a common feature of cancers, with an 
increase in mobility associated with metastasis404.   
Recently, Paganelli et al. assessed the role of Sox9 expression during the differentiation process, and 
the impact of its altered expression.  Firstly, they noted that hepatic differentiation within liver 
mesenchymal stem/progenitor cells resulted in approximately 70% decrease in SOX9 mRNA 
expression.  This information is critical for subsequent experiments, as is appears that only 30% 
SOX9 expression is required for cell viability, as the authors do not note any senescence phenotype 
within their progenitor cells.  Secondly, they revealed that the blunting of SOX9 expression, using a 
shRNA-containing lentivirus, caused an increase in the hepatic marker, tryptophan 2,3 dioxygenase 
(TDO), while subsequently downregulating the expression of CK19 within differentiated progenitor 
cells.  A number of alternative early hepatic markers, however, did not show an increase in 
expression389.  The same authors detected an increase in hepatic SOX9 expression within human 
disease liver samples. Cancers overexpressing SOX9 have shown to have increased proliferation 
coupled with inhibition of senescence.  The proposed mechanism behind these traits is the ability of 
SOX9 to bind to the promoter of Bmi1, a polycomb protein which acts to suppress the tumour 
suppressor, Ink4a/Arf402 giving the reciprocal phenotype compared to SOX9 knockout.  Thus, further 
investigation into its role in differentiation and disease could lead to novel drug targeting strategies to 
regulate its expression in hyperplastic scenarios.   
Since there is a proposed connection between downregulated SOX9 and an increase in hepatocyte 
differentiation, it would be interesting to determine whether the combination of HepaNumb 
expressing, SOX9-downregulated cells differentiated via the 3-component protocol would yield a 
further synergistic upregulation of hepatocyte markers.  A reduction in SOX9 expression could be 
achieved either through the stable expression of a SOX9 shRNA or through the generation of a 
heterozygous CRISPR knockout.  It is predicted that this trio of modifications would result in an 
increased proportion of hepatocyte colonies arising from the HepaRG progenitor cells.  
7.7  Conclusions 
The development of the described methodologies has a broad scope of applicability for models of 
disease.  The generation of biosensing, reporter animals that are able to undergo longitudinal 
assessment of transcription factor activity in response to disease induction or drug intervention has 
significant implications for the number of animals currently being utilised within research.  
  
CHAPTER 7 – DISCUSSION                                                                                                               127 | P a g e  
 
Furthermore, the data shows that this novel platform is able to generate more data per animal when 
used in conjunction with existing germline transgenics.  The specificity of transduction decreases 
confounding background luciferase expression, and is conferred through targeted viral delivery 
methods and viral vector pseudotyping.  The use of this technology specifically within the context of 
hepatic fibrosis has highlighted the temporal activation of NF-κB during the acute phase of the 
disease, with activation of myofibroblasts mirroring this signalling profile when using the GFAP 
reporter.  The signalling profile of SMAD signalling was distinct, with a cyclical expression profile 
exhibited, in particular with increased intensity during the acute phase followed by a stabilisation of 
expression subsequent to the initial injury.  While Notch and Wnt signalling have recently been 
shown to be critical in the differentiation of hepatic progenitors during hepatic or biliary injury, our 
data largely targets hepatocytes, and indicated that the role of Notch and Wnt signalling within 
hepatocytes did not contribute to disease progression or regeneration as they did not show significant 
upregulation of luciferase in response to pBDL.  Further work is required in order to specifically 
target the cholangiocytes with Wnt and Notch biosensing reporters to monitor responses during 
progenitor cell differentiation during cholestasis.  This model could further be used to analyse the use 
of Numb as a potential gene therapy for cholestatic liver disease through its inhibition of the biliary 
cell-inducing Notch pathway.  
Furthermore, this data builds upon the work developed by Dianat et al. who were the first to describe 
the addition of 3 components to HepaRG media in order to specifically enrich the culture for 
functional cholangiocytes.  The data presented in this body of work increases our understanding of the 
role of Notch signalling within the hepatic progenitors in order to guide their differentiation down a 
particular path.  It was shown that the overexpression of JAGGED, in conjunction with the Dianat 
differentiation protocol, resulted in improved yields of cholangiocyte cells within the culture, while 
the overexpression of Numb in this culture media was found to decrease cholangiocyte markers while 
enhancing the presence of hepatocyte-like colonies.  Thus, modulation of the Notch signalling 
pathway within HepaRG cells is a useful development in order to enhance for a particular cell type 
arising from the bipotent progenitors.  This has implications in functional studies as current cell lines 
do not adequately recapitulate the functionality of primary hepatocytes in culture.  
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8.0  Materials and Methods 
8.1  Cloning of the constitutive SFFV- and GW-JDG parental vectors 
Overlap-extension PCR was employed to generate a bicistronic cassette consisting of the 3xFLAG 
with the luciferase and 2A-eGFP as depicted in Figure 61. 
  
 
Figure 61.  Overlap extension concept and cloning of pLNT-SFFV-JDG. 
Diagram depicting primer pairs used during primary amplification of 3xFLAG, firefly luciferase, and eGFP 
amplicons, and secondary PCR primers used in subsequent fusion PCR.  Final fused product (BamHI / SbfI) was 
cloned into the pSEW-Asp-eGFP (BamHI / NsiI) to yield the constitutively expressed reporter construct, pLNT-
SFFV-JDG vector. 
 
8.1.1  Primary PCR reagents and cycling parameters  
Using three plasmid vectors as template, 3xFLAG, FLuc, and 2A-eGFP were each separately 
amplified with gene-specific primers as partially overlapping fragments. Primer F1 was engineered to 
contain a BamHI restriction site, while primer R3 contained an NsiI site (also highlighted in red).  
Primer pairs are listed in  
Table 3 and reaction parameters in (Table 4). 
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Table 3.  Primers used to generate primary products for 3xFLAG-FLuc-2A-eGFP construction. 
Primer Sequence (5' --> 3')
3xFLAG (F1) CTGGGGCCACGAG▼GATCCGCCACCATGGACTACAAAGACCATGACGGTGATTATAAAGATC
3xFLAG (R1) TTCTTGGCGTCCTCCATGCTGCCGCCGCCGCTCTTG
Fluc (F2) GCAGCATGGAGGACGCCAAGAACATCAAGAAGGG
Fluc (R2) CTGCGCGGATCTTGCCGCCCTTCTTGGCC
2A-eGFP (F3) AAGGGCGGCAAGATCCGCGCAGAGGGCCGGGGCTCAT
2A-eGFP (R3) GTCAGCTGGGCAATGCA▲TACTAGTTTGTTGAGTCAAAACTAGAGCCTGGACCA
Note:  Restriction enzyme sites highlighted in red 
 
Table 4.  Reaction parameters to generate primary products for 3xFLAG-FLuc-2A-eGFP construction. 
Reagent and Concentration Volume 
Phusion buffer HF (5X) 10.0 μl
Forward primer (25 μM) 1.0 μl
Reverse primer (25 μM) 1.0 μl
dNTPs (10mM) 1.0 μl
Phusion® polymerase (1U) 0.5 μl
DNA (200 ng/μl) 1.0 μl
dH2O 35.5 μl
Final Volume 50 μl    
PCR amplification of target DNA was achieved by an initial denaturation 98°C for 30 seconds 
followed by 40 cycles of 98°C for 35 seconds, 65°C for 40 seconds, 72°C for 1 minute 42 seconds. 
There was a final elongation step of 72°C for 10 minutes.  
 
8.1.2  Secondary PCR to create the 3XFLAG-FLuc-2A-eGFP bicistronic cassette 
Initially, primary PCR fragments were gel purified using the QIAquick Gel Extraction Kit (Qiagen).  
Excised gel slices were dissolved in guanidine thiocyanate-containing Buffer QG before being applied 
to a silica membrane column.  The column was centrifuged at 13,000 rpm for 1 minute before 
undergoing a series of ethanol washes in Buffer PE.  DNA was eluted in 30 µl dH2O.  The products of 
gel extraction were assembled through overlap-extension secondary PCR using all three primary PCR 
products as template and 3xFLAG (F1) and 2A-eGFP (R3) primers for amplification as shown in 
(Table 5).  PCR amplification was achieved as follows: an initial denaturation step at 98°C for 2 
minutes was followed by 35 cycles of 98°C for 40 seconds, 65°C for 40 seconds, 72°C for 2 minute 
30 seconds. There was a final elongation of 72°C for 10 minutes. 
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Table 5. Reagents and concentrations for secondary overlap-extension PCR. 
Reagent and Concentration Volume 
Phusion buffer HF (5X) 10.0 μl
Forward primer (25 μM) 1.0 μl
Reverse primer (25 μM) 1.0 μl
dNTPs (10mM) 1.0 μl
Phusion® polymerase (1U) 0.5 μl
Template DNA (3xFLAG) 1.0 μl
Template DNA (Fluc) 1.0 μl
Template DNA (2A-eGFP) 1.0 μl
dH2O 33.5 μl
Final Volume 50 μl    
 
8.1.3  Restriction digest and ligation to produce pLNT-SFFV-JDG 
The triple-template DNA amplicon formed from the secondary PCR consists of 3xFLAG-FLuc-2A-
eGFP, and this bicistronic cassette shall hereinafter be termed JDG.  In order to clone the JDG insert 
into a 2nd generation lentiviral expression vector, the amplicon was further purified using the 
QIAquick PCR Purification Kit (Qiagen) as per manufacturer’s instructions.  Briefly, the PCR 
reaction was resuspended in 5 PCR volumes of buffer PB.  The solution was loaded onto the silica 
membrane-containing column and briefly centrifuged before undergoing an ethanol wash with buffer 
PE.  Residual ethanol was removed through the addition of a second centrifuge step, followed by 
elution of purified PCR product in 30 µl of dH2O.  Purified DNA subsequently underwent restriction 
enzyme digestion to form DNA overhangs.  The JDG amplicon was double-digested with BamHI / 
NsiI (NEB) restriction enzymes and ligated into pSEW-Asp-eGFP (Appendix A.i) which was BamHI 
/ SbfI (NEB) digested to remove the Aspergillus-IRES-eGFP bicistronic cassette, leaving the lentiviral 
backbone containing the constitutive SFFV promoter intact.  Since only the four-base overhang needs 
to be complementary, and not the whole restriction recognition sequence, it is possible to ligate a 
molecule that has been digested with NsiI (ATGCA▼T), which has an overhang sequence of TGCA, 
with SbfI, whose recognition sequence is CCTGCA▼GG and also creates an overhang sequence of 
TGCA following digestion.  The reactions are detailed in Table 6.  All restriction digests were carried 
out at 37°C for 4 hours.   
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Table 6. Restriction enzyme digests of JDG insert and pSEW-Asp-eGFP backbone. 
Reagent Insert digestion Vector Backbone digestion
Volumes Volumes
dH2O   - 69.0 μl
Buffer 3 (NEB) 10.0 μl 10.0 μl
BSA (100x) (NEB) 1.0 μl 1.0 μl
Bam HI 5.0 μl 5.0 μl
Nsi I 5.0 μl  -
Sbf  I  - 5.0 μl
Insert 79.0 μl (12.0 μg)  - 
Backbone - pSEW-Asp-GFP  - 10.0 μl (5.0 μg)
TOTAL 100.0 μl 100.0 μl  
 
Both vector and insert were subjected to gel electrophoresis at 90 V/cm2 for 30 minutes on a 1% 
agarose gel containing 5 μl / 100 ml GelRed (1X) to isolate and purify the DNA.  The DNA products 
were gel extracted using the QIAquick gel extraction kit and subsequently ligated using a Quick 
Ligation Kit (NEB) both as per manufacturer’s instructions.  The pLNT-SEW lentiviral backbone and 
JDG PCR product insert were ligated using the volumes of vector, insert, and ligation reagents as 
noted in Table 7 with the reaction performed at room temperature for 5 minutes.  
 
Table 7. Reagents and volumes for quick ligation of pLNT-SFFV-JDG. 
Reagent Volume 
dH2O 2.0 μl
Buffer (2x) 10.0 μl
Digested vector (pSEW-Asp-eGFP) 1.5 μl
Digested insert (JDG) 5.0 μl
Quick ligase 1.5 μl
TOTAL 20 μl  
 
8.1.4  Transformation and positive clone selection of pLNT-SFFV-JDG 
Using 5 µl of the ligation reaction, Stbl3 competent cells were transformed by incubating the DNA 
with the competent cells on ice for 20 minutes.  This was followed by a 30 second heat-shock at 42°C 
and rapid cooling on ice for 2 minutes. 250 µl pre-warmed super optimal broth with catabolite 
repression (SOC) media was added to the competent cells and allowed to recover for 1 hour at 37°C 
in the shaking incubator at 220 rpm. The transformation reaction was plated onto Luria broth (LB)-
containing agar plates supplemented with 100 µg/ml carbenicillin (Sigma), a more stable analogue of 
ampicillin, to select for plasmid-containing clones and incubated overnight at 37°C.  Colonies were 
selected and placed in 5 ml of LB broth containing carbenicillin (100 µg/ml) overnight.  Plasmid 
DNA was isolated using the QIAprep Spin Miniprep Kit (Qiagen).  The overnight culture was 
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pelleted to remove the LB broth before being resuspended in 250 µl buffer P1.  Bacterial alkaline lysis 
was carried out using 250 µl buffer P2 for 5 minutes after which 350 µl buffer P3 was used to 
neutralise and stop the lysis reaction.  Following 10 minutes of centrifugation at 13,000 rpm to 
precipitate the cellular debris the supernatant was transferred to a silicon membrane column.  
Following binding of the DNA to the column using 500 µl Buffer PB followed by centrifugation, the 
column was washed with 750 µl buffer PE before the DNA was eluted in water.  Purified plasmid 
DNA was used in a restriction digestion to determine the presence of a positive clone.  A double 
digest was set up using MluI and NheI restriction enzymes incubated for 1 hour at 37°C with the 
reagents and volumes as outlined in (Table 8). 
 
Table 8.  Restriction digest reagents and volumes for the detection of positive recombinant clones. 
Reagent Volume
dH2O 13.0 µl
Buffer 2 (NEB) 2.0 μl
BSA (10x) (NEB) 2.0 μl
Mlu I 1.0 µl
Nhe I 1.0 µl
Clone Plasmid DNA (0.5 μg) 1.0 µl
TOTAL 20.0 μl  
 
The products of restriction digestion were analysed by agarose gel electrophoresis. Using 4 µl of 
loading dye to the 20 µl restriction digest reaction, the samples were loaded onto a 1% agarose gel 
containing 1x GelRed.  The samples were electrophoresed at 120 V/cm2 for 40 minutes in Tris-
acetate-EDTA (TAE) buffer.  Positive clones were sequenced (Source Bioscience), with predicted 
sequence of the inserts available in Appendix B, and the novel bicistronic vector, hereon termed 
pLNT-SFFV-JDG, available in map format in Appendix A.ii. 
 
8.1.5  Cloning to create the parental pLNT-GW-JDG vector 
Using pLNT-SFFV-JDG vector as template, the JDG insert was excised using a BamHI and MluI 
double digest and subcloned into the pZsGreen-C1 vector (Clontech) (Appendix A.iii) digested with 
the same enzymes.  This construct was termed pZsGreen-JDG, and was used as a subcloning vector 
before the insert could be cloned into its final lentiviral vector.  pZsGreen-JDG was double digested 
with SalI / MluI restriction enzymes and cloned, using quick ligase as per manufacturer’s protocol, 
into pLNT-Gateway-MCS (Appendix A.iv) using the compatible XhoI / MluI sites. This produced a 
novel destination vector with which to recombine pENTR clones into.  SalI (G▼TCGAC) and XhoI 
(C▼TCGAG) generate the same sequence overhangs after digestion, also known as compatible 
  
 
CHAPTER 8 – MATERIALS AND METHODS                                                                                  134 | P a g e  
 
cohesive ends (underlined), and can therefore be ligated together.  The parental vector, pLNT-GW-
MCS (a kind gift from Dr Steven Howe, UCL), is a second generation lentiviral vector containing a 
multiple cloning site downstream of the Gateway reading frame C cassette.  This facilitates cloning of 
transgenes, in this case JDG, downstream of the Gateway cassette into which specific promoters or 
transcription factor activated response elements can be recombined in order to drive expression of the 
downstream transgene.    Restriction enzyme reactions were carried out at 37°C for 4 hours.  The 
Gateway cassette contains dual resistance genes, namely ccdB toxicity and chloramphenicol 
resistance genes.  The ccdB toxicity gene encodes a cytotoxic protein which acts as a potent poison of 
DNA-topoisomerase II complexes.  Ligation reactions were transformed into ccdB-resistant DB3.1 
competent cells (Invitrogen) and selected for using ampicillin (100 μg/ml) (Sigma).  Clones were 
grown overnight in LB broth containing ampicillin (100 μg/ml) and plasmid isolated and purified 
using the QIAprep spin mini-prep kit as per manufacturer’s instructions.  Positive-clone selection was 
performed by Sbf I / MluI double digestion for 1 hour at 37°C. A single colony showing the predicted 
DNA bands after restriction digestion and gel electrophoresis on a 1% agarose gel was selected and 
further amplified overnight in LB broth at 37°C. Plasmid was isolated and purified using the QIAprep 
midi-prep kit (Qiagen) as per manufacturer’s instructions. The resultant pLNT-GW-JDG (Appendix 
A.v) lentiviral cassette has a Gateway cloning acceptor site upstream of the FLuc-2A-eGFP JDG 
bicistronic reporter cassette. 
8.2  Cloning of pLNT-GW-NanoLuc®-2A-eGFP and pLNT-SFFV-VLuc 
In order to analyse multiple pathways in vitro and in vivo simultaneously, alternative luciferases, each 
with particular substrate specificity, can be utilised.  In order to construct such vectors, the luciferases, 
NanoLuc®, as well as the 2A-eGFP fragments were initially amplified in a primary PCR.  The 
template for the secreted NanoLuc® was the pNL1.3 vector (Promega), while the 2A-eGFP fragment 
was amplified from the pLNT-SFFV-JDG vector which is previously described.  The primers were 
engineered with XhoI (C▼TCGAG) and MluI (A▼CGCGT) restriction sites flanking the primers.  
The PCR primers have overlapping sequences to allow subsequent annealing and extension of the 
fragments in subsequent secondary or overlap-extension PCRs which would yield a fused product.  
Primer sequences and primary PCR parameters were set out as in Table 9a.  PCR amplification of 
target DNA was achieved by an initial denaturation of 98°C for 30 seconds followed by 45 cycles of 
98°C for 10 seconds, 57°C for 30 seconds, 72°C for 45 seconds and a final elongation step of 72°C 
for 5 minutes.    Using overlap extension PCR as per Table 9b, NanoLuc was fused to 2A-eGFP to 
yield NLuc2.  PCR cycling parameters were:  initial denaturation 98°C for 2 minutes followed by 35 
cycles of 98°C for 40 seconds, 65°C for 40 seconds, 72°C for 2 minutes with a final elongation step of 
72°C for 10 minutes.  Secondary PCR amplicons were column purified as previously described and 
double-digested with XhoI / MluI, heat inactivated, and directionally cloned into the pLNT-GW-MCS 
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vector digested with the same enzymes.  The vector and insert were ligated using the NEB Quick 
Ligase kit as per manufacturer’s instructions using a 3:1 molar ratio of insert:backbone.  Confirmation 
of correct clones was carried out using a XhoI / MluI restriction digest to excise the NLuc2 bicistronic 
insert.  The resultant plasmid contained the NLuc2 dual luminescent/fluorescent cassette downstream 
of the Gateway® cassette.  The plasmid map is listed in Appendix A.vi.   
The constitutively expressing vargula plasmid was developed by amplifying vargula from the pCMV-
Cypridina vector (ThermoFisher Scientific) using primers designed to contain a BamHI (G▼GATCC) 
and a NotI (GC▼GGCCGC) restriction site on the primers.  Following PCR amplification as outlined 
in Table 9a, the PCR product was cleaned using the Qiagen PCR purification kit before being 
digested with BamHI / NotI and ligated into pENTR-1A digested with the same enzymes.  Correct 
clones were selected by performing a BamHI / NotI digest on clones.  A clone containing the correct 
insert was used in the Gateway® recombination reaction into the pLNT-SFFV-GW vector.  Screening 
for a positive clone was performed by using BamHI / NotI restriction enzymes.  The map of pLNT-
SFFV-Vluc can be found in Appendix A.vii.  PCR amplification of target DNA was achieved by an 
initial denaturation of 98°C for 30 seconds followed by 45 cycles of 98°C for 10 seconds, 57°C for 20 
seconds, 72°C for 30 seconds. There was a final elongation step of 72°C for 5 minutes.  All primers 
used to develop both the pLNT-GW-NLuc2 and pLNT-SFFV-Vluc vectors are given in (Table 10) 
with the relevant restriction sites highlighted in red and the site of cleavage shown by the ▼ symbol.  
 
Table 9.  Primary and Secondary PCR for the generation of NLuc-2A-GFP and VLuc. 
 
Reagent Volume 
Buffer HF (5x) 5.0 μl
GC Enhancer 5.0 μl
dNTPs (10 mM) 1. 0 μl  
Forward primer (10 μM) 1.0 μl
Reverse primer (10 μM) 1. 0 μl
Phusion polymerase 0.5 μl 
DNA 0.5 μl  of each 1° PCR product 
dH2O 33.5 μl  
TOTAL 30 μl  
Reagent Volume
Standard Q5 buffer (5x) 10 μl
dNTPs (10 mM) 1.0 μl
Forward primer (10 μM) 0.5 μl
Reverse primer (10 μM) 0.5 μl
Q5 high-fidelity polymerase 0.5 μl
dH2O 36.5 μl
pNL1.3 (Sec Nluc)  or pCMV-Cypridina DNA template (100 ng)1.0 μl
TOTAL 50 μl
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Table 10. Primers oligonucleotides for amplification of NanoLuc®, 2A-eGFP and vargula. 
Primer Sequence
Nluc Forward CACAC▼TCGAGGCCACCATGAACTCCTTCTCCACAAGCG
Nluc Reverse CAATGAGCCCCGGCCCTCTGCGCGCGCCAGAATGCGTTCGCACAGCCGCCAGCCGGTCAC
2A-eGFP Forward CTGGCGGCTGTGCGAACGCATTCTGGCGCGCGCAGAGGGCCGGGGCTCATTGCTGACCTGTGGAGATG
2A-eGFP Reverse GATGACGCG▼TTTACTTGTACAGCTCGTCCATGCCG
Vluc Forward TATCG▼GATCCGCCACCATGAAGACCCTGATC
Vluc Reverse GAGTGC▼GGCCGCTCACTTGCACTCGTC
 
8.3  Recombination reactions to produce lentiviral reporters. 
The sub-cloning plasmid pENTR-1A (Appendix A.viii) contains Gateway® directional homologous 
recombination arms flanking the chloramphenicol and ccdB bacterial toxicity gene with multiple 
cloning restriction sites on either side. First, the chloramphenicol/ccdB expression cassette was 
removed by performing an EcoRI restriction enzyme digest to remove the cassette, followed by 
religation of the Eco RI sites using quick ligase. We will forthwith describe this as “empty” pENTR. 
Next, overlapping oligonucleotides were designed to encode the adenoviral E1A minimal promoter 
(MP) sequence with flanking XhoI restriction sites at the termini as shown in Table 11. The E1A 
oligos were initially placed at a concentration of 5 μM in a buffer solution (NEB buffer 4) and heated 
to 75°C for 10 minutes, followed by slow cooling to allow the oligos to hybridise.  Once annealed, the 
oligos were subjected to XhoI restriction enzyme digestion, isolated by gel electrophoresis and 
column purified. The E1A minimal promoter sequence was then ligated into the XhoI site in empty 
pENTR vector, the resultant cloning vector was called pENTR-MP.  Subsequently, all transcription 
factor binding elements were cloned into the pENTR-MP vector by Aldevron using the BamHI / 
EcoRI restriction enzyme sites. 
Once the Gateway and pENTR vectors were cloned, a recombination reaction was performed using 
the Gateway® LR Clonase™ Enzyme Mix (Invitrogen) which contains the recombination proteins, 
integrase and excisionase.   The site-specific recombination reaction occurs between regions of 
sequence homology, e.g. the attL sites found flanking the transgene (in this case the response 
elements with MP) within the pENTR vector and the attR sites found flanking the Gateway cassette in 
the destination vector.  Non-recombinants are dually selected against. Bacteria transformed with the 
non-recombined parental vector containing ccdB are killed due to its cytotoxicity in ccdB-sensitive, 
Stbl3 competent cells.  Non-recombined pENTR vectors are selected against through antibiotic 
selection, as the pENTR vectors contain kanamycin resistance, while the destination vector contains 
the ampicillin resistance gene.  Theoretically this should lead to the growth of bacteria transformed 
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only with recombinants on the ampicillin agar plates.  All LR recombination reactions were 
performed as per the Invitrogen Gateway cloning manual.   
 
Table 11.  Sequence of adenoviral E1A minimal promoter oligos. 
Primer Sequence (5' --> 3')
Minimal promoter C▼TCGAGGGGCTATAAAAGGGGGTGGGGGCGCGTTCGTCCTCACTCTCTTCCC▼TCGAG
(Forward)
Minimal promoter GAGCT▲CCCCGATATTTTCCCCCACCCCCGCGCAAGCAGGAGTGAGAGAAGGGAGCT▲C
(Reverse)
 
8.4 Validation of the pLNT-SFFV-JDG vector 
8.4.1  Fluorescence-Activated Cell Sorting for 3xFLAG tag and eGFP 
HEK293T cells transfected with pLNT-SFFV-JDG were washed with PBS (Sigma), trypsinised with 
trypsin-EDTA (Sigma), and centrifuged for 5 minutes at 400x g. Supernatant was removed and cells 
resuspended in PBS.  To each tube, 250 μl Cytofix (BD Biosciences) was added and incubated at 4°C 
for 20 minutes. Subsequently, 2 ml Perm/Wash permeabilisation buffer (BD Biosciences) was added 
followed by centrifugation at 400x g for 5 minutes. The supernatant was decanted and the pellet 
resuspended in residual buffer. To this, 1 μl primary anti-FLAG M2 (Sigma) antibody was added, 
vortexed, and incubated at 4°C for 15 minutes.  Following incubation with the primary antibody, 2 μl 
of the secondary APC goat anti-mouse Ig antibody was added, the cells briefly vortexed, and 
subsequently incubated at 4°C for 15 minutes.  A further 3 ml Perm/Wash was added and the cells 
centrifuged at 400x g for 5 minutes.  The pellet was resuspended in 500 μl PBS.  The CyAn ADP was 
used for flow cytometry with Summit v4.0 used for data capture.  For GFP FACS, samples were 
trypsinised, washed twice in PBS, and flow cytometry performed using the FACS Calibur Flow 
Cytometer with data capture performed using Cell Quest, and data analysis carried out using the 
FlowJo v7.6.4 software.   
 
8.4.2  Western blot for 3xFLAG and eGFP  
Growth medium was removed and cells were subsequently washed twice in PBS pre-warmed to 37°C.  
Cells were resuspended in 300 μl 2x Laemmli sample buffer (Sigma) for 5 minutes and homogenised 
by being passed through a 21G syringe approximately 10 times.  Samples were centrifuged at 13,000x 
g for 2 minutes and the soluble protein containing supernatant separated from the insoluble debris 
pellet by aspiration.  From each sample, 12 µg of total protein quantified by Bradford assay was 
diluted in 300 µl Laemmli sample buffer (2x) for 5 minutes. Samples were boiled for 10 minutes at 
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100°C and centrifuged at 13,000x g for 5 minutes to remove any contaminating insoluble debris.  
Protein was separated by polyacrylamide gel electrophoresis. Protein samples were loaded in up to 20 
μl volumes or 10 μl Novex Sharp Pre-stained Protein Standard (Life Technologies) in 1x MOPS 
buffer (Life Technologies) onto a 10% NuPAGE Novex gel (Life Technologies).  Samples were 
subjected to electrophoresis for 75 minutes at 150 Volts.  After electrophoresis, the protein containing 
gel, filter paper (Millipore), and PVDF transfer membrane (Millipore) were equilibrated in 1x transfer 
buffer (2.4g tris, 9g glycine, and 20 ml methanol) and protein transfer to the PVDF membrane 
performed at 15 volts for 30 minutes.  The transfer membrane was incubated at 4°C overnight in 
blocking solution containing 5 % w/v non-fat powdered milk in 1x PBS and 0.1% Tween-20 (PBS-
TWEEN).  Blocking solution was discarded and the membrane incubated for a further 3 hours at room 
temperature in 10 ml PBS-TWEEN containing 5% w/v non-fat powdered milk, 1.0 µl (1:10,000) 
mouse anti-β-actin antibody (Sigma) as the loading control, and a primary antibody; either 10µl 
(1:1,000) rabbit anti-3xFLAG antibody (Sigma) or 1.0 µl (1:10,000) rabbit anti-GFP antibody 
(Abcam).  The membrane was briefly washed 3 times for 10 minutes in PBS-TWEEN at room 
temperature.  The wash solution was discarded and the secondary goat anti-rabbit and goat anti-mouse 
fluorophore-containing antibodies were each diluted (1:10,000) in PBS-TWEEN containing 5% w/v 
non-fat powdered milk and incubated in foil on the shaker for 1 hour at room temperature.  The 
membrane was briefly washed three times for 10 minutes in PBS-TWEEN on the shaker.  A brief 
final wash was performed using PBS only.  Fluorescent imaging of the membrane was carried out 
using the Odyssey Infrared Imaging System (Li-Cor Biosciences) as per manufacturer’s instructions.  
The green channel (800 nm) was used for sample detection, and red channel (680 nm) for β-actin 
loading control detection.   
8.5  Bradford assay for total protein quantification 
This colourimetric assay is based on the binding of the acidic dye, Coomassie Brilliant Blue G-250, in 
response to varying concentrations of protein followed by spectrophotometric reading405.  Growth 
medium was removed and cells were subsequently washed once in PBS pre-warmed to 37°C.  Cells 
were subjected to lysis using 300 μl per well of a 12-well plate (ie. 3.8 cm2) luciferase lysis buffer (10 
mM Tris phosphate pH 8.0, 1mM EDTA pH8.0, 0.65% NP40, 150 mM NaCl) was added. The cell 
lysis supernatant was subjected to centrifugation for 1 minute at 13,000x g to precipitate cell debris.  
Five microliters of the soluble fraction of cell lysate was aliquoted into wells of a 96-well plate and 
195 μl diluted (1:5) Protein Assay Dye Reagent (Biorad) was added. Samples were incubated for 5 
minutes at room temperature, and the absorbance read at 595 nm using the Promega Glomax 
(Promega) as per manufacturer’s instructions.  
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8.6  Luciferase assay for the assessment of luciferase reporter activity 
Approximately 5x105 cells were lysed in 300 μl luciferase lysis buffer (0.65% NP40, 10 mM Tris (pH 
8.0), 1 mM EDTA (pH 8.0), 150 mM NaCl) and the soluble fraction of the supernatant clarified by 
centrifugation at 13,000x g for 1 minute. Using 20 μl of cell extract, each sample was plated in 
triplicate in an opaque, white, 96-well microplate.  To this, 20 μl assay buffer (25 mM Tris phosphate 
pH 7.8, 1 mM DTT, 1 mM EDTA, 1% Triton X-100, 8 mM MgCl2, 3 ml glycerol, 1.25 mM rATP, 
0.5% BSA)(All purchased from Sigma) was added.  Luciferin substrate (Gold Biotechnology) was 
injected into each well at a final concentration of 1.5 mM. Luminescence output was measured using 
the POLARstar Omega microplate reader (BMG Labtech) and analysis performed using MARS data 
analysis software (BMG Labtech).  Relative photonic light units were normalised relative to total 
protein as determined by Bradford assay.  
8.7  General cell culture  
HEK293T, HeLa, HepG2, Huh7, NIH3T3, MEFs and HDF cells were cultured in Dulbecco’s 
Modified Eagle’s Media (Sigma) supplemented with 10% fetal bovine serum (FBS) (Gibco), 1% 
penicillin/streptomycin (Sigma), 2 mM L-glutamine (Gibco) and 1x non-essential amino acids 
(Gibco).  Primary mouse embryonic fibroblasts (MEFs) and human dermal fibroblasts (HDFs) were 
plated at around 60-70% confluence onto tissue culture plastic pre-coated with 0.1% gelatine and 
incubated at 37°C for 1 hour. 
HepaRG cells were cultured in William’s E medium containing Glutamax and sodium pyruvate 
(Invitrogen) supplemented with 10% FBS (Gibco), 1% pen/strep (Sigma), 1x non-essential amino 
acids, 4 μg/ml human recombinant insulin zinc solution (Gibco), and 50 μM hydrocortisone (Sigma). 
Cells were plated onto plates pre-coated with 50 μg/ml collagen I (Santa Cruz Biotechnology) 
solubilised in 0.02N acetic acid (Sigma) and incubated at room temperature for 1 hour.  
SGHPL5 cells were cultured in Ham’s F-10 medium (Sigma) supplemented with 10% FBS, and 1% 
pen/strep. 
All cell lines were incubated at 5% CO2 humidified atmosphere at 37°C.  
8.8  Isolation and culturing of CD1 and tlr4
-/-
 MEFs  
Pregnant mice were terminally anesthetised using isofluorane approximately 14 days post-coitum.  
The abdominal cavity was doused with 70% ethanol to ensure sterile conditions prior to surgery.  The 
uterine horns containing the embryos were immediately placed in sterile PBS on ice.  Subsequent 
procedures were performed in a sterile hood and on ice inasmuch as possible.  The head and soft 
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organs were removed and the remaining carcass was washed in two changes of ice-cold PBS.  The 
cleaned carcass was subsequently minced as finely as possible using scissors and a clean, sharp 
scalpel.  To each embryo in a 50 ml Falcon tube, 4 ml of trypsin/EDTA (0.25%) was added and 
incubated at 37°C for 5 minutes.  This was mixed by pipetting of the fragments using a P1000, and 
leaving the trypsin to digest material for a further 5 minutes.  After incubation, 20 mls of mEF media 
(DMEM + 10% FBS + Glutamine + Pen/Strep + NEAA) was added to each tube and subsequently 
centrifuged for 5 minutes at 1200 rpm.  The trypsin-containing supernatant was removed as much as 
possible, the pellet resuspended in 15 mls of mEF media, and plated on 0.1% gelatine-coated flasks, at 
a density of 1 embryo per T175 flask.  These were incubated at 37°C and 5% CO2 overnight before 
the media was removed, two washes performed using PBS, and fresh mEF media added.  Cells were 
allowed to proliferate to 90% confluence before being trypsinised and frozen down at P1, or split for 
subsequent experiments.  
8.9  Lentivirus production and titering 
Cells were seeded at approximately 2x107 cells per T175 cm2 flask and incubated at 37°C, 5% CO2 
overnight to achieve up to 90% confluence.  Per flask, 50 μg transgene vector, 17.5 μg pMD.G2 VSV-
g envelope vector, and 32.5 μg pCMVΔ8.74 gag-pol packaging vector were incubated for 5 minutes 
at room temperature in 6ml OptiMEM (Gibco).  To this, another 6 ml OptiMEM containing 1 μl 
polyethylenimine (PEI) (10mM)(Sigma) was added and incubated for a further 20 minutes at room 
temperature. Medium was removed from cells, washed with PBS and 12 mls of PEI/DNA/OptiMEM 
solution was added and the cells incubated at 37C, 5% CO2 for 3 hours.  After incubation, 
PEI/DNA/OptiMEM solution was removed and the cells supplemented with complete DMEM 
containing 1% Penicillin / Streptomycin and 10% FCS.  After 24 hours, the medium was changed and 
the cells supplemented with fresh complete medium.  The 48 hour supernatant was collected and 
filtered through a 0.45 μm PVDF filter (Nalgene), and the pellet resuspended in 50 μl OptiMEM per 
12 ml viral supernatant and stored at 4°C overnight.  This was repeated for the 72 hour supernatant, 
and the two high-titer supernatants pooled and stored at -80°C.  All viruses were titered using a p24 
antigen enzyme-linked immunosobent assay (ELISA) (Zeptometrix) as per manufacturer’s protocol. 
Using samples diluted in water to 10-6 for in vitro preps, and 10-7 for the highly concentrated in vivo 
preps, the samples were incubated overnight in order to be captured by the p24 antibody on the plate.   
The captured antigen was subsequently incubated with anti-HIV-1 antibody conjugated to biotin.  
After washing, a Streptavidin-Peroxidase solution was added to each well.  After the addition of the 
substrate, the absorbance of the samples, in conjunction with the standard curve of known p24 
concentrations, was measured at 450 nm using the Glomax®-Multi+ microplate reader (Promega).  
The resultant optical density of the sample is proportional to the concentration of bound HIV p24 
antigen within each sample, and through generation of an equation for the standard curve, the 
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concentration of the unknown samples were determined to produce a viral titer expressed as viral 
particles/ml (vp/ml).  
8.10  Reporter assays 
Cells transduced with reporter lentivirus at a multiplicity of infection (MOI) of between 5-10 were 
plated at a density of 2x105 cells per well of a 12-well plate. Within 24 hours after plating, the cells 
were activated with their respective ligand/inhibitor as per (Table 12). 
 
Table 12. Table of reporters, agonists, and activation parameters. 
Response Agonist / Conc. Activation Activation Maintenance 
Element Inhibitor Duration Media Media 
NF-κB Ultra-pure LPS (InvivoGen) 0.1 mg/ml 4 hours OptiMem Complete DMEM
SBE Activin A (Peprotech) 100 ng/ml duration Complete DMEM Complete DMEM
WNT Lithium Chloride (LiCl) (Sigma) 50 mM 24 hours Complete DMEM Complete DMEM
Notch Jagged-1 70% Jag-1 duration 1:1 Complete DMEM 1:1 Complete DMEM
cells and Ham's F10 and Ham's F10
 
 
8.11 Development of the px330-Sox9 knockout CRISPR-Cas9 vector 
8.11.1  Cloning of the Sox9 guide-RNA into the px330 backbone 
The px330 backbone was used to clone in the guide RNA into the BbsI restriction site (restriction 
half-site highlighted in red within the oligo (Table 13).  This vector also contains the Cas9 nuclease 
downstream of a constitutive chicken β-actin promoter.  Oligos containing BbsI restriction half sites 
(bold red) were designed using the free online software CHOPCHOP406 and were targeted toward the 
human Sox9 gene, while the negative control was a guide that had no target within the human 
genome.  The guides and the PCR primers used for subsequent amplification and validation of the 
target region are given in Table 13.  Target guides were designed to target exons only, lie directly 
upstream of an NGG PAM motif, be 20 bp in length, begin with a G for optimal U6-driven 
expression, and were designed to have zero predicted off-targets.  Lyophilised oligos were 
resuspended in distilled H2O to a concentration of 100 μM.  Each of the oligos was phosphorylated 
using T4 polynucleotide kinase (NEB) by incubation for 1 hour at 37°C and heat inactivated for 20 
minutes at 65°C (Table 14).  Complementary phosphorylated oligos were mixed in a 1:1 ratio (10 μl 
each) and heated for 10 minutes at 75°C. The oligos were annealed by slow cooling to room 
temperature by turning the heating block off.   
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Table 13.  Oligos used to develop guide RNAs and amplify Sox9 target region. 
Oligo Sequence
Sox9 top strand guide 5' CACCGGAGATTCATACGCGGGCCC 3'
Sox9 bottom strand guide 5' AAACGGGCCCGCGTATGAATCTCC 3'
 -ve control top strand guide 5' CACCGCACTACCAGAGCTAACTCA 3' 
 -ve control bottom strand guide 5' AAACTGAGTTAGCTCTGGTAGTGC 3'
Sox9 amplicon for T7EN assay (forward) 5' GTGCAAGCGCCCCCACTTTTGCTCTTTTTCCTCCCC 3' 
Sox9 amplicon for T7EN assay (forward) 5' AGAGCTTGCCCAGCGTCTTGCTGAGCTCGGCGTTGTGCAAGTGCG 3'
 
Table 14.  Phosphorylation reaction using T4 polynucleotide kinase. 
Reagent Volume (μl)
Stock oligo (100 μM) 2 μl
ATP 2 μl
T4 polynucleotide kinase buffer 2 μl
T4 polynucleotide kinase 0.5 μl
H2O 13.5 μl
Final Volume 20 μl  
 
8.11.2  Ligation of phosphorylated, annealed oligos into BbsI digested px330 
Each of the phosphorylated, annealed oligos was diluted 25-fold for a final concentration of 200 nM.  
Ligation was performed using 50 ng of linearised (BbsI digested) px330 with 5 μl diluted, double-
stranded oligo.  This was ligated using NEB Quick Ligase before being transformed in Stbl3 
competent cells.  A negative control containing 5 μl of H2O instead of the annealed oligos was added 
in order to determine the background ligation potential.  Following this, 4 clones from the px330-
Sox9, 4 clones from the px330-neg, and 1 from the negative control plate were amplified overnight in 
5ml LB broth containing 100 μl/ml carbenicillin.  The plasmid DNA from these clones was isolated 
using the Qiagen Mini-pep kit as previously described, and the samples double digested with 
BbsI/AgeI to determine whether the oligo had annealed into the px330 backbone.  
 
8.11.3  Nucleofection of genome editing plasmids and clonal amplification of HepaRG cells 
To obtain expression of the px330-Sox9 and px330-neg-ctrl vectors within the cells, progenitor 
HepaRG cells were electroporated using the Amaxa nucleofector kit (Lonza).  Firstly, the HepaRG 
cells were trypsinised and resuspended in media.  Cells were centrifuged for 5 minutes at 1200 rpm 
and the pellet resuspended in 3 mls of media before cells were counted 3 times using a 
haemocytometer.  Using the average of the 3 numbers around 4-5x105 cells were re-centrifuged for 5 
minutes at 1200 rpm and the supernatant removed.  To 100 μl buffer, containing the supplied 
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supplement, 8 μg of DNA was added, the cells resuspended in the buffer/supplement/DNA mix, and 
transferred to an Amaxa electrode vessel.  This vessel was placed into the Amaxa nucleofector and the 
T-028 program voltage applied.  Electroporated cells were transferred to pre-coated collagen plates 
and the media replaced the following day.  After 3 days, the cells were plated in a 96-well plate at a 
seeding density of 0.5 cells/well in order to give a greater chance of obtaining a single cell per well.  
Two weeks after plating, the wells were assessed for the formation of single colonies, while those 
which had multiple colonies were marked and disregarded for future work.  Single clonal cell lines 
were transferred to a 6-well plate for DNA isolation and validation of genome editing.  
 
8.11.4  Genomic DNA isolation from clonally amplified cells and PCR of Sox9 target region. 
Cells were trypsinised from the 6-well plate and resuspended in media, centrifuged for 5 minutes at 
300 g and the supernatant removed.  Cells were washed in PBS and centrifuged for a second time.  
DNA was isolated using a genomic DNA isolation kit (Sigma), according to manufacturer’s 
instructions but briefly described below.  One deviation to this protocol was elution of the DNA in 
H2O instead of the supplied elution buffer.  The protocol utilises enzymatic digestion with proteinase 
K at 70°C for 10 minutes to release the DNA.  The column is prepared by adding a buffer solution 
followed by a single centrifugation.  To the cell lysate, 200 μl ethanol (100%) was added, vortexed 
thoroughly to ensure homogeneity, and loaded onto the column.  The column was centrifuged, the 
flow-through removed, and the DNA subsequently bound to the column with binding buffer which is 
also subsequently centrifuged through.  The DNA is washed twice with buffer containing ethanol, 
centrifuged twice to remove any residual buffer, and eluted in 30 μl of RNase/DNase-free water.  All 
DNA samples were quantified and made up to a final concentration of 100 ng/μl.   
The genomic region containing the genome edited target site was amplified using PCR.  The PCR was 
set up as per Table 15.  PCR amplification parameters were an initial denaturation of 98°C for 30 
seconds followed by 30 cycles of 98°C for 10 seconds, 58°C for 20 seconds, 72°C for 30 seconds, 
with a final elongation step of 72°C for 3 minutes. 
 
Table 15.  PCR reaction for amplification of Sox9 genomic region containing CRISPR/Cas9 target site. 
Reagent and Concentration Volume 
Forward Sox9 primer (10 μM) 1.25 μl
Reverse Sox9 primer (10 μM) 1.25 μl
Q5 Hot-start polymerase Master Mix (2x) 12.5 μl
Template genomic DNA (50 ng total DNA per reaction) 0.5 μl
dH2O 9 μl
Final Volume 25 μl  
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8.11.5  SmaI digest and T7 endonuclease I assay to determine occurrence of genome editing 
The PCR product that was visualised on the agarose gel was excised, and subsequently gel extracted.  
The gel extracted product was digested by SmaI restriction enzyme, in order to see whether the 
original site found within Sox9 had been mutated.  The digest was performed using 1 unit of SmaI 
enzyme, and incubated at 25°C for 1 hour before being electrophoresed and examined for the 
presence or absence of the SmaI site in the Sox9 amplified product.  
It was desirable to obtain a mono-allelic Sox9 knockout cell line.  Therefore, in order to remove 
colonies from the screening procedure that were bi-allelic for any mutation, a T7 endonuclease I assay 
was performed.  This protocol relies on the denaturation and slow annealing of DNA producing 
heteroduplexes where the mutation forms a mismatch with the wildtype base.  The T7 endonuclease 
recognises this mismatch and is able to cleave the product, resulting in 2 digested products.  Perfectly 
annealed products will yield only a single, undigested band.  The T7 endonuclease I assay was 
initially set up as in Table 16 in order to denature and hybridise the DNA: 
 
Table 16.  T7 endonuclease assay hybridisation mix. 
Reagent and Concentration Volume 
NEB buffer 2 2.0 μl
Gel extracted Sox9 PCR product (200 ng) variable μl
dH2O variable μl
Final Volume 19 μl  
 
The hybridisation reaction was performed in the Eppendorf PCR cycler  
 5 min, 95°C                           
 ramp down to 85°C at -2°C/sec                   
 ramp down to 25°C at -0.1°C/sec        
 hold at 4°C 
To the hybridised mix, 1 μl (10U) T7 endonuclease I was added and incubate at 37°C for 15 minutes.  
The reaction was stopped by adding 2 μl of 0.25 M EDTA and was electrophoresed immediately on a 
1.5% agarose gel.  
 
8.11.6 Clonal amplification and knockout validation using PCR and restriction digestion 
Nucleofected cells were trypsinised for 1 minute, and resuspended in 5 mls of complete HepaRG 
media.  These cells were centrifuged for 5 minutes at 300 g and the media containing trypsin was 
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removed.  The cell pellet was resuspended in 5 mls of complete HepaRG media and the cells counted 
using a haemocytometer.  Cell counting was performed three times.  Cells were subsequently 
resuspended in complete HepaRG media so that each well of a 96-well plate contained 100 μl of 
media with a cell density of 0.5 cells per well in order to improve the chances of obtaining a single 
cell and subsequently a single clonal colony of cells per well.  The clones were grown for three 
weeks, after which the wells were assessed for the formation of single colonies.  The wells containing 
single colonies were trypsinised and the cells further grown up in a 6-well plate format.  
 
8.11.7  Sequencing of Sox9 homozygous knockout clones 
Clones that showed either the introduction of large insertions or deletions in the amplified PCR 
product, were mono-allelic for the T7 endonuclease I assay, or those which showed a mutation in the 
SmaI restriction site, were sequenced by Source Bioscience in order to confirm and characterise the 
type of mutation.  Sequencing was performed using a 1:2 dilution of the gel-extracted product and the 
Sox9 genomic DNA forward PCR primer was used to prime the DNA during the sequencing reaction. 
8.12  Tissue fixation, embedding, and sectioning 
Mice were anaesthetised with isofluorane as per the code of practice for the humane killing of animals 
under schedule1 of the Animals (Scientific Procedures) Act 1986. The livers were perfused with PBS 
to remove haemoglobin from the livers. Livers were immediately removed, sliced into 5-10mm 
sections, and placed in formalin for 48 hours at 4°C.  For long-term storage, liver sections were 
removed from formalin and stored in 70% ethanol and kept refrigerated at 4°C until embedding.  All 
animal procedures were carried out by Dr Simon Waddington and Mr Dany Perocheau at the UCL 
animal facility under the appropriate UK Home Office Project Licence.    
Prior to embedding, perfusion-fixed tissues were dehydrated by serial washes through a graded series 
of 80%, 90% and 2x 100% ethanol baths each for one hour.  Following dehydration, samples were 
incubated overnight in Histoclear (National Diagnostics) at room temperature.  
Tissues were suspended in 60°C preheated Fibrowax (VWR), and subjected to 575 in/Hg pressure.  
This process was repeated three times to remove residual Histoclear.  Tissues were subsequently 
transferred to a metal dish, filled with Fibrowax, an embedding cassette placed on top, and additional 
wax added to the top of the cassette and allowed to solidify overnight.  Paraffin-embedded samples 
were sectioned into 5 μM sections using a Leica RM2255 microtome, and placed onto positively-
charged 3-aminopropyltriethoxysilane (APES)(Sigma)-coated slides.  Slides were prepared by 
immersion in 0.85% APES solution for 5 seconds, 2 washes in acetone (Sigma) for 5 seconds each, 
followed by 2 washes of distilled water.  Slides were allowed to dry at 37°C overnight before use.  
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8.13  Hematoxylin and eosin staining  
Histological sections were rehydrated by clearing twice in Histoclear for 10 minutes each, followed 
by 5 minutes in absolute industrial methylated spirits (IMS), 3 minutes each in 90%, 70%, and 50% 
IMS, followed by a final bath for 5 minutes in distilled water.  Sections were placed in Weigert’s 
haematoxylin for 5 minutes and then rinsed in running water.  Differentiation, or selective removal of 
excessive staining through controlled leaching in an acid alcohol solution, was performed by 
incubating the slides in acid alcohol (70% EtOH with 0.5% HCl) for approximately 10 minutes in 
order to achieve the desired degree of staining.  Sections were once again rinsed in water and 
subsequently stained in eosin for 5 minutes.  Sections were then dehydrated by rapidly passing 
through 70%, 90% and 100% alcohol for 2-3 seconds followed by a final 100% alcohol bath for 5 
minutes. Sections were incubated in 2 final baths of Histoclear for 10 minutes each and allowed to dry 
before mounting with Histomount (Sigma).  
8.14  Lilley’s trichrome staining                                                                                                                                                                              
Since the histological dyes are aqueous in nature, it is important that the slides are gradually hydrated 
and the clearing agent, Histoclear, is removed so that the dyes can bind affectively.  Sections are 
brought to water by passing the slides through descending concentrations of alcohol solutions with a 
final wash in water. Histological sections were subsequently incubated in Weigert’s haematoxylin for 
5 minutes and rinsed in running water and then distilled water.  Slides were placed in working 
strength picric acid solution for 10 minutes, washed in distilled water, and stained in Xylidine Red 
solution (Sigma) for 1 minute before being rinsed again in distilled water.  Differentiation was 
performed using a 1% phosphomolybdic acid bath for 10 minutes.  Collagen staining was achieved by 
subsequently staining slides in Aniline Blue solution (Sigma) for 1 minute before being placed in 
fresh 1% phosphomolybdic acid for 2 minutes and 1% acetic acid for 3 minutes prior to rapid 
dehydration of samples in 95% and 2x 100% alcohol.  Slides were left to dry before being cleared in 2 
baths of Histoclear for 10 minutes each.  After drying, sections were mounted using Histomount and 
analysed for fibrosis.  
8.15  Immunohistochemistry of liver sections 
Tissue sections mounted on APES-coated glass slides were bathed twice in Histoclear for 10 minutes 
each, and brought to water by immersing in absolute industrial methylated spirits (IMS) for 5 minutes, 
followed by 3 minutes each in 90%, 70%, and 50% IMS, followed by a final bath for 5 minutes in 
distilled water.  Antigen retrieval was performed by heat-induced antigen retrieval in 10 mM citrate 
buffer (pH6.0) (Sigma) or 10 mM Tris HCL (Sigma) as indicated for 40 or 10 minutes respectively 
and then allowed to cool for a further 20 minutes. Samples were incubated for 10 minutes in TBS 
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containing 0.3% Triton X-100 (TBS-T) followed by blocking in TBS-T + 15% normal goat serum 
(NGS) (Vector Laboratories) for 1 hour at room temperature.  Primary antibody was diluted in TBS-
T/10% NGS overnight at 4°C.  Slides were rinsed thrice for 5 minutes each time in TBS followed by 
incubation in secondary antibody diluted in TBS-T/10% NGS for 1 hour at room temperature.  Once 
again the samples were washed thrice for 5 minutes in TBS before removal of background 
fluorescence using 0.3% Sudan Black B (VWR) made up in 70% ethanol for 15 minutes at room 
temperature.  Sections were rinsed thrice with TBS for 5 minutes each followed by a final jet wash 
with TBS.  Sections were mounted using Fluorescence Mounting Medium (Dako).  Staining 
parameters given in Table 17. 
 
Table 17.  Primary and secondary antibodies used for immunohistochemistry. 
Antibody Antigen retrieval Dilution
chicken αGFP (New England Biolabs (ab13970)) 10 mM Na Citrate (pH6.0)  1:300
mouse αHNF-4α (Perseus proteomics (PP-H415-00)) 10 mM Na Citrate (pH6.0)  1:200
rabbit α-SMA (Dako (M0851)) 10 mM Tris HCL (pH10)  1:100 
rabbit α-GFAP (Dako (Z0334)) 10 mM Na Citrate (pH6.0)  1:200 
mouse  αCK7 (Dako (M7018)) 10 mM Tris HCL (pH10)  1:500 
rabbit αPKM2 (Life Technologies (PA5-23034)) 10 mM Na Citrate (pH6.0)  1:200
goat α-rabbit Alexafluor (Life Technolgies (A-11011)  1:500
goat α-mouse Alexafluor (Life Technologies (A-11031)  1:500
goat α-chicken Northern Lights (R&D Systems (NL018))  1:400
4′,6-diamidino-2-phenylindole (DAPI)(Sigma Aldrich (D9542))  1:1000
 
8.16  Hepatocyte and cholangiocyte differentiation utilising the HepaRG cell line  
HepaRG cells were seeded at low density and maintained in William’s E medium containing 
hydrocortisone and insulin as detailed in the general cell culture methods section 2.6.  Cells were 
passaged every 3-4 days onto collagen-coated plates to maintain low confluence for 2 weeks in order 
to encourage the growth of hepatic progenitors.  For hepatocyte maturation, the HepaRG hepatoblasts 
(HepaRG-HB) cells were allowed to grow to confluence after which the culture was supplemented 
with 1.2% DMSO (Sigma) to induce hepatocyte differentiation and maturation (protocol 1) to produce 
HepaHep cells.  In order to differentiate cells into cholangiocytes, termed HepaChol (protocol 2), 
confluent HepaRG-HB cells were treated with IL-6 (10 ng/ml) (R&D Systems) for 2 days, followed 
by 2 days of sodium taurocholate hydrate (10 nM) (Sigma) treatment, and a further 8 days of sodium 
taurocholate hydrate (10 nM) (Sigma) and sodium butyrate (1.8 μM) (Sigma) treatment.   
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8.17 Generation and differentiation of Numb and Jagged overexpressing HepaRG lines 
HepaRG cells were seeded at low density.  The following day, the cells were transduced with either 
high-titer pLNT-SFFV-Numb or pLNT-CMV-Jagged-IRES-GFP virus at an MOI of 20.  The cells 
were cultured for a week before any experiments in order for the virus to integrate and for stable basal 
levels of the proteins to be achieved.  Following stable expression of the proteins, both cell lines were 
differentiated down both the hepatocyte and the cholangiocyte lineages following the above protocol. 
Samples were subsequently stained by immunocytochemistry or lysed for RNA extraction.    
 
8.17.1  Immunocytochemistry of modified and unmodified differentiated  HepaRG cells 
At the end of the HepaRG differentiation experiments using protocol 1 or 2, media was removed from 
cells and cells washed three times in PBS.  Cells were fixed by incubation in 4% paraformaldehyde 
(PFA) (Sigma) for 20 minutes followed by three washes in PBS to remove any residual PFA. 
Blocking buffer (PBS, 0.3% Triton X-100, 1% BSA) was added to the cells and incubated for one 
hour at room temperature to reduce non-specific binding of the primary antibody.  Primary antibody 
resuspended in blocking buffer was added to the cells and incubated overnight at 4°C. Primary 
antibody was removed and the cells washed three times in PBS for 5 minutes. Fluorophore-conjugated 
secondary antibody resuspended in blocking buffer was incubated on the cells for 1 hour at room 
temperature.  This was followed by three washes in PBS.  Cells were incubated in 1x 4',6-diamidino-
2-phenylindole (DAPI)(Sigma) in PBS for 10 minutes before being washed again three times in PBS 
for 5 minutes each time.  Cells were kept in PBS for fluorescent imaging using an Olympus 
microscope and analysed using Cell F imaging software.    Primary and secondary antibody dilutions 
and additional information are given in Table 18. 
 
Table 18.  Primary and secondary antibody information used for immunocytochemistry. 
Antibody Supplier Dilution
mouse αCK19 (cholangiocyte) Dako (M0888)  1:200
mouse αCK7  (cholangiocytes) Sigma (4465P)  1:200 
mouse αHNF-4α (hepatocytes) Perseus (PP-H1415-00)  1:200
mouse αALB (hepatocytes) R&D Systems (MAB1455)  1:200
goat αSox9 (progenitors and cholangiocytes) R&D Systems  (AF3075)  1:500
rabbit α-activated Notch (NICD) Abcam (ab8925)  1:200
rabbit αNon-phospho (active) β-catenin New England Biolabs (8814S)  1:200
rabbit αAcetylated tubulin Cell Signaling (5335S)  1:200
rabbit α-goat Alexafluor Life Technologies (A11079)  1:500
goat α-rabbit Alexafluor Life Technologies (A11011)  1:500
goat  α-mouse Alexafluor Life Technologies (A11031)  1:500
4′,6-diamidino-2-phenylindole (DAPI)(Blue) Sigma Adlrich (D9542)  1:1000  
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8.17.2  qPCR for expression of markers of progenitors, hepatocytes, and cholangiocytes 
8.17.2.1  RNA extraction  
Confluent wells of a 12-well plate were washed twice with PBS to remove any media.  Buffer RLT 
(350 μl) was added directly to the monolayer of cells.  The cells were scraped using a P1000 tip in 
order to completely resuspend and lyse the cells in the lysis buffer.  The lysate was loaded directly 
onto a QIAshredder spin column and centrifuged for 2 minutes on full speed.  To the homogenised 
lysate, 350 μl ethanol (70%) was added and pipetted repeatedly to mix well.  The sample was 
subsequently loaded onto an RNeasy spin column and centrifuged for 15s at 13,000 rpm.  The flow-
through was discarded and 350 μl Buffer RW1 added to the column. Once again the column was 
centrifuged for 15 seconds at 13,000 rpm and the flow-through discarded.  The sample was DNase 
treated on-column using 10 μl of RQ11 DNAse (Promega) in DNase buffer to a total volume of 70 μl. 
This was incubated for 20 minutes at room temperature (20-30°C).  Another 350 μl of RW1as added 
to the column and centrifuged for 15 seconds at 13,000 rpm and the flow-through discarded.  Next, 
500 μl Buffer RPE was added to the RNeasy spin column, centrifuged at 13,000 rpm for 15 seconds 
and the flow-through discarded.  This wash step was repeated a second time and centrifuged at 13,000 
for 2 minutes.  The column was placed in a new 2ml collection tube and centrifuged at full speed for 1 
minute to remove any residual wash buffer.  The column was transferred to a new Eppendorf tube and 
30 μl dH2O added directly to the spin column membrane.  This was incubated at room temperature for 
5 minutes before being centrifuged at full-speed for 30 seconds.  The RNA samples were quantified 
using the NanoDrop™ and placed at -80°C for long-term storage.  
 
8.17.2.2  First-Strand cDNA synthesis 
In order to denature RNA secondary structure, the RNA (up to 1 μg) was incubated with 0.5μg 
Random Primers at 70°C  for 5 minutes and immediately cooled on ice to prevent the reformation of 
any secondary structures.   The following reagents were subsequently added as per Table 19, and 
incubated at 37°C for 1 hour.  A control containing dH2O instead of reverse transcriptase was also set 
up and is designated the No RT control.  cDNA was kept at -20°C for long-term storage. 
Table 19.  First-strand cDNA synthesis reaction. 
 
Reagent and Concentration Volume 
M-MLV 5x Reaction Buffer 5.0 μl
dNTPs (10 μM) 5.0 μl
RNA (up to 1 μg) variable
Random primer (0.5 μg/μl) 1.0 μl
M-MLV reverse transcriptase (200 units) 1.0 μl
Recombinant Rnasin® Ribonuclease inhibitor 0.5 μl
H2O variable
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8.17.2.3  qPCR to quantitate hepatocytes and cholangiocytes from differentiation protocols 
cDNA samples were diluted 1:7  and subsequently used as the template in the qPCR reactions.  The 
reactions were as per Table 20 and Table 21, with cycling parameters as per Table 22 for Sox9, 
OPN, HNF-1β and β-actin Table 23 for Hey1 and β-actin.  The relative expression levels were 
calculated using the Pfaffl method which incorporated the varying primer efficiencies using the 
equation of the standard curve. All primer sequences are given in Table 24. 
 
Table 20.  qPCR reaction for Sox9, OPN, HNF-1β, and Hey1. 
Reagent and Concentration Volume 
SybrMaster Mix (2x) 5.0 μl
Forward primer (10 μM) 0.55 μl
Reverse primer (10 μM) 0.55 μl
cDNA 2.0 μl
H2O 1.9 μl
Final Volume 10 μl  
 
Table 21.  qPCR reaction for ALB and β-actin. 
Reagent and Concentration Volume 
Sybr Select Master Mix (2x) 5.0 μl
Forward primer (10 μM) 0.38 μl
Reverse primer (10 μM) 0.38 μl
cDNA 2.0 μl
H2O 2.25 μl
Final Volume 10 μl  
 
Table 22.  Cycling parameters for qPCR using Sybr Select qPCR mix. 
Temperature Time
50°C 2 minutes 1x
95°C 2 minutes 1x
95°C 3 seconds 40 x
59°C 30 seconds
65°C to 95°C in 0.5°C increments 5 seconds 1x
(Melt curve)  
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Table 23.  Cycling parameters for qPCR using Sybr® greenER™ qPCR mix Sybr Select qPCR mix. 
Temperature Time Cycles
95°C 3 minutes 1x
95°C 3 seconds
60°C 20 seconds 40x
72°C 1 second
65°C to 95°C in 0.5°C increments 5 seconds 1x
(Melt curve)  
 
Table 24.  Primers used in differentiation experiment qPCR reactions. 
Marker Primer Sequence (5' → 3') Amplicon
Size
progenitors / cholangiocytes Sox9 forward GACTTCCGCGACGTGGAC 99 bp
progenitors / cholangiocytes Sox9 reverse GTTGGGCGGCAGGTACTG
cholangiocytes OPN forward CTCAGGCCAGTTGCAGCC 81 bp
cholangiocytes OPN reverse CAAAAGCAAATCACTGCAATTCTC
cholangiocytes HNF-1β forward TGTACACCTGGTACGTCAGAAA 140 bp
cholangiocytes HNF-1β reverse ATGGCTCTGTTGACTGAACTCT
hepatocytes ALB forward TGCAACTCTTCGTGAAACCTATG 135 bp
hepatocytes ALB reverse ACATCAACCTCTGGTCTCACC
Notch signalling HEY1 forward CGGCAGGAGGGAAAGGTT 61 bp
Notch signalling HEY1 reverse CCCAAACTCCGATAGTCCATAGC
Housekeeping gene β-actin forward CGGGACCTGACTGACTACC 292 bp
Housekeeping gene β-actin reverse TGAAGGTAGTTTCGTGGATGC  
 
8.17.3   Notch, Wnt and α1AT reporter expression during differentiation  
HepaRG cells were transduced at an MOI of 10 for each of the reporter constructs prior to plating in a 
12-well plate.  The reporters used were LNT-Notch-NLuc2, LNT-Wnt-NLuc2, and LNT-α1AT-
NLuc2.  The α1AT reporter contains the promoter element of the gene coding for alpha-1 antitrypsin 
(α1AT), a hepatocyte-specific marker.  In conjunction with the secreted Nanoluc vectors, the cells 
were transduced at an MOI of 1 using the constitutively expression LNT-SFFV-Vluc vector in order 
to compensate for cell number during the experiment.  Cells were grown to confluence in a monolayer 
prior to the start of differentiation.  Differentiation was performed using the cholangiocyte and the 
hepatocyte differentiation protocols as per section 7.16.  At the start of the experiment, and every 
second day thereafter, media was removed and assayed for Nanoluc activity using coelenterazine at a 
final concentration of 1 μM, and vargula activity using vargulin at a final concentration of 10 nM.  
Activity of Nanoluc was normalised to the activity of Vargula.   Data for each reporter was plotted at 
each time point for the duration of the differentiation experiment.  
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8.18  Statistical analysis  
Statistical analysis on in vitro data was performed using an unpaired student’s t-test with a p-value of 
<0.05 considered significant for single time-points.  Time course experiments were analysed using 
two-way ANOVA with repeated measures with Bonferroni post-hoc test used for significance.  Dose-
response experiments were analysed using one-way ANOVA with Tukey’s multiple comparison test 
for significance.  Analysis of the different constitutive luciferases was performed using one-way 
ANOVA with Tukey’s post-hoc test.  All data are expressed as mean values ± SEM, with each sample 
being measured in triplicate.   
8.19   In vivo work  
8.19.1  Animals 
All mice used for in vivo experiments were outbred CD1 mice (Charles River).  Mice were time 
mated 3 weeks prior to the expected neonatal injection date.  Neonatal (P0) CD1 mice were 
aneaethetised on ice before being injected either intracranially (5 μl), intravenously (20 μl), 
subcutaneously (10 μl), intranasally (20 μl), or ventral subcutaneously (5 μl)) followed by imaging.  
All animal work was compliant with the rules and regulations set out by the United Kingdom Home 
Office. 
 
8.19.2  Bioluminescence imaging  
Induction of anaesthesia was achieved using 4% isofluorane (Abbott Laboratories) in 100% oxygen, 
before being injected intraperitoneally with 300 μl D-luciferin (Gold Biotechnology) at a 
concentration of 15 mg/ml, a dose of approximately 150 mg/kg.  The mice were connected to an 
anesthesia system in a warmed light-proof detection chamber within in the IVIS in vivo imaging 
system (Perkin Elmer).  Imaging was performed 5 minutes post D-luciferin administration using a 
cooled charge-coupled device (CCCD) camera with image acquisition performed using a 24 cm field-
of-view for greyscale photographic images.  Luminescent images were subsequently acquired using a 
binning factor of 4, with an aperture of f/1.2 and expressed as photons per second per cm2 per 
steradian.  An overlay of the two images was generated using Living Image software (Perkin Elmer) 
to create a pseudo-coloured image to depict fluorescent intensities over each animal.  Regions of 
interest (ROIs) were manually defined using a standard area for each organ.  Prior to agonist-mediated 
activation or surgical induction of disease, each of the animals was imaged three times in order to 
ascertain a robust median baseline measurement of bioluminescent imaging which could then be used 
to express subsequent data points as a fold-change over this baseline value.   
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8.19.3  In vivo reporter analysis 
Activation experiments and bile duct ligations were performed by Dr. Simon Waddington (University 
College London).  D-luciferin administration and bioluminescent image data capture were performed 
by Dr. Suzanne Buckley and Mr Dany Perocheau. 
 
8.19.3.1  NF-κB activation using LPS 
LPS was given intraperitoneally at the time of D-luciferin administration at a dose of 30 μg per 
mouse.  Animals were imaged at T = 0 and T = 4 hours post-LPS.   
 
8.19.3.2  Dexamethasone-mediated abrogation of NF-κB signalling.   
Dexamethasone at a dose of 18 mg/kg was administered 2 hours prior to and concomitantly with LPS 
and luciferin.   
 
8.19.3.3  Bile duct ligation model of cholestasis.  
Firstly, animals were anesthetised with isofluorane.  Abdominal fur was removed with an electric 
shaver and antiseptic applied to the skin.  An abdominal longitudinal incision, ventral to the 
xiphisternum, was made and the peritoneal cavity opened.  The liver was lifted out and the bile duct 
exposed.  A suture was placed around the common hepatic duct downstream of the median and left 
liver lobes, leaving the right and caudate lobe free from ligation. The liver was replaced into the 
abdominal cavity before closure of the peritoneum and cutis plus facia.  The operation area was 
sterilised with antiseptic and the mice administered with 50 µl morphine (6.67 mg/ml) and 100 µl 
bupivacaine hydrochloride (2 mg/kg) for systemic post-operative analgesia. 
 
8.19.4  Statistical analysis of in vivo experiment results 
Analysis of variance (ANOVA) test for significance was used for in vivo experimental data with 
Newman-Keuls post-hoc multiple comparison test. 
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APPENDICES 
Appendix A – Plasmid Maps 
Appendix A.i   Plasmid map of pSEW-Asp-eGFP 
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Appendix A.ii  Plasmid map of pLNT-SFFV-JDG 
 
 
 
 
Appendix A.iii  Plasmid map of pZs-Green-JDG 
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Appendix A.iv  Plasmid map of pLNT-GW-MCS 
 
 
 
Appendix A.v  Plasmid map of pLNT-GW-JDG 
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Appendix A.vi  Plasmid map of pLNT-GW-NLuc2 
 
 
 
Appendix A.vii  Plasmid map of pLNT-SFFV-Vluc 
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Appendix A.viii  Plasmid map of pENTR-1A 
 
 
 
Appendix A.ix  Plasmid map of px330 with BbsI restriction sites for target sequence cloning 
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Appendix B – Predicted sequence of the 3xFLAG-FLuc-2A-eGFP insert 
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Appendix C – Home Office Animals (Scientific Procedures) Act 1986 Project Licence 
 
  
  
APPENDICES                                                                                                                                            VIII | P a g e  
 
Appendix D – Turnitin Plagiarism report 
 
 
The full copy of the Turnitin report can be found on the accompanying CD.   
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